Note: Descriptions are shown in the official language in which they were submitted.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
TITLE OF THE INVENTION
SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE
INHIBITORS
BACKGROUND OF THE INVENTION
Field of the Invention:
The present invention relates to pyrrolo-pyrazole derivatives, to a process
for their
preparation, to pharmaceutical compositions comprising them, and to their use
as
therapeutic agents, particularly in the treatment of cancer and cell
proliferation disorders.
Discussion of the Background
Several cytotoxic drugs such as, e.g., fluorouracil (5-FU), doxorubicin and
camptothecins,
damage DNA or affect cellular metabolic pathways and thus cause, in many
cases, an
indirect block of the cell cycle. Therefore, by producing an irreversible
damage to both
normal and tumor cells, these agents result in a significant toxicity and side-
effects.
In this respect, compounds capable of functioning as highly specific antitumor
agents by
selectively leading to tumor cell arrest and apoptosis, with comparable
efficacy but
reduced toxicity than the currently available drugs, are desirable.
It is well known that progression through the cell cycle is governed by a
series of
checkpoint controls, otherwise referred to as restriction points, which are
regulated by a
family of enzymes known as the Cyclin-dependent kinases (Cdk). In turn, the
Cdks
themselves are regulated at many levels such as, for instance, binding to
cyclins.
The coordinated activation and inactivation of different Cdk/Cyclin complexes
is
necessary for normal progression through the cell cycle. Both the critical Gl-
S and G2-M
transitions are controlled by the activation of different Cdk/Cyclin
activities. In G1, both
Cdk4/Cyclin D and Cdk2/Cyclin E are thought to mediate the onset of S-phase.
Progression through S-phase requires the activity of Cdk2/Cyclin A whereas the
activation
of Cdc2/Cyclin A (Cdkl) and Cdc2/cyclin B are required for the onset of
mitosis. For a
general reference to cyclins and cyclin-dependent kinases see, for instance,
Kevin R.
Webster et al, in Exp. Opin. Invest. Drugs, 1998, Vol. 7(6), 865-887.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
2
Checkpoint controls are defective in tumor cells due, in part, to
disregulation of cdk
activity. For example, altered expression of cyclin E and cdks has been
observed in tumor
cells, and deletion of the cdk inhibitor p27 KIP gene in mice has been shown
to result in a
higher incidence of cancer.
Increasing evidence supports the idea that the cdks are rate-limiting enzymes
in cell cycle
progression and, as such, represent molecular targets for therapeutic
intervention. In
particular, the direct inhibition of cdk/cyclin kinase activity should be
helpful in restricting
the unregulated proliferation of a tumor cell.
SUMMARY OF THE INVENTION
It is an object of the invention to provide compounds which are useful in
treating cell
proliferative disorders caused by and/or associated with an altered cell cycle
dependent
kinase activity. It is another object to provide compounds which have
cdk/cyclin kinase
inhibitory activity.
The present inventors have now discovered that certain pyrazole compounds are
endowed
with cdk/cyclin kinase inhibitory activity and are thus useful in therapy as
antitumor agents
and lack, in terms of both toxicity and side effects, the aforementioned
drawbacks
associated with currently available antitumor drugs.
More specifically, the pyrazole derivatives of the invention are useful in the
treatment of a
variety of cancers including, but not limited to: carcinoma such as bladder,
breast, colon,
kidney, liver, lung, including small cell lung cancer, esophagus, gall-
bladder, ovary,
pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous
cell carcinoma;
hematopoietic tumors of lymphoid lineage including leukaemia, acute
lymphocitic
leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma,
Hodgkin's
lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma;
hematopoietic tumors of myeloid lineage, including acute and chronic
myelogenous
leukemias, myelodysplastic syndrome and promyelocytic leukaemia; tumors of
mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the
central and peripheral nervous system, including astrocytoma neuroblastoma,
glioma and
schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma,
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
3
osteosarcoma, xeroderma pigmentosum, keratoxanthoma, , thyroid follicular
cancer and
Kaposi's sarcoma.
Due to the key role of cdks in the regulation of cellular proliferation, these
pyrazole
derivatives are also useful in the treatment of a variety of cell
proliferative disorders such
as, for example, benign prostate hyperplasia, familial adenomatosis polyposis,
neurofibromatosis, psoriasis, vascular smooth cell proliferation associated
with
atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-
surgical stenosis
and restenosis.
The compounds of the invention may be useful in treatment of Alzheimer's
disease, as
io suggested by the fact that cdk5 is involved in the phosphorylation of tau
protein Q.
Biochem. 117,741-749,1995).
The compounds of this invention, as modulators of apoptosis, may also be
useful in the
treatment of cancer, viral infections, prevention of AIDS development in HIV-
infected
individuals, autoimmune diseases and neurodegenerative disorders.
The compounds of this invention may be useful in inhibiting tumor angiogenesis
and
metastasis, as well as in the treatment of organ transplant rejection and host
versus graft
disease.
The compounds of the invention may also act as inhibitor of other protein
kinases, e.g.,
protein kinase C in different isoforms, Met, PAK-4, PAK-5, ZC-1, STLK-2, DDR-
2,
Aurora 1, Aurora 2, Bub-1, PLK, Chkl, Chk2, HER2, raft, MEK1, MAPK, EGF-R,
PDGF-R, FGF-R, IGF-R, P13K, weel kinase, Src, Abl, Akt, MAPK, ILK, MK-2, IKK-
2,
Cdc7, Nek, and thus be effective in the treatment of diseases associated with
other protein
kinases.
The compounds of the invention are also useful in the treatment and prevention
of
radiotherapy-induced or chemotherapy-induced alopecia.
Accordingly, the present invention provides a method for treating cell
proliferative
disorders caused by and/or associated with an altered cell cycle dependent
kinase activity,
by administering to a mammal in need thereof an effective amount of a pyrazole
derivative
represented by formula (la) or (lb)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
4
N N ,N N
R ~NH R NH
CH3
N CH3 N
OLR (Ia) (Ib)
i O R1
wherein
R is a group -CORa, -CONHRa or -CONWRb wherein Ra and Rb are, each
independently,
hydrogen or an optionally substituted group selected from straight or branched
Cl-C6 alkyl,
C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or;
together with the
nitrogen atom to which they are bonded, Ra and Rb may form an optionally
substituted 5 or
6 membered heterocycle optionally containing one additional heteroatom or
heteroatomic
group selected among N, NH, 0 or S;
Rl is selected from the group consisting of:
a) straight or branched C3-C4 alkyl;
b) cycloalkyl, cycloalkyl-alkyl or alkyl-cycloalkyl wherein the cycloalkyl
moiety
comprises any C3-C6 cycloalkyl group and wherein the alkyl moiety comprises
any straight
or branched Cl-C4 alkyl group:
c) 3-methylthienyl-2-yl; 2-thienyl; phenyl; 2,6-difluorophenyl; 4-
(aminosulfonyl)phenyl; 4-(dimethylaminomethyl)phenyl; 4-(4-
methylpiperazinyl)methyl-
phenyl;
d) a group of formula (Ila) or (11b):
-X Y N
(IIa) (Ilb)
wherein, in formula (IIa), the cycle represents a 5 to 7 membered heterocyclic
ring wherin
X, directly linked to the rest of the molecule, represents a carbon or
nitrogen atom; Y is a
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
carbon, nitrogen, oxygen or sulfur atom or it is an NH group, provided that at
least one of
X and Y is other than a carbon atom; Re is, independently from each other and
in any one
of the free positions of the heterocyclic ring of formula (IIa), a halogen
atom or hydroxy
group or it is an optionally substituted group selected from straight or
branched Cl-C6
5 alkyl, C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl,
amino,
aminocarbonyl, carboxy, oxo (=0), alkoxycarbonyl, alkylcarbonyl or
arylcarbonyl; and n
is 0 or an integer from 1 to 4;
e) a group of formula (11c) or (IId):
d Re
/ _Q
It'd
(IIc) (Ild)
wherein Rd, R'd and Re represent, the same or different and independently from
each other,
a hydrogen atom or a straight or branched CI-C6 alkyl optionally substituted
by one or
more groups selected from hydroxy (-OH), aminocarbonyl (-CONH2) or
methylaminocarbonyl (-CONHCH3);
provided that in formula (Ia), when Rl is a group of formula (IIc) and one of
Rd or R'd is a
hydrogen atom whilst the other of Rd or R'd is ethyl or n-butyl, then R is
other than -CORa
with Ra as 3-bromophenyl, benzyl, 4-tert-butylphenyl, 4-tert-
butylphenylmethyl, 4-
fluorophenylmethyl, cyclopropyl or 2-naphthylmethyl;
or a pharmaceutically acceptable salt thereof.
In a preferred embodiment of the method described above, the cell
proliferative disorder is
selected from the group consisting of cancer, Alzheimer's disease, viral
infections, auto-
immune diseases and neurodegenerative disorders.
Specific types of cancer that may be treated include carcinoma, squamous cell
carcinoma,
hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal
origin,
tumors of the central and peripheral nervous system, melanoma, seminoma,
teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid
follicular cancer, and Kaposi's sarcoma.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
6
In another preferred embodiment of the method described above, the cell
proliferative
disorder is selected from the group consisting of benign prostate hyperplasia,
familial
adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell
proliferation
associated with atherosclerosis, pulmonary fibrosis, arthritis,
glomerulonephritis and post-
surgical stenosis and restenosis. In addition, the inventive method provides
tumor
angiogenesis and metastasis inhibition as well as treatment of organ
transplant rejection
and host versus graft disease. The inventive method may also provide cell
cycle inhibition
or cdk/cyclin dependent inhibition.
In addition to the above, the method object of the present invention provides
treatment and
prevention of radiotherapy-induced or chemotherapy-induced alopecia.
The present invention also provides a pyrazole derivative represented by
formula (Ia) or
(m)
RAN j \NH iN N
R NH
CH3
N CH3
N -i~ O RI RI
wherein
R is a group -CORa, -CONHRa or -CONRaRb wherein Ra and Rb are, each
independently,
hydrogen or an optionally substituted group selected from straight or branched
Cl-C6 alkyl,
C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or;
together with the
nitrogen atom to which they are bonded, Ra and Rb may form an optionally
substituted 5 or
6 membered heterocycle optionally containing one additional heteroatom or
heteroatomic
group selected among N, NH, 0 or S;
Rl is selected from the group consisting of:
a) straight or branched C3-C4 alkyl;
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
7
b) cycloalkyl, cycloalkyl-alkyl or alkyl-cycloalkyl wherein the cycloalkyl
moiety
comprises any C3-C6 cycloalkyl group and wherein the alkyl moiety comprises
any straight
or branched Cl-C4 alkyl group:
c) 3-methylthienyl-2-yl; 2-thienyl; phenyl; 2,6-difluorophenyl; 4-
(aminosulfonyl)phenyl; 4-(dimethylaminomethyl)phenyl; 4-(4-
methylpiperazinyl)methyl-
phenyl;
d) a group of formula (IIa) or (IIb):
(--,)/(RO)n
-x Y N
(IIa) (Ilb)
wherein, in formula (IIa), the cycle represents a 5 to 7 membered heterocyclic
ring wherin
X, directly linked to the rest of the molecule, represents a carbon or
nitrogen atom; Y is a
carbon, nitrogen, oxygen or sulfur atom or it is an NH group, provided that
at, least one of
X and Y is other than a carbon atom; R is, independently from each other and
in any one
of the free positions of the heterocyclic ring of formula (IIa), a halogen
atom or hydroxy
group or it is an optionally substituted group selected from straight or
branched C1-C6
alkyl, C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl,
amino,
aminocarbonyl, carboxy, oxo (=O), alkoxycarbonyl, alkylcarbonyl or
arylcarbonyl; and n
is 0 or an integer from 1 to 4;
e) a group of formula (Rc) or (11d):
d RO
-N -0
Rld
(Ilc) (Ild)
wherein Rd, R'd and R represent, the same or different and independently from
each other,
a hydrogen atom or a straight or branched C1-C6 alkyl optionally substituted
by one or
more groups selected from hydroxy (-OH), aminocarbonyl (-CONH2) or
methylaminocarbonyl (-CONHCH3);
CA 02508069 2011-01-28
51522-35
8
provided that in formula (la), when R, is a group of formula (Ilc) and one of
Rd or
R'd is a hydrogen atom whilst the other of Rd or Rd is ethyl or n-butyl, then
R is
other than -CORa with Ra as 3-bromophenyl, benzyl, 4-tert-butylphenyl, 4-tert-
butylphenylmethyl, 4-fluorophenylmethyl, cyclopropyl or 2-naphthylmethyl;
or a pharmaceutically acceptable salt thereof.
The present invention further provides a compound represented by
formula (la) or (lb)
H H
N N N N
R' ~NH R' II
NH
CH3
N CH3 N
O R (Ia) R (Ib)
t O t
wherein
R is a group -CORa, -CONHRa or -CONRaRb wherein Ra and Rb are,
each independently, hydrogen or an optionally substituted group selected from
straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, aryl, arylalkyl,
heterocyclyl or
heterocyclylalkyl or; together with the nitrogen atom to which they are
bonded, Ra
and Rb may form an optionally substituted 5 or 6 membered heterocycle
optionally
containing one additional heteroatom or heteroatomic group selected among N,
NH, 0 or S; and
R1 is selected from the group consisting of
NH N-Rc
tert-butyl, and O
-01
wherein Rc is, a halogen atom or hydroxygroup or it is an optionally
substituted group selected from straight or branched C,-C6 alkyl, C3-C6
cycloalkyl,
aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, amino, aminocarbonyl,
carboxy,
oxo (=O), alkoxycarbonyl, alkylcarbonyl or arylcarbonyl;
CA 02508069 2011-11-09
51522-35
8a
or a pharmaceutically acceptable salt thereof.
The present invention also includes methods for the synthesis of the pyrazole
derivatives
represented by formulae (la) or (lb) that, unless otherwise provided, may be
conveniently
grouped and defined as compounds of formula (I). Pharmaceutical compositions
comprising the pyrazole derivatives of formula (I) are also included in the
present
invention.
A more complete appreciation of the invention and many of the attendant
advantages
thereof will be readily obtained as the same becomes better understood by
reference to
the following detailed description.
DETAILED DESCRIPTION OF THE INVENTION
Several heterocyclic compounds are known in the art as protein kinase
inhibitors. As an
example, 2-carboxamido-pyrazoles and 2-ureido-pyrazoles, and derivatives
thereof, have
been disclosed as protein kinase inhibitors in the international patent
applications
WO 01/12189, WO 01/12188, WO 02/48114 and WO 02/70515, all in the name of the
applicant itself.
Fused bicyclic compounds comprising pyrazole moieties and possessing kinase
inhibitory
activity have been also disclosed in WO 00/69846 and WO 02/12242 as well as in
WO 03/028720 (PCT/EP02/10534 claiming priority from US patent application
No. 09/962162 of September 26, 2001) and copending PCT/EP03/04862 (claiming
priority
from US patent application 60/381092 of May 17, 2002), all in the name of the
applicant
itself.
The compounds object of the present invention fall within the scope of the
general formula
of the aforementioned WO 02/12242, but are not specifically exemplified
therein.
Unless otherwise specified, when referring to the compounds of formula (I) per
se as well
as to any pharmaceutical composition thereof or to any therapeutic treatment
comprising
them, the present invention includes all of the hydrates, solvates, complexes,
metabolites
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
9
and prodrugs of the compounds of this invention. Prodrugs are any covalently
bonded
compounds, which release the active parent drug according to formula (1) in
vivo.
A metabolite of a compound of formula (1) is any compound into which this same
compound of formula (1) is converted, in vivo, for instance upon
administration to a
mammal in need thereof.
Typically, without however representing a limiting example, upon
administration of a
compound of formula (1), this same derivative may be converted into a variety
of
compounds, for instance including more soluble derivatives like hydroxylated
derivatives,
which are easy to be excreted. Hence, depending upon the metabolic pathway
thus
occurring, any of these hydroxylated derivatives may be regarded as a
metabolite of the
compounds of formula (1).
If a chiral center or another form of an isomeric center is present in a
compound of the
present invention, all forms of such isomer or isomers, including enantiomers
and
diastereomers, are intended to be covered herein. Compounds containing a
chiral center
may be used as a racemic mixture, an enantiomerically enriched mixture, or the
racemic
mixture may be separated using well-known techniques and an individual
enantiomer may
be used alone. In cases in which compounds have unsaturated carbon-carbon
double
bonds, both the cis (Z) and trans (E) isomers are within the scope of this
invention. In cases
wherein compounds may exist in tautomeric forms, such as keto-enol tautomers,
each
tautomeric form is contemplated as being included within this invention
whether existing
in equilibrium or predominantly in one form.
In the present description, unless otherwise specified, with the term straight
or branched
Cl-C6 alkyl, hence comprehensive of Cl-C4 alkyl, we intend any of the groups
such as, for
instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
sec-butyl, n-
pentyl, n-hexyl, and the like.
With the term C3-C6 cycloalkyl we intend, unless otherwise provided, a
cycloaliphatic ring
such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term aryl includes carbocyclic or heterocyclic hydrocarbons with from 1 to
2 ring
moieties, either fused or linked to each other by single bonds, wherein at
least one of the
rings is aromatic; if present, any aromatic heterocyclic hydrocarbon also
referred to as
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
heteroaryl group, comprises a 5 to 6 membered ring with from 1 to 3
heteroatoms or
heteroatomic groups selected among N, NH, 0 or S.
Examples of aryl groups according to the invention are, for instance, phenyl,
biphenyl, a-
or 0-naphthyl, dihydronaphthyl, thienyl, benzothienyl, furyl, benzofuranyl,
pyrrolyl,
5 imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl,
pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl, indolyl, isoindolyl, purinyl, quinolyl, isoquinolyl,
dihydroquinolinyl, quinoxalinyl, benzodioxolyl, indanyl, indenyl, triazolyl,
and the like.
Unless otherwise specified, the term heterocycle or heterocyclyl includes 5 to
6 membered
saturated, partly unsaturated or fully unsaturated heterocycles with from I to
3 heteroatoms
10 or heteroatomic groups selected among N, NH, 0 or S.
Apart from the fully unsaturated heterocycles, previously referred to as
aromatic
heterocycles and encompassed by the term aryl, examples of saturated or partly
unsaturated heterocycles according to the invention are, for instance, pyran,
pyrrolidine,
pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline,
thiazolidine,
dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine,
morpholine and the
like.
When referring to the compounds of the invention wherein Rl is grouped under
(b), Rl
itself may represent a given cycloalkyl group, for instance cyclopropyl; a
given cycloalkyl-
alkyl group, for instance cyclopropylmethyl; or even a given alkyl-cycloalkyl
group, for
instance methylcyclopropyl; all of which have the following formulae:
H3
(~A (-'~V cycloalkyl cycloalkyl.-alkyl alkyl-cycloalkyl
When referring to the compounds of the invention wherein Rl is a group of
formula (IIa),
the 5 to 7 membered heterocyclic ring is directly linked to the rest of the
molecule through
the X atom, as follows:
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
11
iN NRN N N
R R NH
CH3
CH3 (la) N (Ib)
N
O X O X
YI Y
Examples of these 5 to 7 membered heterocycles include any 5 to 6 membered
heterocycle
among those already reported and, additionally, 7 membered heterocycles such
as, for
instance, azepine, diazepine, oxazepine and the like.
Any Rc, if present, is at any one of the free positions of the heterocyclic
ring of formula
(Ila) by replacement of a hydrogen atom.
When referring to the compounds of the invention wherein Rl is a group of
formula (llc)
or (11d), ureido and carbamate derivatives may be thus identified, having the
following
sub-formulae:
N/ N
Rr d /Ra
O i O O
Rd
According to the present invention and unless otherwise provided, any of the
above Ra, Rb
and R groups may be optionally substituted, in any of their free positions,
by one or more
groups, for instance 1 to 6 groups, independently selected from: halogen,
nitro, oxo groups
(=0), cyano, alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl,
alkynyl,
hydroxyalkyl, aryl, arylalkyl, heterocyclyl, cycloalkyl, hydroxy, alkoxy,
aryloxy,
heterocyclyloxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy,
cycloalkenyloxy,
alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl,
cycloalkyloxycarbonyl,
amino, ureido, alkylamino, dialkylamino, arylamino, diarylamino, formylamino,
alkylcarbonylamino, arylcarbonylamino, heterocyclylcarbonylamino,
alkoxycarbonylamino, alkoxyimino, alkylsulfonylamino, arylsulfonylamino,
formyl,
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
12
alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl,
aminocarbonyl,
alkylaminocarbonyl, dialkylaminocarbonyl, alkylsulfonyl, arylsulfonyl,
aminosulfonyl,
alkylaminosulfonyl, dialkylaminosulfonyl, arylthio and alkylthio.
In this respect, with the term halogen atom we intend a fluorine, chlorine,
bromine or
iodine atom.
With the term alkenyl or alkynyl we intend any of the aforementioned straight
or branched
C2-C6 alkyl groups further bearing a double or triple bond. Non limiting
examples of
alkenyl or alkynyl groups of the invention are, for instance, vinyl, allyl, 1-
propenyl,
isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1-hexenyl, ethynyl,
2-propynyl,
4-pentynyl, and the like.
With the term polyfluorinated alkyl or alkoxy we intend any of the above
straight or
branched Cl-C6 alkyl or alkoxy groups which are substituted by more than one
fluorine
atom such as, for instance, trifluoromethyl, trifluoroethyl, 1,1,1,3,3,3-
hexafluoropropyl,
trifluoromethoxy and the like.
With the term alkoxy, aryloxy, heterocyclyloxy and derivatives thereof we
intend any of
the above alkyl, aryl or heterocyclyl groups linked to the rest of the
molecule through a
oxygen atom (-0-).
From all of the above, it is clear to the skilled person that any group which
name is a
composite name such as, for instance, cycloalkylalkyl, arylalkyl,
heterocyclylalkyl, alkoxy,
alkylthio, aryloxy, arylalkyloxy, alkylcarbonyloxy, arylalkyl,
heterocyclylalkyl and the
like, have to be intended as conventionally construed by the parts from which
they derive.
As an example, a group such as heterocyclylalkyloxy is an alkoxy group, e.g.
alkyloxy,
wherein the alkyl moiety is further substituted by a heterocyclyl group, and
wherein alkyl
and heterocyclyl are as above defined.
Pharmaceutically acceptable salts of the compounds of formula (I) include the
acid
addition salts with inorganic or organic acids, e.g., nitric, hydrochloric,
hydrobromic,
sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic,
glycolic, lactic, oxalic,
malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic,
methanesulphonic,
isethionic and salicylic acid. Preferably, the acid addition salt of the
compounds of the
invention is selected between the hydrochloride or mesylate salt.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
13
Pharmaceutically acceptable salts of the compounds of formula (1) also include
the salts
with inorganic or organic bases, e.g., alkali or alkaline-earth metals,
especially sodium,
potassium, calcium or magnesium hydroxides, carbonates or bicarbonates,
acyclic or cyclic
amines, preferably methylamine, ethylamine, diethylamine, triethylamine,
piperidine and
the like.
A first class of preferred compounds of formula (Ia) or (lb) is represented by
the
derivatives wherein R is a group -CORa, Ra is as above defined and Rl is tert-
butyl.
Another class of preferred compounds of formula (Ia) or (lb) is represented by
the
derivatives wherein R is a group -CONBRa, Ra is as above defined and Rl is
tert-butyl.
Another class of preferred compounds of formula (la) or (lb) is represented by
the
derivatives wherein R is a group -CONRaRb, Ra and Rb are as above defined and
Rl is tert-
butyl.
Another class of preferred compounds of formula (Ia) or (Ib) is represented by
the
derivatives wherein R is as above defined and Rl is a group of formula (IIa)
selected from:
O
NH N- R
wherein R has the above reported meanings.
Another class of preferred compounds of formula (la) or (Ib) is represented by
the
derivatives wherein R is as above defined and Rl is a group of formula (IIa)
selected from:
-N - NH - \ N- Re
-N\ J N~~1N`Rc
wherein n and R have the above reported meanings.
Particularly preferred, within the above classes, are the compounds of formula
(la) wherein
R is a group -COR with Ra as 4-fluorophenyl or cyclobutyl, and Rl is as
defined in the
general formula.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
14
Also particularly preferred are the compounds of formula (la) wherein R is as
defined in
the general formula, and Rl is a group selected from tert-butyl, 1-methyl-
piperidyl-4-yl, 1-
methyl-piperazinyl-4-yl, 2-(R,S)-tetrahydrofuranyl-2-yl, 2-(R)-
tetrahydrofuranyl-2-yl or 2-
(S)-tetrahydrofuranyl-2-yl.
For a general reference to any specific compound of formula (1) of the
invention,
optionally in the form of a pharmaceutically acceptable salt, see the
experimental section.
As formerly indicated, a further object of the present invention is
represented by the
process for preparing the compounds of formula (1).
Therefore, the compounds of formula (I) and the pharmaceutically acceptable
salts may be
obtained by a process comprising:
a) reacting a compound of formula (IIIa) or (IIIb)
ZX (IIIa) (Illb)
' 5~ H2N COOH H2N COOH
with acrylonitrile so as to obtain the corresponding derivative of formula
(Na) or (Nb)
NC-,'/1~H COOH NC,,//'--H Y COOH
(IVa) (IVb)
b) protecting the amino group of the compound of formula (Na) or (Nb) so as to
obtain
the corresponding derivative of formula (Va) or (Vb) 'ZVI' NC-,',/'--~N COOH
NC'~,,\` i COOH
Q (Va) Q (Vb)
wherein Q is a suitable amino protecting group;
c) reacting the compound of formula (Va) or (Vb) with a suitable alkylating
agent so as to
obtain the corresponding ester derivative of formula (VIa) or (VIb)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
V
NC,,,,Z'~i COOAIk NC,,_,-~~N COOAIk
Q (Via) Q (Vlb)
wherein Alk stands for a suitable Cl-C4 alkyl group;
d) reacting the compound of formula (VIa) or (VIb) with sodium hydride (NaH)
so as to
obtain the corresponding derivative of formula (Vila) or (VIIb)
Q~ O Q~ O
N
(Vila) N (Vllb)
L L
5 CN CN
e) reacting the compound of formula (VIIa) or (VIIb) with hydrazine hydrate so
as to
obtain the compound of formula (ViIIa) or (VIIIb)
Q-, N k-- \ Q-'N -N
NH NH
(Villa) NH2 (Vlllb) NH2
f) reacting the compound of formula (VIIIa) or (VIIIb) with ethyl
chloroformate so as to
10 obtain the derivative of formula (IXa) or (IXb), each one in any of the two
regioisomeric
forms
Q-'-N N
-COOEt COOEt
N N (lXa) (lXbkRN
NH2 NH2
and reacting the compounds of formula (I(a) or (IXb) according to any one of
the
alternative steps (g. 1), (g.2) or (g.3)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
16
g.1) with a compound of formula (X)
RaCO-Z (X)
wherein Ra is as above defined and Z is a halogen atom, so as to obtain the
compound of
formula (XIa) or (Xlb)
Q-, Q~ rN COOEt COOEt
N
(XIa) (XIb)
HNC HNC
R R
wherein R is a group -CORa;
g.2) with a compound of formula (XII)
Ra-NCO (XII)
wherein Ra is as above defined so as to obtain the compound of the formula
(XIa) or (XIb)
wherein R is a group -CONHRa; or
g.3) with a suitable amine of formula (XIII) in the presence of triphosgene or
of a suitable
chloroformate
}f aRb (XIII)
wherein Ra and Rb are as above defined, so as to obtain the compound of
formula (XIa) or
(XIb) wherein R is a group -CONRaRb;
h) deprotecting the amino group of the compound of formula (XIa) or (Xlb)
prepared
according to any one of steps from (g.l) to (g.3), so as to obtain the
corresponding
derivative of formula (XIVa) or (XTVb)
HN COOEt HN N COOEt
V N
(XIVa) (XIVb)
HNC HN.
R R
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
17
wherein R has the above reported meanings; and reacting the compound of
formula (XIVa)
or (XIVb) according to any one of the alternative steps (i.1), (i.2), (i.3) or
(i.4)
i.1) with an acyl halide derivative of formula (XV)
Rl-COZ (XV)
wherein Rl is as set forth in formula (Ia) or (Ib) under groups (a), (b), (c),
(IIa) with X as a
carbon atom and (IIb), and Z is a halogen atom, so as to obtain a compound of
formula
(XVIa) or (XVIb)
O O
)--N HN k(4
R~ COOEt RI COOEt
NH NH
(XVIa) (XVIbHN. HNC
R R
wherein R and Rl are as above defined;
i.2) with a 5 to 7 membered heterocyclic compound of formula (XVII) or a
suitable amine
of formula (XVIII), in the presence of triphosgene
x Y
\ y (XVII) HN(Rd)R'd (XVIII)
wherein X is NH and Y, R , n, Rd and Rd have the above reported meanings, so
as to
obtain the corresponding compounds of formula (XVIa) or (XVIb) wherein R is as
above
defined and Rl is either a group of formula (Ha) with X as a nitrogen atom and
R, Y, R
and n as above defined, or of formula (IIc) wherein Rd and R'd are as above
defined;
i.3) with a carboxylic acid of formula (XIX) in the presence of a suitable
condensing agent
Ri-000H (XIX)
so as to obtain a compound of formula (XVIa) or (XVIb) wherein Rl is as set
forth in
formula (la) or (Ib) under groups (a), (b), (c) or it is a group of formula
(IIa) with X as a
carbon atom or of formula (Ilb), and R, Y, R and n are as above defined;
i.4) with a compound of formula (XX)
Ri-COZ (XX)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
18
wherein R1 is a group of formula (IId) and Z is a chlorine or bromine atom, so
as to obtain
the a compound of formula (XVIa) or (XVIb) wherein R is as defined above and
Rl is a
group of formula (11d); and
j) reacting the compound of formula (XVIa) or (XVIb) prepared according to any
one of
steps from (i. 1) to (i.4) under basic conditions, so as to obtain the
corresponding derivative
of formula (la) or (Ib) wherein R and Ri are as above defined; and,
optionally,
k) converting them into other compounds of formula (la) or (Ib), respectively,
and/or into
pharmaceutically acceptable salts thereof.
The above process is an analogy process which can be carried out according to
methods
well known in the art.
From all of the above, it is clear to the person skilled in the art that if a
compound of
formula (Ia) or (Ib), prepared according to the above process, is obtained as
a mixture of
isomers, their separation into the single isomers of formula (la) or (Ib),
carried out
according to conventional techniques, is still within the scope of the present
invention.
Likewise, the conversion into the free compound (Ia) or (Ib) of a
corresponding salt
thereof, according to well-known methods, is still within the scope of the
invention.
According to step (a) of the process, a compound of formula (IIIa) or (1IIb)
is reacted with
acrylonitrile in the presence of a suitable base, for instance sodium
hydroxide. The reaction
is preferably carried out in water at a temperature ranging from about -10 C
to room
temperature.
According to step (b) of the process, the amino group of the compound of
formula (Na) or
(IVb) is protected according to conventional methods, for instance with tert-
butoxycarbonyl anhydride (Boc2O) and in the presence of a suitable solvent
such as
acetonitrile or dichloromethane, so as to get the corresponding derivative of
formula (Va)
or (Vb) wherein the amino protecting group Q just represents tert-
butoxycarbonyl (boc).
According to step (c) of the process, the carboxy group of the compound of
formula (Va)
or (Vb) is converted into the corresponding alkyl ester derivative, for
instance by operating
in the presence of a suitable alkyl halide, for instance methyl iodide.
The reaction is carried out in the presence of a suitable solvent such as
dimethylformamide
and under basic conditions, for instance by using sodium or potassium
hydrogencarbonate.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
19
According to step (d) of the process, the compound of formula (Via) or (VIb)
is converted
into the corresponding cyclic derivative of formula (VIIa) or (VIIb) through
reaction with
sodium hydride. The reaction is carried out in the presence of a suitable
solvent such as
dioxane or tetrahydrofuran at refluxing temperature.
According to step (e) of the process, the compound of formula (Vila) or (VIIb)
is reacted
with hydrazine hydrate, preferably with an excess of hydrazine monohydrated,
for instance
up to 10 equivalents, in the presence of a suitable solvent such as
halogenated
hydrocarbons, lower alcohols or admixtures thereof. The reaction is preferably
carried out
in the presence of ethanol, by adding hydrazine to a solution of the compound
of formula
(Vila) or (VIIb) and under stirring for a suitable time, for instance about 48
hours, at the
temperature ranging from about 20 C to about 70 C. Preferably, the above
reaction is
carried out also in the presence of glacial acetic acid.
According to step (f) of the process, the compound of formula (VIIIa) or
(VIIIb) is reacted
with ethyl chloroformate so as to get the corresponding derivative of formula
(IXa) or
(IXb). The reaction is carried out according to well-known operative
conditions, in the
presence of a suitable base, for instance diisopropylethylamine, and of a
suitable solvent
such as tetrahydrofuran.
Clearly, the ethoxycarbonyl group may be bound to any one of the pyrazole
nitrogen atoms
of both compounds of formula (VIIIa) and (VIIib) so as to give rise to the
following
regioisomers of formula (IXa) or (IXb)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
COOEt
Q~'N -N Q-~.N Q-'N N
COOEt
COOEt N (IXa)
NH2 NH2 NH2
COOEt
Q~N \ Q~'N N COOEt
`.1
N'COOEt N N
(IXb)
NH2 NH2 NH2
E n t his respect, each couple of regioisomers of formula (IXa) or (IXb) may
be conveniently
separated according to well-known methods, for instance under chromatographic
conditions, and each regioisomer so isolated subsequently worked out. In the
alternative,
5 the mixture of regioisomers can be treated as such in the subsequent steps
of the process,
without providing any separation.
In fact, as the ethoxycarbonyl group leading to two distinct regioisomers is
finally removed
at the end of the process, it is clear to the skilled person that both the
above pathways can
be carried out for preparing the compounds of formula (Ia) or (lb) of the
invention.
10 Preferably, however, the process is carried out by first separating and
isolating the
regioisomers of formula (IXa) or (IXb) from their mixture, as reported in the
working
examples, and by subsequently reacting them to the desired compounds.
According to step (g.1) of the process, the compound of formula (IXa) or (IXb)
is reacted
with a suitable derivative of formula (X) wherein Z represents a halogen atom,
preferably
15 chlorine or bromine.
Typically, the compound of formula (IXa) or (IXb) is dissolved in a suitable
solvent such
as dichloromethane, dimethylformamide, tetrahydrofuran, dioxane or the like,
and a
suitable base such as triethylamine, diisopropylethylamine, sodium carbonate
or the like is
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
21
added. The compound of formula (X) is then added and the mixture stirred for a
time of
about 2 to about 15 hours, at a temperature ranging from about 20 C to about
80 C.
A suitable catalyst such as dimethylamino-pyridine may be optionally used.
According to step (g.2) of the process, the compound of formula (IXa) or (IXb)
is reacted
with an isocyanate derivative of formula (XII), by operating substantially as
set forth in
step (g. 1) of the process, except that the base may not be required.
According to step (g.3) of the process, the compound of formula (IXa) or (IXb)
is reacted
with an amine of formula (XIII) in the presence of triphosgene or of a
suitable
chloroformate, for instance 4-nitrophenyl chloroformate, so as to get the
corresponding
ureido derivative. The reaction is carried out in tetrahydrofuran (TI F) or in
a suitable
halogenated hydrocarbon, preferably dichloromethane (DCM), and in the presence
of a
suitable amine such as diisopropylethylamine or triethylamine at a temperature
ranging
from about -70 C to room temperature.
According to step (h) of the process, the protected amino group in formula
(XIa) or (XIb)
is deprotected under well-known operative conditions, for instance under
acidic conditions
in the presence of trifluoroacetic or hydrochloric acid.
The compound of formula (XIa) or (XIb) is thus suspended in a suitable solvent
such as
dichloromethane or dioxane, and treated with a concentrated solution of the
selected acid.
Alternatively, commercially available solutions of gaseous hydrogen chloride
dissolved in
dioxane (4 M HCl) may be advantageously employed. The mixture is then stirred
for a
time of about 2 hours to about 15 hours at a temperature ranging from about 20
C to about
40 C.
According to any one of steps (i.1), (i.2), (i.3) or (i.4) of the process, the
compound of
formula (XIVa) or (X[Vb) is further reacted with a suitable derivative so as
to obtain the
corresponding carboxamido, ureido or carbamate derivative of formula (XVIa) or
(XVlb).
Step (i.1) is carried out with an acyl halide, preferably chloride, of formula
(XV) in a
suitable solvent such as dichloromethane and under basic conditions, for
instance in the
presence of a suitable amine such as diisopropylethylamine.
The reaction allows to obtain carboxamido derivatives of formula (XVIa) or
(XVIb)
wherein Rl is as defined in formula (1) under groups from (a) to (c), (IIa)
with X as a
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
22
carbon atom and (IIb); from the above, it is clear to the skilled person that
the atom of the
Rl group which is directly linked to the carbonyl moiety of formula (XVIa) or
(XVIb) is a
carbon atom.
Step (i.2) is carried out with a heterocyclic derivative of formula (XVII) or
of an amine of
formula (XVIII), in the presence of triphosgene, substantially as described
under step (g.3)
of the process.
In this respect, step (i.2) allows to obtain ureido derivatives of formula
(XVIa) or (XVIb)
wherein Rl is a group of formula (IIa) with X as a nitrogen atom or of formula
(IIc) and
wherein Y, R , n, Rd and R'd are as above defined.
Likewise, the condensation of step (i.3) is carried out with a carboxylic acid
derivative of
formula (XIX), in the presence of a suitable condensing agent such as, for
instance,
dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide
(EDC)
or O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU), and by
operating
according to well-known methods for preparing carboxamido derivatives.
According to step (i.4) of the process, the compound of formula (XIVa) or
(XIVb) is
reacted with a suitable derivative of formula (XX) wherein Rl is a group of
formula (IId)
and R is as set forth in formula (la) or (Ib), so as to obtain the
corresponding carbamate
derivatives of formula (XVIa) or (XVIb).
In this respect, the compound of formula (XIVa) or (XIVb) is dissolved in a
suitable
solvent such as dichloromethane, dimethylformamide, tetrahydrofuran, dioxane
or the like,
and a suitable base such as triethylamine, diisopropylethylamine, sodium
carbonate or the
like is added therein. The compound of general formula (XX) is then added and
the
mixture stirred for a time of about 2 hours to about 15 hours, at a
temperature ranging from
about 20 C to about 80 C. According to a preferred embodiment, a suitable
catalyst such
as dimethylamino pyridine may be optionally used.
According to step (j) of the process, the compound of formula (XVIa) or (XVIb)
being
obtained in any one of steps from (i. 1) to (i.4) is reacted with a suitable
base, for instance
triethylamine, and in the presence of a suitable solvent such as methanol or
ethanol so as to
obtain the desired compound of formula (Ia) or (Ib).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
23
Finally, as per step (k) of the process, these latter compounds (Ia) or (Ib)
may be optionally
converted into pharmaceutically acceptable salts as formerly reported and by
working
according to conventional methods or, alternatively, may converted into
additional
compounds of formula (Ia) or (Ib).
Just as a non limiting example, compounds of formula (Ia) or (lb) bearing a
carboxyester
function may be converted into a variety of derivatives according to methods
well known
in the art to convert carboxyester groups into carboxamides, N-substituted
carboxamides,
N,N-disubstituted carboxamides, carboxylic acids, and the like.
The operative conditions are those widely known in the art and may comprise,
for instance
in the conversion of a carboxyester group into a carboxamide group, the
reaction with
ammonia or ammonium hydroxide in the presence of a suitable solvent such as a
lower
alcohol, dimethylformamide or mixtures thereof; preferably the reaction is
carried out with
ammonium hydroxide in a methanol/dimethylformamide mixture, at a temperature
ranging
from about 50 C to about 100 C.
Analogous operative conditions apply in the preparation of N-substituted or
N,N-
disubstituted carboxamides wherein a suitable primary or secondary amine is
used in place
of ammonia or ammonium hydroxide.
Likewise, carboxyester groups may be converted into carboxylic acid
derivatives through
basic or acidic hydrolysis conditions, widely known in the art.
As an additional example, compounds of formula (Ia) or (Ib) bearing an amino
function
may be easily converted into the corresponding carboxamido or ureido
derivatives.
From all of the above it is clear to the skilled person that according to step
(k) of the
process, any compound of formula (Ia) or (Ib) bearing a functional group which
can be
further derivitized to another functional group, by working according to
methods well
known in the art thus leading to other compounds of formula (Ia) or (lb), has
to be
intended as comprised within the scope of the present invention.
According to any variant of the process for preparing the compounds of formula
(1), the
starting material and any other reactant is known or easily prepared according
to known
methods.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
24
As an example, whilst the starting materials of formula (IIIa) or (IIIb) are
commercially
available, the compounds of formula (X), (XII), (XIII), (XV), (XVII), (XVIII),
(XIX) and
(XX) are known or can be easily prepared according to known methods.
The intermediate compounds of formula (VIIa) or (VIIb) of the process
Q-' O Q~ O
N
(Vlla) N (VIIb)
L L
CN CN
wherein Q represents a suitable nitrogen protecting group, for instance tert-
butoxycarbonyl
(boc), are novel and, hence, respresent a further object of the invention.
As it will be readily appreciated, if the compounds of formula (I) prepared
according to the
process described above are obtained as an admixture of isomers, their
separation into the
single isomers of formula (I), according to conventional techniques, is within
the scope of
the present invention. Conventional techniques for racemate resolution
include, for
instance, partitioned crystallization of diastereoisomeric salt derivatives or
preparative
chiral HPLC.
In addition, it is clear from the above that a given compound of formula (Ia)
or (lb) may be
prepared either by starting from the mixture of the regioisomers of formula
(IXa) or (IXb)
or, alternatively, from each one of the two regioisomers themselves.
When preparing the compounds of formula (I) according to any one of the
aforementioned
process variants, optional functional groups within the starting materials or
the
intermediates thereof and which could give rise to unwanted side reactions,
need to be
properly protected according to conventional techniques. Likewise, the
conversion of these
latter into the free deprotected compounds may be carried out according to
known
procedures.
In addition, the compounds of formula (I) of the invention may be also
prepared according
to combinatorial chemistry techniques widely known in the art, by
accomplishing the
aforementioned reactions between the several intermediates in a serial manner
and by
working under solid-phase-synthesis (SPS) conditions.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
As an example, the compounds of formula (XIa) or (XIb) which are prepared
according to
any one of steps (g. 1), (g.2) or (g.3) can be supported onto a suitable
polymeric resin. More
particularly, the ethoxycarbonyl group in formula (Xia) or (XIb) may be
removed under
basic conditions, for instance in the presence of triethylamine or
diisopropylamine, and the
5 resultant compound anchored to the above supporting resin, through the
pyrazole nitrogen
atom itself
Q''N k~N Resin Q---N kN
Resin
HNC HNC
R R
The supported intermediate thus obtained may be then reacted according to step
(h) and
any one of steps (i. 1), (i.2), (i.3) or (i.4) of the process, so as to obtain
the corresponding
to compound of formula (la) or (Ib) of the invention still supported on the
polymeric resin.
Subsequent resin cleavage, for instance under basic or acidic conditions
according to
known methods, allows to obtain the desired compounds of formula (1a) or (1b).
Clearly, by performing the above reactions of the process in a serial manner,
that is by
following a combinatorial approach for instance as set forth above, several
compounds of
15 formula (la) and (lb) may be thus prepared and collected.
Therefore, it is a further object of the present invention a library of two or
more
compounds of formula (la)
N N
R~ RNH
CH3
N CH3
(la)
O Ri
wherein
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
26
R is a group -CORa, -CONHRa or -CONRaRb wherein Ra and Rb are, each
independently,
hydrogen or an optionally substituted group selected from straight or branched
Cl-C6 alkyl,
C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or;
together with the
nitrogen atom to which they are bonded, Ra and Rb may form an optionally
substituted 5 or
6 membered heterocycle optionally containing one additional heteroatom or
heteroatomic
group selected among N, NH, 0 or S;
Rl is selected from the group consisting of:
a) straight or branched C3-C4 alkyl;
b) cycloalkyl, cycloalkyl-alkyl or alkyl-cycloalkyl wherein the cycloalkyl
moiety
comprises any C3-C6 cycloalkyl group and wherein the alkyl moiety comprises
any straight
or branched Cl-C4 alkyl group:
c) 3-methylthienyl-2-yl; 2-thienyl; phenyl; 2,6-difluorophenyl; 4-
(aminosulfonyl)phenyl; 4-(dimethylaminomethyl)phenyl; 4-(4-
methylpiperazinyl)methyl-
phenyl;
d) a group of formula (Ila) or (11b):
%
-X Y
(IIa) (Ilb)
wherein, in formula (IIa), the cycle represents a 5 to 7 membered heterocyclic
ring wherin
X, directly linked to the rest of the molecule, represents a carbon or
nitrogen atom; Y is a
carbon, nitrogen, oxygen or sulfur atom or it is an NH group, provided that at
least one of
X and Y is other than a carbon atom; R is, independently from each other and
in any one
of the free positions of the heterocyclic ring of formula (Ila), a halogen
atom or hydroxy
group or it is an optionally substituted group selected from straight or
branched Cl-C6
alkyl, C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl,
amino,
aminocarbonyl, carboxy, oxo (=O), alkoxycarbonyl, alkylcarbonyl or
arylcarbonyl; and n
is 0 or an integer from 1 to 4;
e) a group of formula (IIc) or (IId):
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
27
d Re
R -N -O
Rld
(Ilc) (Ild)
wherein e, R'd and Re represent, the same or different and independently from
each other,
a hydrogen atom or a straight or branched Ci-C6 alkyl optionally substituted
by one or
more groups selected from hydroxy (-OH), aminocarbonyl (-CONH2) or
methylaminocarbonyl (-CONHCH3);
provided that in formula (Ia), when Rl is a group of formula (tIc) and one of
e or R'd is a
hydrogen atom whilst the other of Rd or R'd is ethyl or n-butyl, then R is
other than -CORa
with Ra as 3-bromophenyl, benzyl, 4-tert-butylphenyl, 4-tert-
butylphenylmethyl, 4-
fluorophenylmethyl, cyclopropyl or 2-naphthylmethyl;
or a pharmaceutically acceptable salt thereof.
Likewise, it is a further object of the present invention a library of two or
more compounds
of formula (Ib)
iN NN.
R NH
N
(Ib)
O R1
wherein
R is a group -CORa, -CONHRa or -CONRaRb wherein Ra and Rb are, each
independently,
hydrogen or an optionally substituted group selected from straight or branched
Cl-C6 alkyl,
C3-C6 cycloalkkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or;
together with the
nitrogen atom to which they are bonded, Ra and Rb may form an optionally
substituted 5 or
6 membered heterocycle optionally containing one additional heteroatom or
heteroatomic
group selected among N, NH, 0 or S;
RI is selected from the group consisting of
a) straight or branched C3-C4 alkyl;
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
28
b) cycloalkyl, cycloalkyl-alkyl or alkyl-cycloalkyl wherein the cycloalkyl
moiety
comprises any C3-C6 cycloalkyl group and wherein the alkyl moiety comprises
any straight
or branched Cl-C4 alkyl group:
c) 3-methylthienyl-2-yl; 2-thienyl; phenyl; 2,6-difluorophenyl; 4-
(aminosulfonyl)phenyl; 4-(dimethylaminomethyl)phenyl; 4-(4-
methylpiperazinyl)methyl-
phenyl;
d) a group of formula (IIa) or (IIb):
/~ (R )n
-X(\ Y N
(IIa) (IIb)
wherein,in formula (IIa), the cycle represents a 5 to 7 membered heterocyclic
ring wherin
X, directly linked to the rest of the molecule, represents a carbon or
nitrogen atom; Y is a
carbon, nitrogen, oxygen or sulfur atom or it is an NH group, provided that at
least one of
X and Y is other than a carbon atom; R is, independently from each other and
in any one
of the free positions of the heterocyclic ring of formula (IIa), a halogen
atom or hydroxy
group or it is an optionally substituted group selected from straight or
branched Cl-C6
alkyl, C3-C6 cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl,
amino,
aminocarbonyl, carboxy, oxo (=0), alkoxycarbonyl, alkylcarbonyl or
arylcarbonyl; and n
is 0 or an integer from 1 to 4;
e) a group of formula (IIc) or (IId):
R d e
-N -Q
R'd
(IIc) (lid)
wherein Rd, Rd and R represent, the same or different and independently from
each other,
a hydrogen atom or a straight or branched C1-C6 alkyl optionally substituted
by one or
more groups selected from hydroxy (-OH), aminocarbonyl (-CONH2) or
methylaminocarbonyl (-CONHCH3);
or a pharmaceutically acceptable salt thereof.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
29
For a general reference to the above libraries of compounds of formula (1) see
the
experimental section.
From all of the above, it is clear to the skilled person that once a library
of pyrrolo-
pyrazole derivatives is thus prepared, for instance consisting of a few
hundreds or even a
few thousands of compounds of formula (la) or (Ib), the said library can be
very
advantageously used for screening towards given kinases, as formerly reported.
See, for a general reference to libraries of compounds and uses thereof as
tools for
screening biological activities, J. Med. Chem. 1999, 42, 2373-2382; and
Bioorg. Med.
Chem. Lett. 10 (2000), 223-226.
PHARMACOLOGY
The compounds of formula (I) are active as protein kinase inhibitors and are
therefore
useful, for instance, to restrict the unregulated proliferation of tumor
cells.
In therapy, they may be used in the treatment of various tumors, such as those
formerly
reported, as well as in the treatment of other cell proliferative disorders
such as psoriasis,
vascular smooth cell proliferation associated with atherosclerosis and post-
surgical stenosis
and restenosis and in the treatment of Alzheimer's disease.
The inhibiting activity of putative Cdk/Cyclin inhibitors and the potency of
selected
compounds was determined through a method of assay based on the use of the SPA
technology (Amersham Pharmacia Biotech).
The assay consists of the transfer of radioactivity labelled phosphate moiety
by the kinase
to a biotinylated substrate. The resulting 33P-labelled biotinylated product
is allowed to
bind to streptavidin-coated SPA beads (biotin capacity 130 pmol/mg), and light
emitted
was measured in a scintillation counter.
Inhibition assay of Cdk2/Cyclin A activity
Kinase reaction: 4 pM in house biotinylated histone H1 (Sigma # H-5505)
substrate, 10
pM ATP (0.1 microCi P33y-ATP), 4.2 ng Cdk2/Cyclin A complex, inhibitor in a
final
volume of 30 l buffer (TRIS HC1 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2
mg/ml BSA) were added to each well of a 96 U bottom. After 30 min at r.t.
incubation,
reaction was stopped by 100 gl PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 M
ATP, containing I mg SPA beads. Then a volume of 110 t.l is transferred to
Optiplate.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
After 20 min. incubation for substrate capture, 100 l 5M CsCl were added to
allow
statification of beads to the top of the plate and let stand 4 hours before
radioactivity
counting in the Top-Count instrument
IC50 determination: inhibitors were tested at different concentrations ranging
from
5 0.0015 to 10 p.M. Experimental data were analyzed by the computer program
GraphPad
Prizm using the four parameter logistic equation:
y = bottom+(top-bottom)/(1+10A((logIC50-x)* slope))
where x is the logarithm of the inhibitor concentration, y is the response; y
starts at bottom
and goes to top with a sigmoid shape.
10 Ki calculation:
Experimental method: Reaction was carried out in buffer (10 mM Tris, pH 7.5,
10 mM
MgCl2, 0.2 mg/ml BSA, 7.5 mM DTT) containing 3.7 nM enzyme, histone and ATP
(constant ratio of cold/labeled ATP 1/3000). Reaction was stopped with EDTA
and the
substrate captured on phosphomembrane (Multiscreen 96 well plates from
Millipore).
15 After extensive washing, the multiscreen plates are read on a top counter.
Control (time
zero) for each ATP and histone concentrations was measured.
Experimental design: Reaction velocities are measured at different four ATP,
substrate
(histone) and inhibitor concentrations. An 80-point concentration matrix was
designed
around the respective ATP and substrate Km values, and the inhibitor IC50
values (0.3, 1,
20 3, 9 fold the Km or IC50 values). A preliminary time course experiment in
the absence of
inhibitor and at the different ATP and substrate concentrations allow the
selection of a
single endpoint time (10 min) in the linear range of the reaction for the Ki
determination
experiment.
Kinetic parameter estimates: Kinetic parameters were estimated by simultaneous
25 nonlinear least-square regression using [Eq.1] (competitive inhibitor
respect to ATP,
random mechanism) using the complete data set (80 points):
Ym=A=B
V= = [Eq. 1]
a=Ka=Kb+a=Ka=B+a= Kb *,4+,4 =B+a=a =I =(Kb+~)
Ki
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
31
where A=[ATP], B=[Substrate], I=[inhibitor], Vm= maximum velocity, Ka, Kb, Ki
the
dissociation constants of ATP, substrate and inhibitor respectively. a and 0
the
cooperativity factor between substrate and ATP binding and substrate and
inhibitor binding
respectively.
In addition the selected compounds have been characterized on a panel of
ser/threo kinases
strictly related to cell cycle (Cdk2/Cyclin E, Cdkl/cyclin B1, CdkS/p25,
Cdk4/Cyclin Dl),
and also for specificity on MAPK, PKA, EGFR, IGF1-R, Aurora-2 and Akt.
Inhibition assay of Cdk2/Cvclin E activity
Kinase reaction: 10 M in house biotinylated histone Hl (Sigma # H-5505)
substrate, 30
pM ATP (0.3 microCi P33y-ATP), 4 ng GST-Cdk2/Cyclin E complex, inhibitor in a
final
volume of 30 l buffer (TRIS HCI 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2
mg/ml BSA) were added to each well of a 96 U bottom. After 60 min at r.t.
incubation,
reaction was stopped by 100 Id PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 M
ATP, containing I mg SPA beads. Then a volume of 110 l is transferred to
Optiplate.
After 20 min. incubation for substrate capture, 109 l 5M CsCI were added to
allow
statification of beads to the top of the plate and let stand 4 hours before
radioactivity
counting in the Top-Count instrument
IC50 determination: see above
Inhibition assay of Cdkl/Cvclin B1 activity
Kinase reaction: 4 M in house biotinylated histone Hl (Sigma # H-5505)
substrate, 20
M ATP (0.2 microCi P33y-ATP), 3 ng Cdk1/Cyclin B complex, inhibitor in a final
volume of 30 l buffer (TRIS HCl 10 mM pH 7.5, MgCl2 10 mM, DTT 7.5 mM + 0.2
mg/ml BSA) were added to each well of a 96 U bottom. After 20 min at r.t.
incubation,
reaction was stopped by 100 l PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 M
ATP, containing I mg SPA beads. Then a volume of 110 l is transferred to
Optiplate.
After 20 min. incubation for substrate capture, 109 .l 5M CsC1 were added to
allow
statification of beads to the top of the Optiplate and let stand 4 hours
before radioactivity
counting in the Top-Count instrument.
IC50 determination: see above
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
32
Inhibition assay of C05/n25 activity
The inhibition assay of Cdk5/p25 activity was performed according to the
following
protocol.
Kinase reaction: 10 M biotinylated histone Hl (Sigma # H-5505) substrate, 30
M ATP
(0.3 microCi P337-ATP), 15 ng CDK5/p25 complex, inhibitor in a final volume of
30 l
buffer (TRIS HCI 10 mM pH 7.5, MgCl 10 mM, DTT 7.5 mM + 0.2 mg/ml BSA) were
added to each well of a 96 U bottom. After 30 min at r.t. incubation, reaction
was stopped
by 100 l PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 M ATP, containing 1 mg
SPA beads. Then a volume of 110 l is transferred to Optiplate.
1o After 20 min. incubation for substrate capture, 100 l 5M CsCl were added to
allow
statification of beads to the top of the plate and let stand 4 hours before
radioactivity
counting in the Top-Count instrument.
IC50 determination: see above
Inhibition assay of Cdk4/Cyclin Dl activity
Kinase reaction: 0,4 uM M mouse GST-Rb (769-921) (# sc-4112 from Santa Cruz)
substrate, 10 pM ATP (0.5 pCi P33y-ATP), 100 ng of baculovirus expressed GST-
Cdk4/Cyclin D1, suitable concentrations of inhibitor in a final volume of 50
l buffer
(TRIS HCl 10 mM pH 7.5, MgC12 10 mM, 7.5 mM DTT+ 0.2mg/ml BSA) were added to
each well of a 96 U bottom well plate. After 40 min at 37 C incubation,
reaction was
stopped by 20 p1 EDTA 120 mM.
Capture: 60 l were transferred from each well to MultiScreen plate, to allow
substrate
binding to phosphocellulose filter. Plates were then washed 3 times with 150
pl/well PBS
Ca/Mg free and filtered by MultiScreen filtration system.
Detection: filters were allowed to dry at 37 C, then 100 l/well scintillant
were added and
33P labeled Rb fragment was detected by radioactivity counting in the Top-
Count
instrument.
IC50 determination: see above
Inhibition assay of MAPK acti
vity
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
33
Kinase reaction: 10 pM in house biotinylated MBP (Sigma # M-1891) substrate,
15 M
ATP (0.15 microCi P33y-ATP), 30 ng GST-MAPK (Upstate Biothecnology # 14-173),
inhibitor in a final volume of 30 l buffer (TRIS HC110 mM pH 7.5, MgC12 10
mM, DTT
7.5 mM + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 30 min
at r.t.
incubation, reaction was stopped by 100 gl PBS + 32 mM EDTA + 0.1% Triton X-
100 +
500 M ATP, containing 1 mg SPA beads. Then a volume of 110 l is transferred
to
Optiplate.
After 20 min. incubation for substrate capture, 100 l 5M CsCl were added to
allow
statification of beads to the top of the Optiplate and let stand 4 hours
before radioactivity
counting in the Top-Count instrument.
IC50 determination: see above
Inhibition assay of PKA activity
Kinase reaction: 10 M in house biotinylated histone Hl (Sigma # H-5505)
substrate, 10
M ATP (0.2 microM P33y-ATP), 0.45 U PKA (Sigma # 2645), inhibitor in a final
volume
of 30 l buffer (TRIS HCl 10 mM pH 7.5, MgC12 10 mM, DTT 7.5 mM + 0.2 mg/ml
BSA)
were added to each well of a 96 U bottom. After 90 min at r.t. incubation,
reaction was
stopped by 100 l PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 M ATP,
containing
1 mg SPA beads. Then a volume of 110 l is transferred to Optiplate.
After 20 min. incubation for substrate capture, 100 l 5M CsCl were added to
allow
statification of beads to the top of the Optiplate and let stand 4 hours
before radioactivity
counting in the Top-Count instrument.
IC50 determination: see above
Inhibition assay of EGFR activity
Kinase reaction: 10 M in house biotinylated MBP (Sigma # M-1891) substrate, 2
M
ATP (0.04 microCi P33y-ATP), 36 ng insect cell expressed GST-EGFR, inhibitor
in a final
volume of 30 l buffer (Hepes 50 mM pH 7.5, MgC12 3 mM, MnC12 3 mM, DTT 1 mM,
NaVO3 3 M + 0.2 mg/ml BSA) were added to each well of a 96 U bottom. After 20
min at
r.t. incubation, reaction was stopped by 100 gl PBS + 32 mM EDTA + 0.1 %
Triton X-100
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
34
+ 500 M ATP, containing 1 mg SPA beads. Then a volume of 110 l is
transferred to
Optiplate.
After 20 min. incubation for substrate capture, 100 1 5M CsC1 were added to
allow
statification of beads to the top of the Optiplate and let stand 4 hours
before radioactivity
counting in the Top-Count instrument.
IC50 determination: see above
Inhibition assay of IGF1-R activity
The inhibition assay of IGF1-R activity was performed according to the
following
protocol.
Kinase reaction: 10 M biotinylated MBP (Sigma cat. # M-1891) substrate, 0-20
M
inhibitor, 6 M ATP, 1 microCi 33P-ATP, and 22.5 ng GST-IGFI-R (pre-incubated
for 30
min at room temperature with cold 60 M cold ATP) in a final volume of 30 l
buffer (50
mM HEPES pH 7.9, 3 mM MnC12, 1 mM DTT, 3 M NaVO3) were added to each well of
a 96 U bottom well plate. After incubation for 35 min at room temperature, the
reaction
was stopped by addition of 100 l PBS buffer containing 32 mM EDTA, 500 M
cold
ATP, 0.1% Triton X100 and 10mg/ml streptavidin coated SPA beads. After 20 min
incubation, 110 L of suspension were withdrawn and transferred into 96-well
OPTIPLATEs containing 100 l of 5M CsCl. After 4 hours, the plates were read
for 2 min
in a Packard TOP-Count radioactivity reader.
Inhibition assay of Aurora-2 activity
Kinase reaction: 8 M biotinylated peptide (4 repeats of LRRWSLG), 10 M ATP
(0.5
uCi P33y-ATP), 15 ng Aurora2, inhibitor in a final volume of 30 l buffer
(ItEPES 50 mM
pH 7.0, MgC12 10 mM, 1 mM DTT, 0.2 mg/ml BSA, 3 M orthovanadate) were added to
each well of a 96 U bottom well plate. After 30 minutes at room temperature
incubation,
reaction was stopped and biotinylated peptide captured by adding 100 l of
bead
suspension.
Stratification: 100 l of CsC12 5 M were added to each well and let stand 4
hour before
radioactivity was counted in the Top-Count instrument.
IC50 determination: see above
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
Inhibition assay of Cdc7/dbf4 activity
The inhibition assay of Cdc7/dbf4 activity was performed according to the
following
protocol.
The Biotin-MCM2 substrate is trans-phosphorylated by the Cdc7/Dbf4 complex in
the
5 presence of ATP traced with 733-ATP. The phosphorylated Biotin-MCM2
substrate is then
captured by Streptavidin-coated SPA beads and the extent of phosphorylation
evaluated by
f counting.
The inhibition assay of Cdc7/dbf4 activity was performed in 96 wells plate
according to
the following protocol.
10 To each well of the plate were added:
- 10 l substrate (biotinylated MCM2, 6 M final concentration)
- 10 l enzyme (Cdc7/Dbf4, 12.5 nM final concentration)
- 10 l test compound (12 increasing concentrations in the nM to M range to
generate a
dose-response curve)
15 - 10 l of a mixture of cold ATP (10 M final concentration) and radioactive
ATP
(1/2500 molar ratio with cold ATP) was then used to start the reaction which
was
allowed to take place at 37 C.
Substrate, enzyme and ATP were diluted in 50 mM HEPES pH 7.9 containing 15 mM
MgC12, 2 mM DTT, 3 M NaVO3, 2mM glycerophosphate and 0.2mg/ml BSA. The
20 solvent for test compounds also contained 10% DMSO.
After incubation for 20 minutes, the reaction was stopped by adding to each
well 100 l of
PBS pH 7.4 containing 50 mM EDTA, 1 mM cold ATP, 0.1% Triton X100 and 10 mg/ml
streptavidin coated SPA beads.
After 15 minutes of incubation at room temperature to allow the biotinylated
MCM2-
25 streptavidin SPA beads interaction to occur, beads were trapped in a 96
wells filter plate
(Unifilter' GF/B ) using a Packard Cell Harvester (Filtermate), washed with
distilled
water and then counted using a Top Count (Packard).
Counts were blank-subtracted and then the experimental data (each point in
triplicate) were
analyzed for IC50 determination using a non-linear regression analysis (Sigma
Plot).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
36
Given the above inhibition assays, the compounds of formula (1) of the
invention resulted
to possess a remarkable cdk inhibitory activity. See, as an example, the
following
experimental data (IC50) of two representative, compounds of the invention of
formula (Ia)
and (Ib) being tested against Cdk2/Cyclin A:
Compound 1: N-[5-(2,2-dimethylpropanoyl)-6,6-dimethyl-1,4,5,6-
tetrahydropyrrolo[3,4-
c]pyrazol-3-yl]-4-fluorobenzamide (IC50 0.030 M); and
Compound 2: N-[5-(2,2-dimethylpropanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-
c]pyrazol-6-
spirocyclopropan-3-yl]-4-fluorobenzamide (IC50 0.025 M).
Surprisingly, the said inhibitory activity resulted to be markedly superior
that that of a very
close compound of the prior art WO 02/12242, herewith referred to as Reference
compound (see compound 1143, bottom of page 76; and example 19, compound
bridging
pages 242-3 of WO 02/12242), used for comparative purposes and tested against
Cdk2/Cyclin A, as formerly reported:
Reference Compound: N-[5-acetyl-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-
3-yl]-
(3-bromo)benzamide (IC50 1.7 M)
Br
F I N N~ F / I H N OyNNH
CH3 O O _ CH3
N CH3 N NN CH3
OAC(CH3)3 O~C(CH3)3
Compound I Compound 2 Reference compound
So far, the novel compounds of the invention are unexpectedly endowed with a
cdk
inhibitory activity significantly higher than that of the structurally closest
prior art
compounds of WO 02/12242 and are thus particularly advantageous, in therapy,
against
proliferative disorders associated with an altered cell cycle dependent kinase
activity.
The compounds of the present invention can be administered either as single
agents or,
alternatively, in combination with known anticancer treatments such as
radiation therapy
or chemotherapy regimen in combination with cytostatic or cytotoxic agents,
antibiotic-
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
37
type agents, alkylating agents, antimetabolite agents, hormonal agents,
immunological
agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2
inhibitors),
matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase
inhibitors, anti-
growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-
angiogenesis
agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-
raf signal
transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors,
tubulin binding
agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
If formulated as a fixed dose, such combination products employ the compounds
of this
invention within the dosage range described below and the other
pharmaceutically active
agent within the approved dosage range.
Compounds of formula (I) may be used sequentially with known anticancer agents
when a
combination formulation is inappropriate.
The compounds of formula (I) of the present invention, suitable for
administration to a
mammal, e.g., to humans, can be administered by the usual routes and the
dosage level
depends upon the age, weight, conditions of the patient and administration
route.
For example, a suitable dosage adopted for oral administration of a compound
of formula
(1) may range from about 10 to about 500 mg per dose, from 1 to 5 times daily.
The
compounds of the invention can be administered in a variety of dosage forms,
e.g., orally,
in the form tablets, capsules, sugar or film coated tablets, liquid solutions
or suspensions;
rectally in the form suppositories; parenterally, e.g., intramuscularly, or
through
intravenous and/or intrathecal and/or intraspinal injection or infusion.
The present invention also includes pharmaceutical compositions comprising a
compound
of formula (1) or a pharmaceutically acceptable salt thereof in association
with a
pharmaceutically acceptable excipient, which may be a carrier or a diluent.
The pharmaceutical compositions containing the compounds of the invention are
usually
prepared following conventional methods and are administered in a suitable
pharmaceutical form. For example, the solid oral forms may contain, together
with the
active compound, diluents, e.g., lactose, dextrose saccharose, sucrose,
cellulose, corn
starch or potato starch; lubricants, e.g., silica, talc, stearic acid,
magnesium or calcium
stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic
gum, gelatine
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
38
methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone;
disintegrating agents,
e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing
mixtures;
dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates,
laurylsulphates; and,
in general, non-toxic and pharmacologically inactive substances used in
pharmaceutical
formulations. These pharmaceutical preparations may be manufactured in known
manner,
for example, by means of mixing, granulating, tabletting, sugar-coating, or
film-coating
processes.
The liquid dispersions for oral administration may be, e.g., syrups, emulsions
and
suspensions. As an example, the syrups may contain, as carrier, saccharose or
saccharose
with glycerine and/or mannitol and sorbitol.
The suspensions and the emulsions may contain, as examples of carriers,
natural gum,
agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or
polyvinyl
alcohol. The suspension or solutions for intramuscular injections may contain,
together
with the active compound, a pharmaceutically acceptable carrier, e.g., sterile
water, olive
oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable
amount of
lidocaine hydrochloride.
The solutions for intravenous injections or infusions may contain, as a
carrier, sterile water
or preferably they may be in the form of sterile, aqueous, isotonic, saline
solutions or they
may contain propylene glycol as a carrier.
The suppositories may contain, together with the active compound, a
pharmaceutically
acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene
sorbitan fatty
acid ester surfactant or lecithin.
With the aim of better illustrating the present invention, without posing any
limitation to it,
the following examples are now given.
General methods
Before taking into consideration the synthetic preparation of the specific
compounds of
formula (1) of the invention, for instance as reported in the following
examples, attention
should be given to the fact that some compounds are herewith listed and
indicated
according to their chemical name whilst others, most of them, have been
conveniently and
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
39
unambiguously identified through a coding system, together with their 1H-NMR
data (see
following tables Ill, IV and V) and HPLC/Mass data (see following table VI).
Each code, in particular, identifies a single specific compound of formula
(la) or (1b) and
consists of three units A-M-B.
A represents any substituent R [see formula (la) or (Ib)] and is attached to
the rest of the
molecule through the -NH-group; each specific A group is represented and
consecutively
numbered in the following table I.
Likewise, B represents any substituent R1 [see formula (Ia) or (Ib)] and is
attached to the
rest of the molecule through the carbonyl (CO) group; each specific B group is
represented
and consecutively numbered in the following table II.
M refers to the central core of the divalent moiety which is substituted by
groups A and B;
in particular, M may vary from Ml or M2 as per the formulae below, each
identifying the
central core of a compound having formula (Ia) or (lb), respectively:
HN N HN N
A ~NH A C \NH
- CH3
N CH3 N
M1 J
M2 )
B B
For ease of reference, all of the A and B groups of tables I and II have been
identified with
the proper chemical formula also indicating the point of attachment with the
rest of the
molecule M.
Therefore, just as an example, the compound A06-M1-B01 of table III represents
the
compound of formula (Ia) having the central M1 core, being substituted by the
group A06
and by the group BO1, in the positions indicated by the arrows; likewise, the
compound
A04-M2-B08 of table V represents the compound of formula (lb) having the
central M2
core, being substituted by the group A04 and by the group B08, in the
positions indicated
by the arrows:
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
F
CI
N N
N NRNH ~NH
F
0
0 CH3
CH3 N
N
O C(CHs)a
N
CH3
0
A06-M 1-BO l A04-M2-B08
Table I
A01 0 A02 0
I~ M F I B M
F / /
A03 A04 F 0
F I B M I~ M
F / F /
A05 0 A06 0
F I\ M I\ M
/ CI /
F
A07 0 A08 0
xf'M (JM
F3C /
A09 A10 0
M \ J M
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
41
All 0 A12 O
S:.711 M M
A13 0 A14 0
C! M vl- M
A15 >[A O A16 0
M I \ M
F3C`O /
A17 0 A18 0
s I\ M
\~ I\ M c
r -A
A19 0 A20 0
M M
HN
A21 0 A22 0
\ M M
~N~N / \
A23 0 A24 0
/ I \ M ~NAM
A25 0 A26 0
0(NAM ~\H~M
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
42
A27 0 A28 0
\ I M
N M
F H
A29 0 A30 0
,NJM em
A31 0 A32 0
\Na I \ M ~p \ M
O /
A33 0 A34 0
N"') M \ M
LN I / N I /
\/
F
A35 0 A36 0
I\ M p I\ M
~N / N /
iN
A37 0 A38 0
" M
%em
O`
v O
~O
A39 0 A40 0
M lul M
\
O NC
NH2
A41 0 A42 CN O
NC I \ M 6)M
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
43
A43 F A44
6)IM ~O /
A45 0 A46 ~O O
/O \
Am A M
A47 O A48 / /
n õll O
\~ M \ \ I
M
A49 0 A50 0
em em
A51 0 A52 0
em M
A53 0 A54 0
F3C M
OQ)LM ~ /
A55 co- O
M
Table II
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
44
BOl M~ B02 M` /p
B03 M B04 M
~N~
B05 M B06 M
N OH
B07 M )D/ S B08 M,
~N~
B09 M,N BlO M,N^
LI-10
Bll MAN B12 MAN
OH
B13 MAN B14 M
O
OH
B15 M B16 MAN
O
NH2
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
B17 M,N B18 M,N
N3
O__________
B19 M B20 M
I / O
B21 M tN,, B22 M
VN
B23 M,N^~OH B24 M,N . OH
OH OH
B25 M, N -,,,.,OH B26 M, N'-N',' OH
H
B27 M,B28 M,NiN-1
H H
B29 H B30 MAN
M,N
OH
O NH2
B31 M,N^ B32 H
LN
MAN
OH
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
46
B33 MAN OH B34 M0
-N NHZ
B35 M.N B36 MAN
NHZ
OH
B37 MAaF B38 M, N^
LNH
B39 M, N^ B40 M, lo,OH
~N N
NHz ~B41 M,N B42 M,
~
OH LN NN" OH
F
B43 M.Oi~ B44
M
B45 M` B46 M O
wT HN NH
HO
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
47
B47 M I \ B48 M I \
N /N`
N
B49 M, NH B50 M
B51 Mr--.o B5
2 M B53 F B54 M \
M \
/ / S02NH2
F
B55 MAN
NH2
0
Example 1
N-(2-cyanoethyl)-2-methylalanine
50 g (0.48 mol) of 2-methylalanine were added to a cooled solution (water/ice)
of NaOH
(19.6 g) in water (100 ml). Once the solution had turned clear, 34 ml (0.50
mol) of
acrylonitrile were dropped on cooling. The mixture was left overnight. After
18 hours, 28
ml of acetic acid were added on cooling (water/ice); a white solid
precipitated; 200 ml of
95% ethanol were dropped in the flask, stirring was continued for 1 hour, then
the mixture
was allowed to stand in a fridge for 2-3 hours. After filtration, the solid
was collected and
dried in an oven at 80 C. The filtrates were evaporated and taken up with
ethanol (160 ml).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
48
On cooling a further amount of product was obtained, which was filtered and
dried. 72 g of
the title compound were obtained from the first filtration. Total yield: 95%.
ESI MS: m/z 157 (MH+);
1H NMR (400 MHz, DMSO-d6): S 7.47 (s, 1H), 2.70 (t, 2H), 2.48 (t, 2H), 1.18
(s, 6H).
By working in an analogous manner the following compound was prepared:
1-[(2-Cyanoethyl)amino]cyclopropanecarboxylic acid
El MS: m/z 154 (M), 136 (M-H20), 114 (M-CH2CN), 68 (100%, cyclopr=C=O);
1H NMR (400 MHz, DMSO-d6): S 7.47 (s, 1H), 2.86 (t, 2H, J = 6.6 Hz), 2.48 (t,
2H, J =
6.6 Hz), 1.09 (dd, 2H, J = 6.9 Hz, J = 4.1 Hz), 0.86 (dd, 2H, J = 6.9 Hz, J =
4.1 Hz).
Example 2
N-(tent-butoxycarbonyl)-N-(2-cyanoethyl)-2-methylalanine
44.5 g (0.285 mol) of N-(2-cyanoethyl)-2-methylalanine and 51.7 g of
tetramethylammonium hydroxide pentahydrate were dissolved in acetonitrile (2
1) at 40 C
and when a clear solution was obtained, 112 g of Boc2O were added. The mixture
was left
for 24 hours at 40 C. The, day after, further 20 g of Boc2O were added while
maintaining
the temperature of 40 C. Every 8-12 hours 20 g of Boc2O were added up to a
total of 192
g. After 4 days the solvent was evaporated, the residue taken up with water
(1000 ml) and
washed twice with ethyl ether (500 ml). The aqueous fraction was brought to pH
3-4 with
citric acid and extracted with ethyl acetate, washed with water (200 ml) and
concentrated.
52 g of the title compound were obtained. (yield: 72%).
ESI MS: m/z 274 (M+NH4);
1H NMR (400 MHz, DMSO-d6): S 3.52 (t, 2H, J = 6.8 Hz)), 2.68 (t, 2H, J = 6.8
Hz), 1.18-
1.38 (m, 15H).
By working in an analogous manner the following compound was prepared:
1-[(tert-Butoxycarbonyl)(2-cyanoethyl)amino]cyclopropanecarboxylic acid
ESI MS: m/z 272 (M+NH4), 255(MH+);
1H NMR (400 MHz, DMSO-d6): 6 12.55 (bs, 1H), 3.33 (m, 2H), 2.71 (m, 2H), 0.97-
1.63
(m, 131).
Example 3
Methyl N-(tert-butoxycarbonyl)-N-(2-cyanoethyl)-2-methylalaninate
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
49
62 g (0.23 mol) of N-(tert-butoxycarbonyl)-N-(2-cyanoethyl)-2-methylalanine
were
dissolved in 350 ml of DMF and 50 g of KHCO3 were added. Few minutes after, 30
ml of
methyl iodide (Me]) were dropped and the mixture was stirred at room
temperature for 6
hours. Then a further 15 ml of Mel were added. The mixture was left at room
temperature
overnight. After dilution with 1.5 1 of water, the solution was extracted with
ethyl acetate
(3 times). The organic phases were washed with a small amount of water, dried
over
sodium sulfate, evaporated and dried at the mechanical pump. 60.5 g (97%) of
methyl N-
(tent-butoxycarbonyl)-N-(2-cyanoethyl)-2-methylalaninate were thus obtained.
ESI MS: m/z 288 (M+NH4);
'H NMR (400 MHz, DMSO-d6): S 3.55 (m, 5H), 2.70 (t, 2H, J = 6.7 Hz)), 1.40 (s,
6H),
1.36 (s, 9H).
By working in an analogous manner the following compound was prepared:
Methyl 1-[(tert-butoxycarbonyl)(2-cyanoethyl)amino]cyclopropanecarboxylate
ESI MS: m/z 286 (M+NH4);
1H NMR (400 MHz, DMSO-d6): 6 3.61 (s, 31-1), 3.42 (t, 2H, J = 6.7 Hz), 2.71
(m, 211),
1.07-1.62 (m, 13H).
Example 4
tert-Butyl 4-cyano-3-hydroxy-2,2-dimethyl-2,5-dihydro-lH-pyrrole-l-carboxylate
45 g of methyl N-(tert-butoxycarbonyl)-N-(2-cyanoethyl)-2-methylalaninate were
dissolved in dioxane (240 ml) under nitrogen and 7.9 g of sodium hydride were
added. The
mixture was refluxed for 6 hours (120 C internal temperature), and then left
to stand
overnight at room temperature (TLC: CH2C12/EtOH 90/10). The solvent was
evaporated,
water was added (1000 ml) and the mixture was brought to pH 3-4 with citric
acid. The
aqueous layer was extracted 4 times with ethyl acetate, the extracts washed
with a limited
amount of water and evaporated. Then the residue was taken up with hexane,
evaporated
and crystallized from hexane. 33.1 g of tent-butyl 4-cyano-3-hydroxy-2,2-
dimethyl-2,5-
dihydro-lH-pyrrole-l-carboxylate were thus obtained (yield: 85%).
ESI MS: m/z 237 (M-H-);
1H NMR (400 MHz, DMSO-d6): 6 4.06-4.10 (2s, 2H, conformers), 1.48 (s, 611),
1.47 (s,
911).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
By working in an analogous manner the following compound was prepared:
tert-Butyl 6-cyano-7-oxo-4-azaspiro[2.4]heptane-4-carboxylate
ESI MS: m/z 235 (M-H-);
1H NMR (400 MHz, DMSO-d6): S 4.63 (t, 1H, J = 9.8 Hz), 4.24 (t, 1H, J = 10.2
Hz), 3.74
5 (t, 1H, J = 10.2 Hz), 1.67-2.16 (m, 21-1), 1.34-1.41 (s, 91-1), 0.93-1.20
(m, 2H).
Example 5
tert-Butyl 3-amino-6,6-dimethyl-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-
carboxylate
32 g of tert-Butyl 4-cyano-3-hydroxy-2,2-dimethyl-2,5-dihydro-1H pyrrole-l-
carboxylate
(0.134 mol) were added to 430 ml of absolute ethanol. To this solution, 9 ml
(0.18 mol) of
10 hydrazine hydrate were added, followed by 12 ml of glacial AcOH (1.5 eq);
The mixture
was stirred at 60 C for 48 hours, the ethanol was removed, the residue was
taken up with
400 ml of sodium hydrogencarbonate solution, and extracted several times with
ethyl
acetate up to total extraction of the desired product. The organic phases were
dried and
evaporated. After purification by flash chromatography (eluent: CHC13/EtOH
97/3) and
15 trituration with a mixture of hexane/ethyl acetate 9/1, 25 g of title
compoud were obtained.
Total yield 30.5 g (yield: 88 10)
ESI MS: m/z 253 (MH+);
1H NMR (400 MHz, DMSO-d6): S 4.06-4.10 (2s, 2H, conformers), 1.48 (2s, 6H,
conformers), 1.47 (2s, 9H, conformers).
20 By working in an analogous manner the following compound was prepared:
tent-Butyl-3-amino-2,6-dihydropyrrolo [3,4-c]pyrazole-6-spirocyclopropane-
5(4H)-
carboxylate
ESI MS: m/z 251 (MH+);
1H NMR (400 MHz, DMSO-d6): 6 11.12 (bs, 1H), 5.13 (bs, 211), 4.16-4.33 (m,
2H), 1.57-
25 1.91 (m, 2H), 1.38 (s, 911), 0.65-0.83 (m, 2H).
Example 6
5-tert-Butyl 2-ethyl 3-amino-6,6-dimethylpyrrolo [3,4-c]pyrazole-2,5(4H,6H)-
dicarboxylate and 5-tert-butyl 1-ethyl 3-amino-6,6-dimethyl-4,6-
dihydropyrrolo[3,4-
c]pyrazole-1,5-dicarboxylate
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
51
15 g of tert-Butyl 3-amino-6,6-dimethyl-2,6-dihydropyrrolo[3,4-c]pyrazole-
5(4H)-
carboxylate (59.4 mmol) were dissolved in anhydrous THE (150 ml) and treated,
at 0 C
under Ar atmosphere, first with N,N-diisopropylethylamine (50 ml) and then
with C1CO,Et
(4.65 ml, 1 eq.) dropwise. 90 minutes later, the solvent was diluted with
EtOAc (1 1),
washed with water and then with brine, dried over sodium sulfate and
evaporated. The
crude product was purified by flash chromatography (hexane/EtOAc 2/8) to
afford 7.3 g of
5-tent-butyl 2-ethyl 3-amino-6,6-dimethylpyrrolo[3,4-c]pyrazole-2,5(4H,6H)-
dicarboxylate
as the major compound in 38% yield, together with 5.7 g of 5-tert-butyl 1-
ethyl 3-amino-
6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylate in 30% yield.
5-tert-Butyl 2-ethyl 3-amino-6,6-dimethylpyrrolo [3,4-c]pyrazole-2,5(4H,6H)-
dicarboxylate
ESI MS: m/z 325 (MH+);
1H NMR (400 MHz, DMSO-d6): 6 4.35 (q, 211), 4.10 (2s, 211, conformers), 1.50-
1.51 (m,
611), 1.41-1.43 (2s, 9H, conformers), 1.29 (t, 311).
5-tert-Butyl 1-ethyl 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-
1,5-
dicarboxylate
ESI MS: m/z 325 (MH+);
'H NMR (400 MHz, DMSO-d6): S 4.28 (q, 211, J = 7.1 Hz), 4.09-4.14 (2s, 211,
conformers), 1.66-1.67 (m, 611), 1.41-1.44 (2s, 914, conformers), 1.27 (t,
311, J = 7.1 Hz).
By working in an analogous manner the following compounds were prepared:
5-tert-Butyl 2-ethyl 3-amino-pyrrolo [3,4-c]pyrazole-6-spirocyclopropane-
2,5(4H,6H)-
dicarboxylate
ESI MS: m/z 323 (MH+);
1H NMR (400 MHz, DMSO-d6): S 4.30 (q, 2H, J = 7.1 Hz), 4.27 (bs, 211), 1.65-
2.01 (m,
211), 1.38 (s, 9H) 1.27 (t, 31L J = 7.1 Hz), 0.82-0.96 (m, 211).
5-tert-Butyl 1-ethyl 3-amino-4,6-dihydropyrrolo [3,4-c] pyrazole-6-
spirocyclopropane-
1,5-dicarboxylate
ESI MS: m/z 323 (MH+);
1H NMR (400 MHz, DMSO-d6): S 4.26 (bs, 21-1), 4.21 (q, 211, J = 7.0 Hz), 1.36-
1.97 (m,
13H), 1.23 (t, 311, J = 7.0 Hz).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
52
Example 7
5-tert-Butyl 1-ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-4,6-dihydro
pyrrolo [3,4-c] pyrazole-1,5-dicarb oxylate
5-tert-Butyl 1-ethyl 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-
1,5-
dicarboxylate (2.0 g, 6.16 mmol) was dissolved in THE (40 ml), treated first
with N,N-
diisopropylethylamine (5.4 ml, 30.80 mmol) and then, at 0 C, with 4-
fluorobenzoyl
chloride (800 l, 6.77 mmol) dissolved in THE (8 ml) dropwise. The reaction
mixture was
stirred at room temperature for 5 hours, concentrated and dissolved in DCM,
washed with
saturated sodium hydrogencarbonate aqueous solution and with brine. The
organic phase
was dried over sodium sulfate, evaporated and purified by flash chromatography
(eluent:
hexane/EtOAc 80/20) to afford 2.5 g of the title compound in 90% yield.
ESI MS: m/z 447 (MH+);
1H NMR (400 MHz, DMSO-d6): 6 11.47 (s, 11-1), 8.04-8.17 (m, 2H), 7.25-7.37 (m,
211),
4.44-4.47 (2s, 2H, conformers), 4.43 (q, 2H, J = 7.1 Hz), 1.73-1.75 (2s, 6H,
conformers),
1.43-1.46 (2s, 9H, conformers), 1.33 (t, 3H, J = 7.1 Hz).
By working in an analogous manner the following compounds were prepared.
5-tert-Butyl 2-ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethylpyrrolo[3,4-
c]pyrazole-
2,5(4H,6H)-dicarboxylate
ESI MS: m/z 447 (MH+);
1H NMR (400 MHz, DMSO-d6): S 10.78 (s, 111), 7.95-7.99 (m, 211), 7.40-7.47 (m,
2H),
4.51-4.49 (2s, 2H, conformers), 4.43 (q, 2H, J = 7.1 Hz), 1.59-1.60 (2s, 6H),
1.43-1.46 (2s,
9H, conformers), 1.34 (t, 3H, J = 7.1 Hz).
5-tert-Butyl 2-ethyl 3-[(4-fluorobenzoyl)amino]-pyrrolo[3,4-c]pyrazole-6-
spirocyclopropane-2,5(4H,6H)-dicarboxylate
ESI MS: m/z 445 (MH+);
1H NMR (400 MHz, DMSO-d6): S 10.81 (s, 1H), 7.95-8.06 (m, 2H), 7.39-7.49 (m,
211),
4.67 (bs, 2H), 4.41 (q, 2H, J = 7.1 Hz), 1.80-2.10 (m, 21-1), 1.41 (s, 9H),
1.32 (t, 3H, J = 7.1
Hz), 0.93-1.06 (m, 2H).
Example 8
5-tert-Butyl 1-ethyl 3-({[(3-fluorophenyl)amino]carbonyl}amino)-6,6-
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
53
dimethyl-4,6-dihydropyrrolo [3,4-c] pyrazole-1,5-dicarb oxylate
5-tert-Butyl 1-ethyl 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-
l,5-
dicarboxylate (3.0 g, 9.24 mmol) was dissolved in anhydrous THE (50 ml),
treated at room
temperature with 3-fluorophenyl-isocyanate (1.4 g, 10.21 mmol, 1.1 eq) and
stirred
overnight. The following day the reaction mixture was evaporated, taken up
with DCM
and washed with brine. The organic phase was dried over sodium sulfate and
evaporated to
dryness. Purification by flash chromatography (CH2Cl2/MeOH 90/10) afforded
3.05 g
(yield 71%) of the title compound.
ESI MS: m/z 462 (MH+);
1H NMR (400 MHz, DMSO-d6): S 9.74 (s, 1H), 9.05 (s, 11-1), 7.44 (m, 1H), 7.33
(m, 1H),
7.16 (m, 1H), 6.84 (m, 1H), 4.43 (m, 4H), 1.76 (2s, 611), 1.48 (2s, 911,
conformers), 1.36 (t,
3H, J = 7.1 Hz).
Example 9
5-tert-Butyl 1-ethyl 3-[(piperidine-l-carbonyl)-amino]-6,6-dimethyl-4,6-
dihydro
pyrrolo[3,4-c]pyrazole-1,5-dicarboxylate
To a solution of triphosgene (550 mg, 1.85 mmol, 0.4 eq) in tetrahydrofuran
(50 ml) was
added, at -40 C, a solution of 5-tert-butyl 1-ethyl 3-amino-6,6-dimethyl-4,6-
dihydropyrrolo[3,4-c]pyrazole-l,5-dicarboxylate (1.5 g, 4.62 mmol) in
tetrahydrofuran (50
ml) and N,N-diisopropylethylamine (1.8 ml, 2.2 eq). After 3 hours, a solution
of piperidine
(690 l, 1.5 eq) and N,N-diisopropylethylamine (1.2 ml, 1.5 eq) in
tetrahydrofuran (25 ml)
was added. The reaction was allowed to reach room temperature in 2 hours (TLC:
EtOAc/hexane 90/10). After evaporation of the solvent the solid was dissolved
in DCM
and the solution was washed with brine, the organic phase was dried over
sodium sulfate
and concentrated. The solid was purified by flash chromatography (eluent:
EtOAc/hexane
50/50). The solid was treated with diisopropylether and filtered to afford
1.45 g of the title
compound in 72% yield.
ESI MS: m/z 436 (MH+);
1H NMR (400 MHz, DMSO-d6): 6 9.36 (s, 1H), 4.46 (m, 411), 3.40 (m, 4H), 1.76
(2s, 61-1),
1.54 (m, 61-1), 1.44 (2s, 9H, conformers), 1.36 (t, 3H, J = 7.1 Hz).
Example 10
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
54
Ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-
c]pyrazole-
1(411)-carboxylate hydrochloride
5-tert-Butyl 1-ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-4,6-
dihydropyrrolo[3,4-
c]pyrazole-1,5-dicarboxylate (2.5 g, 5.59 numol) was dissolved in dioxane (50
ml) and
treated with HCl 4M in dioxane (28 ml, 20 eq). After 2 hours at 40 C (TLC:
CH2C12/MeOH 90/10) the reaction mixture was concentrated and the residue was
treated
with diethyl ether, filtered to afford the title compound (2.09 g) as a solid
in 98% yield.
ESI MS: m/z 347 (MH+);
111 NMR (400 MHz, DMSO-d6): S 11.28 (s, 111), 8.06-8.11 (m, 211), 7.28-7.34
(m, 211),
4.40 (q, 211, J = 7.1 Hz), 3.92 (s, 211), 1.42 (s, 611), 1.33 (t, 311, J = 7.1
Hz).
By working in an analogous manner the following compounds were prepared:
Ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-
c]pyrazole-
2(4H)-carboxylate hydrochloride
ESI MS: m/z 347 (MH+);
111 NMR (400 MHz, DMSO-d6): 6 10.92 (s, 111), 9.89 (s, 111), 8.02 (m, 211),
7.49 (m, 211),
4.61 (s, 211), 4.51 (q, 211, J = 7.1 Hz), 1.69 (s, 611), 1.39 (t, 3H, J = 7.1
Hz).
Ethyl 3-[(4-fluorobenzoyl)amino]-5,6-dihydropyrrolo [3,4-c]pyrazole-6-
spirocyclopropane-2(411)-carboxylate hydrochloride
ESI MS: m/z 345 (MH+);
111 NMR (400 MHz, DMSO-d6): 5 10.87 (bs, 111), 10.00 (bs, 211), 7.93-8.04 (m,
211), 7.39-
7.53 (m, 211), 4.69 (bs, 211), 4.41 (q, 211, J = 7.1 Hz), 1.68 (dd, 211, J =
8.6 Hz, J = 6.1 Hz),
1.41 (dd,2H,J=8.6Hz,J=6.1 Hz), 1.33 (t,3H,J=7.1 Hz).
Example 11
Ethyl5-(2,2-dimethylpropanoyl)-3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-
dihydropyrrolo[3,4-c]pyrazole-1(411)-carboxylate
Ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-
c]pyrazole-1(411)-
carboxylate hydrochloride (2.0 g, 5.77 mmol) in dichloromethane (70 ml) was
treated, at
0 C, with N,N-diisopropylethylamine (1.6 ml, 9.2 mmol, 1.6 eq) and with
pivaloyl
chloride (780 L, 6.3 mmol, 1.1 eq). Gradually, the reaction was brought to
room
temperature and stirred overnight (TLC: CH2CI2/EtOAc 90/10). The solution was
washed
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
with saturated sodium hydrogencarbonate aqueous solution and brine. The
organic phase
was dried over sodium sulfate, evaporated and purified by flash chromatography
(eluent:
CH2C12/EtOAc 90/10) to afford 2.03 g of the title compound in 82% yield.
ESI MS: m/z 431 (MH+);
5 1H NMR (400 MHz, DMSO-d6): S 11.51 (s, 111), 8.05-8.14 (m, 211), 7.23-7.37
(m, 21-1),
4.90 (s, 211), 4.42 (q, 2H, J = 7.1 Hz), 1.80 (s, 61-1), 1.33 (t, 311, J = 7.1
Hz), 1.22 (s, 911).
By working in an analogous manner the following compound was prepared:
Ethyl 5-(2,2-dimethylpropanoyl)-3-[(4-fluorobenzoyl)aminoj-5,6-dihydro
pyrrolo [3,4-c]pyrazole-6-spirocyclopropane-2(411)-carboxylate
1o ESI MS: m/z 429 (MH+);
'H NMR (400 MHz, DMSO-d6): S 10.81 (bs, 11-1), 7.96-8.04 (m, 211), 7.38-7.48
(m, 211),
5.10 (bs, 2H), 4.42 (q, 2H, J = 7.1 Hz), 2.33 (dd, 211, J = 6.8 Hz, J = 4.2
Hz), 1.32 (t, 311, J
= 7.1 Hz), 1.22 (s, 911), 0.90 (dd, 2H, J = 6.8 Hz, J = 4.2 Hz).
Example 12
15 N-[5-(2,2-dimethylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-
c]pyrazol-
3-yl]-4-fluorobenzamide
Ethyl 5-(2,2-dimethylpropanoyl)-3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-
dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate (2.0 g, 4.64 mmol) was
dissolved in
methanol (60 ml), treated with TEA (6.45 ml, 46.4 mmol, 10 eq) and stirred
overnight at
20 room temperature. (TLC: CH2C12/MeOH 95/5). After evaporation, the solid was
treated
with diethyl ether/hexane and filtered to afford 1.43 g of the title compound
in 86% yield.
ESI MS: m/z 359 (MH+);
'H NMR (400 MHz, DMSO-d6): S 12.41 (bs, 111), 10.91 (bs, 111), 7.98-8.11 (m,
2H), 7.20-
7.44 (m, 211), 4.66-4.92 (bs, 211), 1.64 (s, 6H), 1.21 (s, 911).
25 By working in an analogous manner the following compounds were prepared:
N-[5-(2,2-dimethylpropanoyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-6-
spirocyclopropan-3-yl]-4-fluorobenzamide
ESI MS: m/z 357 (MH+);
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
56
1H NMR (400 MHz, DMSO-d6): 8 11.59-12.47 (bs, 11-1), 10.94 (bs, 111), 8.02-
8.11 (m,
2H), 7.27-7.37 (m, 2H), 4.99 (s, 211), 2.25 (dd, 2H, J = 6.5 Hz, J = 4.4 Hz),
1.20 (s, 9H),
0.79 (dd, 2H, J = 6.5 Hz, J = 4.4 Hz).
N-{6,6-dimethyl-5-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,4,5,6-
tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-fluorobenzamide
ESI MS: m/z 373 (MH+);
1H NMR (400 MHz, DMSO-d6): 8 12.49 (bs, 1H), 10.96 (bs, 1H), 8.09 (m, 211),
7.34 (m,
2H), 4.86 (m, 2H), 4.56 (t, 1H), 3.83 (m, 2H) 2.02 (m, 2H), 1.86 (m, 2H), 1.68
(s, 6H).
aD +27.7 (c=0.50, MeOH)
N-{6,6-dimethyl-5-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,4,5,6-
tetrahydropyrrolo[3,4-
c]pyrazol-3-yl}-4-fluorobenzamide
ESI MS: m/z 373 (MH+);
1H NMR (400 MHz, DMSO-d6): 8 12.49 (bs, 111), 10.96 (bs, 1H), 8.09 (m, 2H),
7.34 (m,
2H), 4.86 (m, 2H), 4.56 (t, 1H), 3.83 (m, 211) 2.02 (m, 2H), 1.86 (m, 2H),
1.68 (s, 6H).
aD -25.9 (c=0.76, McOH)
Example 13
4-(1-Methyl-piperidin-4-yloxy)-benzoic acid methyl ester
To a solution of 1-methyl-piperidin-4-ol (6.8 g. 59 mmoles), PPh3
(triphenylphosphine,
15.5 g, 59 mmoles) and 4-hydroxy-benzoic acid methyl ester (6 g, 39 mmoles) in
THE
(150 ml) at 0 C, diethyl azodicarboxylate (9.5 ml, 59 mmoles) in THE (30 ml)
was slowly
added. The reaction mixture was allowed to warm to room temperature over a
period of 24
hours. It was then evaporated and the residue redissolved in 5% aqueous citric
acid (700
ml). The solution was washed with ethyl acetate (3 x 250 ml), made alkaline
with
concentrated N 1440H (pH - 8) and then extracted with dichloromethane (3 x 250
ml). The
combined dichloromethane extracts were washed with brine, dried and evaporated
to give
an oil which was purified by flash chromatography on silica gel using
dichloromethane-
MeOH (90: 10) as eluent, to give the title compound as a yellow oil (7.4 g,
75%).
ESI MS: m/z 250 (MH+);
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
57
1H NMR (400 MHz, DMSO-D6) S ppm 1.7 (m, 2 H) 2.0 (m, 2 H) 2.2 (m, 5 H) 2.7 (m,
2
H) 3.8 (s,3H)4.5(m, 1 H) 7.1 (d,J=9.0Hz,2H)7.9(d,J=9.0Hz,2H).
Example 14
4-(1-Methyl-piperidin-4-yloxy)-benzoic acid, hydrochloride
4-(1-Methyl-piperidin-4-yloxy)-benzoic acid methyl ester (7.3 g, 29 mmoles)
was
dissolved in 6N aq HCl (220 ml). After heating at 85 C for 6 hours, the
solvent was
removed in vacuo. The residue was taken up with water and evaporated twice and
then
taken up with acetone two more times. The solid obtained was finally
triturated in acetone
to give the hydrochloride salt as a white powder (6.4 g, 80% yield).
111 NMR (400 MHz, DMSO-D6) 6 ppm 2.0 (m, 4 H) 2.8 (m, 3 H) 3.3 (m, 4 H) 4.7
(m, 1
H) 7.1 (m,21)7.9(m,2H)9.9(d,J=20.4Hz, 1H) 12.6 (s, 1H).
Example 15
4-(4 Hydroxy piperidin-1-yl)benzoic acid ethyl ester
A mixture of 4-fluoro-benzoic acid ethyl ester (1.68 g, 10 mmoles), piperidin-
4-ol (1.12 g,
11 mmoles) and anhydrous potassium carbonate (1.38 g, 10 mmoles) in DMSO (10
ml)
was heated at 120 C for 6 hours. After cooling, the mixture was poured into
water and ice
(500 ml) and extracted with ethyl acetate. The organic layer was washed with
water and
brine, dried and evaporated. The residue was purified by flash chromatography
on silica
gel using hexane/EtOAc (10/30) as eluent to give the title compound as a white
solid (1.6
g, 64%).
ESI MS: m/z 250 (MH+);
111 NMR (400 MHz, DMSO-D6) S ppm 1.3 (t, J=7.1 Hz, 3 H) 1.4 (m, 2 H) 1.8 (m, 2
H)
3.0(m,2H)3.7(m,2H)4.2(q,J=7.1Hz,21-1)4.7(d,J--4.3Hz,1H)6.9(m,2H)7.7(m,
2H).
Example 16
4-(4-Fluoro-piperidin-1-yl)benzoic acid ethyl ester
To a solution of 4-(4-hydroxy-piperidin-1-yl)benzoic acid ethyl ester (1.25 g.
5 mmoles) in
dry dichloromethane (30 ml) at room temperature under an inert atmosphere, it
was slowly
added DAST (0.97 g, 6 mmoles) in dichloromethane (5 ml). The reaction mixture
was
stirred at room temperature for 1 hour and then quenched with aqueous NaHCO3.
The
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
58
organic layer was washed with brine, dried and evaporated. The residue was
purified by
flash chromatography on silica gel using hexane/EtOAc (70/30) as eluent to
give the title
compound as a white solid (0.7 g, 56%).
ESI MS: m/z 252 (MH+);
111 NMR (400 MHz, DMSO-D6) S ppm 1.3 (t, J=7.1 Hz, 3 H) 1.8 (m, 2 H) 2.0 (m,
211)
3.3 (m, 2 H) 3.6 (m, 211) 4.2 (s, 2 H) 4.8 (s, 1H)7.0(s,2H)7.8(s,2H).
Example 17
4-(4 Fluoro-piperidin-1-yl)benzoic acid
A mixture of 4-(4-fluoro-piperidin-1-yl)benzoic acid ethyl ester (0.7 g, 2.7
mmoles) in
ethanol (50 ml) and a solution of 2N sodium hydroxide (20 ml) was stirred at
room
temperature for 24 hours. The ethanol was then evaporated, the solution
diluted with water
(20 ml) and neutralized with 2N HCI. The acid separated as a white solid which
was
washed with water and dried under vacuum (0.52 g, 82%).
ESI MS: m/z 224 (MH+);
111 NMR (400 MHz, DMSO-D6) S ppm 1.8 (m, 2 H) 2.0 (m, 2 H) 3.3 (m, 2 H) 3.5
(m, 2
H) 5.0 (s, 1 H) 7.0 (s, 2 H) 7.8 (s, 2 H) 12.2 (s, 1 H).
By working as described in any previous example, that is by using any proper
starting
material and any suitable reactant according to the process previously
disclosed, additional
compounds of formula (Ia) and (Ib) were also prepared, as reported in the
following table
III. For explanatory notes concerning the coding system identifying each
specific
compound of formula (la) and (Ib) see the "general method" at the beginning of
the
experimental section.
Table III
A02M1B01 1H NMR (400 MHz, DMSO-d6): 6 12.45 (bs, 1H), 10.99 (s, 1H),
7.84 (m, 211), 7.52 (m, 111), 7.40 (m, 1H), 4.86 (s, 211), 1.65 (s, 6171),
1.21 (s, 911).
A03MIB01 1H NMR (400 MHz, DMSO-d6): S 12.46 (bs, 1H), 11.01 (s, 1H),
8.05 (m, 1H), 7.88 (m, 1H), 7.54 (m, 111), 4.86 (s, 211), 1.65 (s, 611),
1.21 (s, 911).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
59
A04M1BO1 'H NMR (400 MHz, DMSO-d6): S 12.45 (bs, 1H), 10.89 (s, 111), 7.7
(m, 1H), 7.38 (m, 1H), 7.20 (s, 1H), 4.89 (s, 2H), 1.68 (s, 6H), 1.24
(s, 9H).
A05M1B01 1H NMR (400 MHz, DMSO-d6): 6 12.54 (bs, 1H), 11.07 (s, 1H),
7.76 (s, 2H), 7.51 (s, 1H), 4.89 (s, 2H), 1.68 (s, 6H), 1.25 (s, 9H).
A06M1BO1 1H NMR (400 MHz, DMSO-d6): S 12.43 (bs, 1H), 10.98 (s, 111),
7.98 (d, 2H, J = 8.0 Hz), 7.54 (d, 2H, J = 8.0 Hz), 4.86 (s, 2H), 1.65
(s, 6H), 1.21 (s, 9H).
A07M1BO1 1H NMR (400 MHz, DMSO-d6): S 12.47 (bs, 11-1), 11.16 (s, 1H),
8.16 (d, 2H, J = 7.9 Hz), 7.85 (d, 2H, J = 7.9 Hz), 4.88 (s, 211), 1.65
(s, 6H), 1.21 (s, 9H).
A08M1BO1 1H NMR (400 MHz, DMSO-d6): S 12.50 (bs, 1H), 11.17 (s, 1H),
9.13 (s, 1H), 8.76 (m, 1H), 8.33 (m, 1H) 7.51 (m, 1H), 4.91 (s, 2H),
1.69 (s, 6H), 1.25 (s, 91-1).
A09M1BOI 111 NMR (400 MHz, DMSO-d6): S 12.54 (bs, 1H), 11.25 (s, 1H),
8.75 (d, 2H), 7.91 (d, 2H), 4.92 (s, 2H), 1.69 (s, 6H), 1.25 (s, 911).
"A10M1BO1 'H NMR (400 MHz, DMSO-d6): S 12.47 (bs, 1H), 11.00 (s, 1H),
8.12 (m, 1H), 7.86 (m, 1H), 7.12 (m, 1H), 4.86 (s, 2H), 1.68 (s, 6H),
1.25 (s, 9H).
Al1M1BO1 1H NMR (400 MHz, DMSO-d6): S 12.11 (bs, 1H), 10.77 (s, 1H),
8.45 (s, 1H), 7.69 (m, 2H), 4.89 (s, 2H), 1.68 (s, 6H), 1.25 (s, 9H).
A12MIBO1 'H NMR (400 MHz, DMSO-d6): S 12.22 (bs, 1H), 10.31 (s, 1H),
4.76 (s, 2H), 2.12 (m, 3H), 1.61 (s, 6H), 1.19 (s, 9H), 0.87 (d, 6H, J
= 6.5 Hz).
A13M1BOI 1H NMR (400 MHz, DMSO-d6): 8 12.21 (bs, 1H), 10.19 (bs, 1H),
4.80 (s, 211), 3.28 (m, 11-1), 2.25-1.70 (m, 6H), 1.60 (s, 611), 1.20 (s,
9H).
A14MIBO1 1H NMR (400 MHz, DMSO-d6): S 12.35 (bs, 1H), 10.38 (bs, 1H),
4.75 (s, 211), 1.82 (m, 1H), 1.60 (s, 6H), 1.20 (s, 9H), 0.78 (m, 4H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
A15MlB0l 1H NMR (400 MHz, DMSO-d6): 8 12.3 (bs, 11-1), 9.89 (s, 111), 4.80
(s, 21-1), 1.64 (s, 6H), 1.23 (s, 9H), 1.21 (s, 9H).
A16M1B01 'H NMR (400 MHz, DMSO-d6): 6 12.35 (bs, 1H), 11.02 (s, 1H),
8.09 (d, 2H, J = 8.2 Hz), 7.47 (d, 2H, J = 8.2 Hz), 4.85 (s, 2H), 1.64
(s, 6H), 1.21 (s, 9H).
A19M1B01 1H NMR (400 MHz, DMSO-d6): 5 12.48 (bs, 1H), 10.82 (s, 1H),
8.43 (m, 111), 7.45 (m, 1H), 6.70 (m, 1H), 4.85 (s, 2H), 1.67 (s,
6H), 1.25 (s, 9H).
A20M1B01 'H NMR (400 MHz, DMSO-d6): S 12.26 (bs, 1H), 10.38 (s, 1IH),
4.80 (s, 2H), 3.04 (m, 2H), 2.52 (m, 3H), 1.64 (m, 10H), 1.23 (s,
9H).
A22M1B01 'H NMR (400 MHz, DMSO-d6): 6 12.43 (bs, 1H), 11.06 (s, 1H),
8.3-7.6 (m, 7H), 4.99 (s, 2H), 1.71 (m, 6H), 1.26 (s, 9H).
A23M1B01 1H NMR (400 MHz, DMSO-d6): 6 12.48 (bs, 1H), 11.07 (s, 1H),
8.68 (s, 1H), 8.08 (m, 411), 7.66 (m, 2H), 4.95 (s, 2H), 1.70 (m, 6H),
1.27 (s, 9H).
A24M1B01 'H NMR (400 MHz, DMSO-d6): 8 12.05 (bs, 1H), 8.87 (s, 1H), 7.19
(m, 4H), 6.91(bs, 1H), 4.73 (s, 2H), 4.32 (d, 2H, J = 5.85 Hz), 2.30
(s, 3H), 1.63 (s, 6H), 1.22 (s, 9H).
A25M1B01 1H NMR (400 MHz, DMSO-d6): 6 12.31-12.05 (2bs, 111), 8.48 (s,
1H), 7.30 (m, 5H), 7.00 (bs, 1H), 4.73 (s, 2H), 4.33 (d, 2H, J = 5.85
Hz), 1.63 (s, 6H), 1.22 (s, 9H).
A28M1B0I 'H NMR (400 MHz, DMSO-d6): 6 12.07 (bs, 1H), 8.99 (s, 1H), 4.72
(s, 2H), 3.40 (m, 411), 1.63 (s, 6H), 1.5 (m, 6H), 1.22 (s, 91-1).
A29M1B0I 1H NMR (400 MHz, DMSO-d6): 6 12.36 (bs, 1H), 10.08 (s, 111),
4.82 (s, 2H), 3.15 (bs, 2H), 2.32 (s, 6H), 1.65 (s, 6H), 1.23 (s, 9H).
A02M2B01 1H NMR (400 MHz, DMSO-d6): 6 12.29 (bs, 1H), 11.05 (s, III),
7.9-7.35 (m, 3H), 5.03 (s, 2H), 2.29 (m, 2H), 1.24 (s, 9H), 0.84 (m,
2H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
61
A04M2B01 1H NMR (400 MHz, DMSO-d6): S 12.21 (bs, 1H), 10.90 (s, 1H),
7.79 (m, 1H), 7.40 (m, 1H), 7.21 (m, 1H), 5.03 (s, 2H), 2.29 (m,
2H), 1.24 (s, 9H), 0.83 (m, 21-1).
A05M2B01 1H NMR (400 MHz, DMSO-d6): 6 12.30 (bs, 111), 11.17 (s, 1 H),
7.77 (s, 2H), 7.51 (s, 1H), 5.04 (s, 2H), 2.29 (m, 211), 1.24 (s, 9H),
0.84 (m, 2H).
A06M2B01 1H NMR (400 MHz, DMSO-d6): 6 12.28 (bs, 111), 11.04 (s, 1H),
8.03 (d, 2H, J = 8.0 Hz), 7.61 (d, 2H, J = 8.0 Hz), 5.03 (s, 2H), 2.29
(m, 2H), 1.24 (s, 911), 0.83 (m, 211).
A07M2B01 'H NMR (400 MHz, DMSO-d6): 612.32 (bs, 1H), 11.22 (s, 1H),
8.21 (d, 211, J = 7.9 Hz), 7.91 (d, 2H, J = 7.9 Hz), 5.05 (s, 2H), 2.29
(m, 2H), 1.24 (s, 9H), 0.84 (m, 211).
A10M2B01 1H NMR (400 MHz, DMSO-d6): 612.23 (bs, 1H), 11.02 (s, 1H),
8.10 (m, 1H), 7.87 (m, 1H), 7.22 (m, 1H), 5.01 (s, 2H), 2.29 (m,
2H), 1.24 (s, 9H), 0.84 (m, 21-1).
A12M2B01 1H NMR (400 MHz, DMSO-d6): 612.03 (bs, 1H), 10.36 (bs, 1H),
4.95 (s, 2H), 2.26 (m, 2H), 2.17 (m, 2H), 2.09 (m, 1H), 1.22 (s, 9H),
0.93 (m, 611), 0.80 (m, 211).
A13M2B01 1H NMR (400 MHz, DMSO-d6): 6 12.05 (bs, 1H), 10.28 (bs, 1H),
4.96 (s, 2H), 3.32 (m, 1H), 2.25 (m, 8H), 1.23 (s, 9H), 0.78 (m, 2H).
A14M2B01 1H NMR (400 MHz, DMSO-d6): 6 12.03 (bs, 1H), 10.72 (bs, 1H),
4.91 (s, 2H), 2.25 (m, 2H),1.82 (m, 1H), 1.20 (s, 911), 0.80 (m, 6H).
A15M2B01 'H NMR (400 MHz, DMSO-d6): 5 12.01 (bs, 1H), 9.92 (s, 1H), 4.94
(s, 2H), 2.25 (m, 2H), 1.22 (s, 1811), 0.78 (m, 2H).
A19M2B01 1H NMR (400 MHz, DMSO-d6): 512.21 (bs, 11-1), 10.82 (s, 1H),
7.92 (m, 1H), 7.49(m, Ill), 6.69 (m, 1H), 5.01 (s, 2H), 2.29 (m,
2H), 1.24 (s, 9H), 0.83 (m, 2H).
A27M2B01 'H NMR (400 MHz, DMSO-d6): 6 11.98 (bs, 1H), 9.02 (s, 2H), 7.45
(1n, 1H), 7.33 (m, 1H), 7.13 (m, 1H), 6.81 (m, 1H), 4.96 (s, 2H),
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
62
2.27 (m, 211), 1.23 (s, 9H), 0.81 (m, 2H).
A28M2B01 'H NMR (400 MHz, DMSO-d6): S 11.83 (bs, 1H), 9.03 (s, 111), 4.87
(s, 2H), 3.41 (m, 4H), 2.23 (m, 2H), 1.58 (m, 2H), 1.49 (m, 4H),
1.22 (s, 9H), 0.76 (m, 211).
A30M1B01 'H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.7 (s, 6 H) 4.9
(s, 2 H) 7.4-8.1 (m, 5 H) 11.2 (s, 1 H) 12.5 (s, 1 H)
A31M1B01 1H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.7 (s, 6 H)1.7
(m,2H)2.0(m,2H)2.2(s,3H)2.3(m,2H)2.7(m,2H)4.5(m,
1H)4.9(s,2H)7.0(d,J=7.9Hz,2H)8.0(d,J 7.9 Hz,2H) 10.7
(s,1H)12.4(s,1H)
A32M1BO1.HC1 1H NMR (400 MHz, DMSO-d6): (mixture of two conformers) S
ppm 1.25 (s, 18 H) 1.68 (s, 12 H) 1.84 (m, 2H) 2.07 (m, 4H)
2.29 (d, J=14.0 Hz, 2 H) 2.80 (d, J=5.0 Hz, 3 H) 2.82 (d, J=5.0 Hz,
3H)3.11(m,2H) 3.20(m,2H) 3.40(m,2H) 3.52 (d, J=14.0
Hz, 2 H) 4.67 (m, 1 H) 4.87 (m, 1 H) 4.89 (s, 4 H) 7.21 (dd,
J=8.8,2.3 Hz, 1H) 7.25 (dd, J=8.8, 2.3 Hz, 111) 7.45 (m, 2 H)
7.5-7.7 (m, 4 H) 9.90 (bs, 1 H) 9.97 (bs, I H) 10.93 (s, 2 H) 12-13
(bs,2H).
A33M1B01.2HC1 1H NMR (400 MHz, DMSO-d6): S ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 2.8
(s,3H)3.4(m, 10 H) 4.9 (s,2H)7.6(s,2H)8.1 (d, J=7.9 Hz, 2 H)
10.4(s,1H)11.0(s,1H)
A34M1BO1.HC1 1H NMR (400 MHz, DMSO-d6): S ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 1.9
(m, 4 H) 3.4 (m, 4 H) 4.9 (m, 1H)4.9(s,2H)7.0(d,J=9.1Hz,2
H) 7.9(d,J 9.0 Hz, 2H) 10.6 (s, 1 H)
A35M1B0I 1H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.6 (s, 6 H) 2.3
(s,3H)2.5(m,4H)3.1 (m, 2H)3.3(m,2H)4.8(s,2H)6.9(d,
J=8.2Hz,2H)7.9(d,J=8.4Hz,2H)10.5(s,1H)12.3(s,IH)
A36M1BOI 1H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.6 (s, 6 H) 2.1
(m,2H)2.5(t,. -8.0Hz,2H)3.9(t,J=7.0Hz,2H)4.8(s,2H)7.8
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
63
(d,J=8.9Hz,2H)8.0(d,J8.8Hz,2H)10.8(s,1H)12.4(s,1H)
A37M1B01 1H NMR (400 MHz, DMSO-d6): S ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 4.1
(m,2H)4.5(m,2H)4.9(s,211)7.7(d,J8.2Hz,211)8.1 (d,
J=7.8 Hz, 2 H) 10.9 (s, 111) 12.4 (s, 1 H)
A38M1B01 1H NMR (400 MHz, DMSO-d6): S ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 3.8
(s, 3 H) 3.9 (s, 3 H) 4.9 (s, 2 H) 7.1 (d,J=8.5Hz, 1H)7.6(d,J1.2
Hz, 1 H) 7.7 (dd, J=8.5, 2.0 Hz, I H) 10.8 (s, 1 H) 12.4 (s, 1 H)
A38M2B01 1H NMR (400 MHz, DMSO-d6): S ppm 0.8 (m, 2 H) 1.2 (s, 9 H) 2.3
(m,2H)3.8(s,3H)3.9(s,3H)5.0(s,2H)7.1(m,1H)7.6(m,1
H) 7.7 (m,1H)10.8(s,1H)12.2(s,1H)
A39MIB01 1H NMR (400 MHz, DMSO-d6): S ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 4.9
(s, 2H) 7.5 (s, 1H)8.0(d,J=7.3Hz,2H)8.05(d,J7.3Hz,2H)
8.11 (s,1H)11.0(s,1H)12.5(s,1H)
A40M1B01 1H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.6 (s, 3 H) 4.9
(s, 2 H) 8.0 (d, J=8.4 Hz, 2 H) 8.1 (d, J=8.5 Hz, 2 H) 11.2 (s, 1 H)
12.5(s,1H)
A41M1B0I 1H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.7 (s, 6 H) 4.9
(s, 2 H) 7.7 (t, J=7.6 Hz, 1 H) 8.1 (d, J=7.6 Hz, 1 H) 8.3 (d, J=7.9
Hz,1H)8.4(s,1H)11.2(s,1H)12.5(s,1H)
A43MIB01 1H NMR (400 MHz, DMSO-d6): S ppm 1.2 (s, 9 H) 1.7 (s, 6 H) 4.9
(s, 2 H) 7.3 (m, 2 H) 7.6 (m, I H) 7.7 (m, 1 H) 10.9 (s, I H) 12.4 (s,
1H)
A44M1B01 1H NMR (400 MHz, DMSO-d6): S ppm 1.25 (s, 9 H) 1.68 (s, 6 H)
3.85(s,3H)4.88(s,2H)7.03(m,2H)8.01(d,J8.29Hz,2H)
10.74 (s,IH)12.40(s,IH)
A45MIBOI 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 3.8
(s,3H)4.9(s,2H)7.2(m, I H) 7.4 (m, IH)7.6(m,2H) 10.9 (s, 1
H)12.5(s,1H)
A46MIBOI 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.3 (s, 9 H) 1.7 (s, 6 H) 4.0
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
64
(s,3H)4.9(s,2H)7.1 (t,J=7.4Hz, 1H)7.2(d,J=8.3Hz, 1H)7.6
(t, J=7.8 Hz, 1 H) 7.8 (dd, J=7.7, 1.7 Hz, 1 H) 10.3 (s, 1 H) 12.4 (s,
1H)
A47M1B01 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.2 (s, 9 H) 1.6 (s, 6 H) 3.6
(s,2H)4.8(s,2H)7.25(m,1H)7.32(m,4H)10.7(s,1H)12.3
(s, 1 H)
A48M1B01 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.16 (s, 9 H) 1.60 (s, 6 H)
3.78(s,2H)4.75(s,2H)7.47(m,3H)7.80(s, 1H) 7.86 (m,3H)
10.74 (s,1H)12.30(s,1H)
A49M1B01 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.23 (s, 9 H) 1.67 (m, 14 H)
2.79 (m, 111) 4.80 (s, 2 H) 10.37 (s, 1 H) 12.23 (s, 1 H)
A50M1B01 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.32 (m, 6 H) 1.23 (s, 9 H)
1.74(m,4H)1.64(s,6H)2.36(m,1H)4.79(s,2H)10.30(s,1H)
12.21 (s, 1H)
A51MIB01 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.2 (s, 9 H) 1.6 (s, 6 H) 2.0
(m, 4H) 3.9 (m,2H)4.4(dd,J8.2,5.6Hz, 1 H)4.8(s,211) 10.1
(s,1H)12.3(s,1H)
A52M1BO1.HC1 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.2 (s, 9 H) 1.6 (s, 6 H) 1.9
(m,4H)2.6(m, 1 H)2.8(m,3H)3.0(m,2H)3.4(m,2H)4.8(s,
2 H) 9.6 (s,1H)10.6(s,1H)12.4(s,1H)
A53M1B01 'H NMR (400 MHz, DMSO-d6): 6 ppm 1.2 (s, 9 H) 1.4 (m, 1 H) 1.5
(m, 1 H) 1.6 (s, 6H) 1.7 (m,2H)2.0(s,3H)2.6(m,211)3.0(t,
J=13.0 Hz, 1 H) 3.8 (d, J=13.7 Hz, 1 H) 4.4 (d, J12.9 Hz, 1 H) 4.8
(s,2H)10.4(s,1H)12.3(s,1H)
A54MIB01 1H NMR (400 MHz, DMSO-d6): 6 12.52 (bs, 1H), 11.23 (s, 1H),
8.30 (m, 2H), 7.96 (m, 1H), 7.76 (m, 1H), 4.91 (bs, 2H), 1.69 (s,
6H), 1.25 (s, 9H).
AOIM1B02 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.65 (s, 6 H), 2.0 (m, 4 H)
3.79 (m, 2 H), 4.53 (t, IH),4.83(m,2H),7.3(m,2H),8.05(m,2
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
H), 10.92 (s, 111), 12.45 (s, I H).
A48M1B02 1H NMR (400 MHz, DMSO-d6): S ppm 1.59 (s, 3 H) 1.60 (s, 3 H)
1.86(m,4H)3.70(m,21-1)3.76(s,2H)4.44(t,J=6.52Hz, 1 H)
4.55 (d, J=12.44 Hz, 1H)4.72(d,J==12.56 Hz, 1 H) 7.46 (m,3H)
7.78 (s, 1 H) 7.86 (m, 3 H) 10.74 (s, 1 H) 12.32 (s, 1 H)
A03M1B14 1H NMR (400 MHz, DMSO-d6): S ppm 1.7 (s, 6 H) 2.0 (m, 4 H) 3.8
(m,2H)4.6(t,.J=6.6Hz, 1H)4.7(d,J=12.4 Hz, 1 H) 4.9 (d,
J=12.4 Hz, 1 H) 7.6 (ddd, J=10.5, 8.5, 8.4 Hz, 1 H) 7.9 (m, 1 H) 8.1
(m,1H)11.1(s,1H)12.5(s,IH)
aD +24.5 (c=1.08, MeOH)
A12M1B14 1H NMR (400 MHz, DMSO-d6): S ppm 0.92 (d, J-6.58 Hz, 6 H)
1.65 (d, J=2.44 Hz, 6H) 1.96(m,5H)2.16(d,J=6.95Hz,2H)
3.80 (m, 2 H) 4.53 (dd, J=6.95, 6.10 Hz, 1 H) 4.68 (m, 2 H) 10.37
(s,1H)12.30(s,1H)
aD +24.0 (c=1.00, MeOH)
A13M1B14 1H NMR (400 MHz, DMSO-d6): S ppm 1.64 (s, 6 H) 1.97 (m, 10 H)
3.25 (m, 1 H) 3.80 (m, 2 H) 4.55 (t, J-6.58 Hz, I H) 4.70 (m, 2 H)
10.26 (s,1H)12.28(s,1H)
aD +24.7 (c=1.09, McOH)
A32M1B14.HC1 1H NMR (400 MHz, DMSO-d6): (mixture of two conformers) S
ppm 1.68 (s, 12 H) 1.8-2.1 (m, 10 H) 2.30 (d, J14.0 Hz, 2 H)
2.80 (d, J=5.0 Hz, 3 H) 2.83 (d, J=5.0 Hz, 3 H) 3.1-3.3 (m, 4 H)
3.45 (m, 2 H) 3.52 (d, J=14.0 Hz, 2 H) 3.7-3.8 (m, 4 H) 4.56 (dd,
J=7.0,6.0Hz,2H) 4.66(m,11-1) 4.71,4.88(2 d,J=13Hz,4H)
4.87 (m, 1H) 7.21 (dd, J8.0, 2.3 Hz, 1H) 7.26 (dd, J=8.8,2.3 Hz,
1H) 7.46 (m, 2 H) 7.5-7.7 (m, 4 H) 9.89 (bs, 2 H) 10.94 (s, 2 H)
12-13 (bs, 2 M.
aD +17.4 (c=1.02, MeOH)
A33M1B14.2HC1 'H NMR (400 MHz, DMSO-d6): 5 ppm 1.7 (s, 3 H) 1.7 (s, 3 H) 2.0
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
66
(m, 4 H) 2.8 (s, 3 11) 3.7 (m, 10 H) 3.8 (m,2B)4.6(dd,J=7.3,5.9
Hz, 1 H) 4.7 (d, .F--12.4 Hz, 1 H) 4.9 (d, J=12.4 Hz, 1 H) 7.6 (d,
J=7.3Hz,2H)8.0(d,J=8.2Hz,2H)10.3(s,1H)11.0(s,1H)
aD +14.7 (c=1.09, McOH)
A31M1B14 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.7 (s, 6 H) 2.1 (m, 8 H) 2.8
(m,3H)3.3(m,4H)3.8(m,2H)4.6(dd,J=7.2,6.1Hz, 1H)4.7
(m,1H)4.7(d,J=12.6Hz,1H)4.9(d,J=12.6 Hz,1H)7.1(m,2
H)8.0(m,2H)9.9(m,1H)10.8(s,IM12.2(s,1H)
aD (as hydrochloride salt) +17.0 (c=1.08, MeOH)
AO1M2B14 1H NMR (400 MHz, DMSO-d6): 6 12.25 (bs, 1H), 10.98 (bs, 1H),
8.11 (m, 2H), 7.34 (m, 2H), 4.96 (m, 2H), 4.56 (t, 1H), 3.77 (m, 211)
2.24 (m, 2H), 2.03 (m, 2H), 1.87 (m, 211), 0.93 (s, 2H).
aD +15.9 (c=1.06, MeOH)
A12M1B21.HCO2H 1H NMR (400 MHz, DMSO-d6): 5 ppm 0.9 (d, J=6.6 Hz, 6 H) 1.2
(s,3H)1.5(m,2H)1.7(s,6H)2.2(m,12H)4.7(s,2H)8.2(s,1
H) 10.4 (s,1H)12.3(s,1H)
A01M1B21.HC1 1H NMR (400 MHz, DMSO-d6): (mixture of two conformers) 6
ppm1.29(s,3H) 1.38 (s,3H) 1.65(m,2H) 1.70(s,3H) 1.73
(s,3H) 1.95 (d,J=14.0Hz,2H) 2.08 (m, 2H) 2.46 (d, J=14.0
Hz, 2 H) 2.74 (d, J=5.0 Hz, 3 H) 2.79 (d, J---5.0 Hz, 3 H) 2.87 (m,
2 H) 3.13 (m, 2 H) 3.3-3.5(m, 4H) 4.86 (s, 4H) 7.35 (t, J=8.9
Hz, 4 H) 8.09 (dd, J=8.9, 5.5 Hz, 4H) 9.5 (bs, 1 H) 9.7 (bs, 1 H)
11.01 (s, 1 H) 11.03 (s, 1 H) 12-13 (bs, 2 H).
AO1M1B22.HC1 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.69 (s, 6 H) 2.16 (m, 6 H)
3.32(m,6H)4.89(s,2H)7.36(t,J=8.66Hz,2H)8.08(dd,
J=9.02, 5.49 Hz, 2 H) 9.58 (s, I H) 11.01 (s, 1 H) 12.55 (s, I
H)
A48M1B43 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.16 (t, J=7.13 Hz, 3 H)
1.57 (s, 6H) 3.76 (s, 2H) 4.00 (q, J=7.07 Hz, 2H) 4.38 (s, 2 H)
7.48 (m, 3 H) 7.79 (s, 111) 7.87 (m, 3 H) 10.73 (s,IH) 12.32 (s, 1H)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
67
Example 18
N-{6,6-dimethyl-5-[(1-methylpiperidin-4-yl)carbonyl]-2,4,5,6-
tetrahydropyrrolo[3,4-
c]pyrazol-3-yl}-4-fluorobenzamide
Ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-dihydropyrrolo[3,4-
c]pyrazole-1(4H)-
carboxylate hydrochloride (0.5 g, 1.3 mmol), in dichloromethane (25 ml), was
treated with
N,N-diisopropylethylamine (1.13 ml, 6.5 mmol, 5 eq) and TBTU (0.542 g, 1.69
mmol, 1.3
eq), at room temperature for 1 hour, and then 1-methyl-piperidine-4-carboxylic
acid
hydrochloride (0.29 g, 1.61 mmol, 1.2 eq) was added. The reaction was stirred
overnight
(TLC: CH2Cl2/MeOH 90/10). The solution was washed with saturated sodium
hydrogencarbonate aqueous solution and brine, the organic phase was dried over
sodium
sulfate and concentrated. The residue was dissolved in methanol (16 ml),
treated with TEA
(2 ml, 14.3 mmol, 11 eq) and stirred overnight at room temperature. (TLC:
CH2C12/MeOH/NH4OH 90/10/l). After evaporation, the solid was purified by flash
chromatography (eluent: CH2C12/MeOH/NH4OH 90/10/2). The solid was treated with
diisopropylether and filtered to afford 0.36 g of the title compound in 69%
yield.
ESI MS: m/z 400 (MH+);
1H NMR (400 MHz, DMSO-d6): S 12.48 (bs, 111), 10.97 (bs, 1H), 8.09 (m, 211),
7.35 (m,
211), 4.75 (bs, 2H), 2.87 (m, 2H), 2.40 (m, 1H), 2.24 (s, 3H), 2.05 (m, 2H),
1.67 (m, 10H).
By working in an analogous manner the following compound was prepared:
N-[5-[(1-methylpiperidin-4-yl)carbonyl]-2,4,5,6-tetrahydropyrrolo [3,4-
c]pyrazol-6-
spirocyclopropan-3-yl]-4-fluorobenzamide
ESI MS: m/z 398 (MH+);
1H NMR (400 MHz, DMSO-d6): S 12.20 (bs, 1H), 11.00 (s, 1H), 8.10 (m, 2H), 7.36
(m,
2H), 4.91 (s, 2H), 2.84 (m, 2H), 2.40 (m, 1H), 2.23 (m, 5H), 2.0 (m, 2H), 1.65
(m, 411),
0.89 (m, 2H).
By working in analogous manner and by using the proper starting material and
any suitable
reactant, as per the aforementioned process, additional compounds of formula
(Ia) and (Ib)
were also prepared, as reported in the following table IV
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
68
Table IV
AO1M1B03.HC1 1H NMR (400 MHz, DMSO-d6): S 11.02 (s, 111), 9.56 (bs, 1H), 8.11
(m, 211), 7.36 (m, 2H), 4.80 (bs, 211), 3.43 (m, 211), 3.07 (m, 211) 2.75
(d, 311), 2.69 (m, 1H), 1.94 (m, 411), 1.67 (m, 611).
A02M1B03.HC1 'H NMR (400 MHz, DMSO-d6) S ppm 1.68 (m, 6 H) 1.93 (m, 4 H)
2.74(m,4H)3.07(m,2H)3.42(m,2H)4.81 (s, 2 H) 7.46 (m, 1 H)
7.59 (td, J=7.96,5.91 Hz, 1 H) 7.82 (ddd, J10.00, 2.32, 1.59 Hz, 1
H) 7.87 (dt, J=7.90, 1.11 Hz, 1 H) 9.49 (s, I H) 11.09 (s, 1 H)
A03M1B03.HC1 1H NMR (400 MHz, DMSO-d6) S ppm 1.69 (m, 6 H) 1.93 (m, 4 H)
2.74(m,4H)3.02(m,2H)3.34(m,2H)4.79(s,2H)7.40(m, 1 H)
7.53(m,1H)7.60(m,1H)9.48(s,IU)11.11(s,1H)
A04M1B03 1H NMR (400 MHz, DMSO-d6): 6 12.48 (bs, 1H), 10.93 (s, 1H), 7.75
(m, 111), 7.40 (m, 1H), 7.22 (m, 1H), 4.75 (bs, 211), 2.85 (m, 211),
2.38 (m, 111), 2.21 (bs, 3H), 2.01 (m, 211), 1.67 (m, 10H).
A05MIB03.HC1 1H NMR (400 MHz, DMSO-d6): 6 12.6 (bs, 111), 11.19 (s, 1H), 9.49
(bs, 111), 7.72 (m, 2H), 7.51 (m, 111), 4.80 (bs, 211), 3.46 (m, 211),
3.06 (m, 2H), 2.76 (bd, 3H), 2.71 (m, 1H), 1.97 (m, 2H), 1.81 (m,
211), 1.67 (s, 611).
A06MIB03.HC1 1H NMR (400 MHz, DMSO-d6): 612.55 (bs, 1H), 11.06 (s, 1H), 9.66
(bs, 1H), 8.02 (m, 211), 7.63 (m, 211), 4.81 (s, 2H), 3.4 (m, 2H), 3.01
(m, 2H), 2.75 (bs, 3H), 2.68 (m, 111), 1.95 (m, 2H), 1.84 (m, 211),
1.67 (s, 6H).
A07M1B03.HC1 1H NMR (400 MHz, DMSO-d6): S 12.60 (bs, 1H), 11.25 (s, 1H), 9.50
(bs, 1H), 8.19 (d, 211, J = 7.9 Hz), 7.92 (d, 211, J = 7.9 Hz), 4.83 (s,
2H), 3.4 (m, 2H), 3.01 (m, 2H), 2.78 (bd, 3H), 2.75 (m, 1H), 1.9 (m,
2H), 1.8 (m, 211), 1.67 (s, 6H).
A09M1B03.2HC1 1H NMR (400 MHz, DMSO-d6) 6 ppm 11.38 (s, 1H), 9.68 (s, 1H),
8.83 (d, J=6.22 Hz, 211), 7.98 (d, J6.22 Hz, 21-1), 4.82 (s, 211), 3.4
(m, 2H), 3.07 (m, 211), 2.75 (bd, 3H), 2.69 (m, 1H), 1.90 (m, 411),
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
69
1.69 (s, 6 H)
A1OM1B03.HC1 1H NMR (400 MHz, DMSO-d6): S 12.52 (bs, 1H), 11.07 (s, 11-1),
9.50
(bs, 1H), 8.12 (m, 1H), 7.86 (m, 1H), 7.22 (m, 1H), 4.79 (bs, 2H),
3.42 (m, 2H), 3.08 (m, 2H), 2.76 (m, 4H), 1.94 (m, 2H), 1.82 (m, 2H),
1.67 (s, 6H).
Al 1M1B03.HCI 1H NMR (400 MHz, DMSO-d6): S 12.41 (bs, 1H), 10.83 (s, 1H), 9.55
(s, 1H), 8.43 (dd, J=2.80,1.46 Hz, 1H), 7.67 (dd, J=5.12, 1.46 Hz,
1H), 7.65 (dd, J5.12, 2.80 Hz, 1H), 4.79 (s, 2H), 3.47 (m, 211), 3.06
(m, 2H), 2.74 (m, 4H), 1.88 (m, 4H), 1.68 (s, 6H).
A12M1B03 1H NMR (400 MHz, DMSO-d6): S 12.29 (bs, 1H), 10.40 (s, 1H), 4.65
(s, 2H), 2.86 (m, 2H), 2.35 (m, 1H), 2.22 (bs, 3H), 2.17 (d, 2H, J =
7.07 Hz), 2.02 (m, 3H), 1.64 (m, 1011), 0.92 (d, 6H, J = 6.6 Hz).
A12M1B03.HC1 'H NMR (400 MHz, DMSO-d6): S 12.29 (s, 1H), 10.41 (bs, 1H), 9.57
(s, 1H), 4.71 (s, 2H), 3.46 (m, 2H), 3.07 (m, 2H), 2.75 (bd, 311), 2.69
(m, 1H), 2.17 (d, 2H, J = 6.95 Hz), 2.04 (m, 1H), 1.92 (m, 4H), 1.67
(s, 6H), 0.92 (d, 6H, J = 6.7 Hz).
A13M1B03 1H NMR (400 MHz, DMSO-d6): S 12.29 (bs, 1H), 10.27 (s, 1H), 4.69
(s, 211), 3.35 (m, 111), 2.87 (m, 2H), 2.38 (m, 111), 2.24 (bs, 3H), 2.20
(m, 6H), 2.07 (m, 2H), 1.63 (m, 10H).
A13M1B03.HC1 1H NMR (400 MHz, DMSO-d6): 812.34 (bs, 1H), 10.30 (s, 1H), 9.48
(bs, 1H), 4.75 (s, 2H), 3.47 (m, 2H), 3.31 (m, 1H), 3.09 (m, 2H), 2.75
(bd, 3H), 2.70 (m, 1H), 2.23-1.76 (m, 1011), 1.64 (s, 6H).
A13M1B03.CH3SO3H 1H NMR (400 MHz, DMSO-d6): 812.33 (bs, 1H), 10.31 (s, 111),
9.21
(bs, 1H), 4.75 (s, 2H), 3.44 (m, 2H), 3.24 (m, 1H), 3.09 (m, 2H), 2.78
(bd, 3H), 2.72 (m, 111), 2.35 (s, 3H), 2.23-1.72 (m, 1OH), 1.64 (s, 611).
A14M1B03 1H NMR (400 MHz, DMSO-d6): 812.30 (bs, 1H), 10.72 (s, 1H), 4.63
(s, 2H), 2.86 (m, 2H), 2.34 (m, 1H), 2.23 (bs, 3H), 2.04 (m, 2H), 1.83
(m, 1H), 1.63 (m, 10H), 0.79 (m, 4H).
A16M1B03 1H NMR (400 MHz, DMSO-d6): 5 12.30 (bs, 1H), 11.10 (s, 1H), 8.13
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
(d, 2H, J = 7.9 Hz), 7.51 (d, 2H, J = 7.9 Hz), 4.75 (s, 211), 2.86 (m,
211), 2.39 (m, 111), 2.22 (s, 311), 2.03 (m, 211), 1.69 (m, 1011).
A17M1B03 1H NMR (400 MHz, DMSO-d6): S 12.48 (bs, 111), 10.98 (s, 111), 7.79
(m, 111), 7.61 (m, 111), 7.54 (m, 111), 7.45 (m, 211), 7.25 (m, 211), 7.10
(m, 211), 4.72 (s, 211), 2.82 (m, 211), 2.34 (m, 111), 2.19 (s, 311), 1.96
(m, 211), 1.66 (m, 1011).
A19M1B03.HC1 'H NMR (400 MHz, DMSO-d6): S 10.87 (s, 111), 9.55 (bs, 111), 7.93
(dd, J=1.71, 0.85 Hz, 111), 7.44 (dd, J=3.48, 0.79 Hz, 111), 6.70 (dd,
J=3.48, 1.77 Hz, 111), 4.77 (bs, 211), 3.30 (m, 211), 3.05 (m, 211), 2.74
(m, 411), 1.93 (m, 211), 1.84 (m, 211), 1.67 (s, 611).
A21M1B03 1H NMR (400 MHz, DMSO-d6): 8 12.40 (bs, 111), 11.00 (s, 111), 8.65
(d, 1H, J = 2.5 Hz), 8.16 (d, 211, J = 8.3 Hz), 8.01 (d, 2H, J = 8.3 Hz),
7.83 (d, 1H, J = 1.6 Hz), 6.62 (dd, 1H, J = 2.5 Hz), 4.47 (s, 211), 2.86
(m, 211), 2.38 (m, 111), 2.22 (s, 311), 2.03 (m, 211), 1.69 (m, 1011).
A22M1B03 1H NMR (400 MHz, DMSO-d6): S 12.44 (bs, 1H), 11.12 (s, 111), 8.25
(m, 111), 8.09 (m, 111), 8.03 (m, 111), 7.75 (m, 111), 7.60 (m, 311), 4.82
(bs, 211), 2.84 (m, 211), 2.38 (m, 111), 2.19 (s, 311), 1.98 (m, 211), 1.70
(m, IOH).
A23M1B03 1H NMR (400 MHz, DMSO-d6): 612.51 (bs, 111), 11.11 (s, 111), 8.67
(bs, 111), 8.07 (m, 411), 7.66 (m, 211), 4.80 (bs, 211), 2.86 (m, 211),
2.38 (m, 111), 2.22 (s, 311), 2.02 (m, 211), 1.69 (m, l OH).
A24M1B03 'H NMR (400 MHz, DMSO-d6): S 12.11 (bs, 111), 8.82 (s, 111), 7.19
(m, 411), 6.81 (m, 111), 4.61 (s, 211), 4.29 (d, 2H, J = 5.80 Hz), 2.85
(m, 211), 2.33 (m, 111), 2.30 (s, 311), 2.21 (s, 311), 2.03 (m, 211), 1.63
(m, 1011).
A25M1B03 'H NMR (400 MHz, DMSO-d6): S 12.08 (bs, 111), 8.85 (s, 111), 7.30
(m, 511), 6.91 (bs, 111), 4.61 (s, 211), 4.32 (d, 211, J = 5.90 Hz), 2.86
(m, 211), 2.35 (m, 111), 2.30 (s, 311), 2.05 (m, 211), 1.63 (m, 1011).
A26M1B03 1H NMR (400 MHz, DMSO-d6): 8 12.00 (bs, 111), 8.67 (s, 111), 6.45
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
71
(bs, 1H), 4.59 (s, 2H), 3.06 (m, 2H), 2.83 (m, 2H), 2.34 (m, 1H), 2.19
(s, 3H), 1.96 (m, 2H), 1.65 (m, 4H), 1.62 (s, 6H), 1.43 (m, 2H), 0.88
(t, 3H).
A27M1B03 1H NMR (400 MHz, DMSO-d6): 612.25 (bs, 1H), 9.05 (s, 1H), 7.45
(m, 1H), 7.33 (m, 1H), 7.13 (m, 1H), 6.81 (m, 1H), 4.68 (s, 2H), 2.89
(m, 2H), 2.40 (m, 11), 2.26 (s, 3H), 2.1 (m, 2H), 1.65 (m, 101).
A28M1B03.HC1 1H NMR (400 MHz, DMSO-d6): 612.13 (bs, 11), 9.05 (bs, 1H), 4.64
(s, 2H), 3.5-3.2 (m, 8H), 2.75 (m, 4H), 1.94 (m, 21), 1.82 (m, 211),
1.63 (m, 12H).
A30MO1B03 ' 1H NMR (400 MHz, DMSO-d6): 612.48 (bs, 1H), 10.93 (bs, 1H), 8.0
(m, 21), 7.61 (m, 1H), 7.51 (m, 2H), 4.76 (bs, 2H), 2.86 (m, 2H),
2.38 (m, 1H), 2.23 (bs, 3H), 2.03 (m, 21), 1.67 (m, 10H).
AO1M1B04.HCI 1H NMR (400 MHz, DMSO-d6): 61.24 (t, J=7.32 Hz, 3 H) 1.69 (s, 6
H) 1.98 (m, 4 H) 2.78 (m, 1 H) 3.09 (dd, J=7.32, 5.00 Hz, 4 H) 3.50
(d,J=11.71Hz,2H)4.80(s,2H)7.36(t,J=8.78 Hz, 2 H) 8.09 (m, 2
H)9.30(s,1H)11.01(s,1H)12.56(s,111).
A03M1BO4.HCI 1H NMR (400 MHz, DMSO-d6): 6 1.24 (t, J=7.32 Hz, 3 H) 1.69 (s, 6
H) 1.91 (m, 4 H) 2.77 (m, 1 1) 3.31 (m, 6 H) 4.80 (s, 2 H) 7.61 (m, 1
H)7.91(m,1H)8.07(m,1H)9.24(s,1H)11.11(s,11)12.59(s,1
M.
A12MO1B04.HC1 1H NMR (400 MHz, DMSO-d6): 6 0.92 (d, J=6.5 8 Hz, 61) 1.24 (t,
J=7.26 Hz, 3H) 1.65(s,6H)1.88(m,411)2.06(m, 1 2.17 (d,
.T--7.07Hz,2H)2.70(m, 11) 3.23 (m, 6H) 4.72 (s, 2H) 9.32 (s, I
1) 10.41 (s,IH)12.34(s,IH).
A13MO1B04.HC1 'H NMR (400 MHz, DMSO-d6): 61.25 (t, J=7.32 Hz, 3 H) 1.65 (s, 6
H)2.03(m,10H)2.77(m,1H)3.28(m,711)4.75(s,2H)9.31(s,1
H) 10.30 (s,1H)12.35(s,IH).
A27M01 B04.HC1 1H NMR (400 MHz, DMSO-d6): 6 1.24 (t, J=7.32 Hz, 3 H) 1.66 (s,
6
H)1.89(m,4H)2.75(s,1H)3.18(m,6H)4.73(s,2H)6.80(m,1
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
72
H) 7.08 (ddd, J 8.17, 1.95, 0.73 Hz, 1 H) 7.32 (td, J=8.17, 6.95 Hz, 1
H) 7.52 (dt, J=11.89, 2.35 Hz, 1 H) 9.10 (s, 1 H) 9.22 (s, 1 H) 9.27 (s,
1H)12.24(s,1H)
AO1MIB05 'H NMR (400 MHz, DMSO-d6): S 12.48 (bs, 1H), 10.97 (s, 1H), 8.09
(m, 2H), 7.35 (m, 2H), 4.75 (s, 2H), 3.00 (m, 2H), 2.44 (m, 1H), 2.24
(m, 211), 1.8-1.5 (m, 5H), 1.67 (s, 6H), 0.38 (m, 4H).
A03M1B05.HC1 1H NMR (400 MHz, DMSO-d6): S 0.82 (m, 2 H) 0.99 (s, 2 H) 1.68 (s,
6H)1.91(m,4H)2.79(m,1H)3.38(m,5H)4.81(s,2H)7.62(m,
1 H) 7.92 (ddd, J=8.72, 4.27, 1.40 Hz, 1 H) 8.08 (ddd, J=11.52, 7.80,
2.13Hz,1H)9.14(s,1H)11.12(s,1H)12.57(s,11-1)
A12M1B05.HC1 1H NMR (400 MHz, DMSO-d6): S 0.82 (m, 2 H) 0.93 (d, J6.58 Hz,
6H)1.00(s,2H)1.65(s,6H)1.90(m,4H)2.06(m,1H)2.17(d,
J=7.07 Hz, 2 H) 2.76 (m, 1 H) 3.36 (m, 5H) 4.73 (s, 2H) 9.20 (s, 1
H) 10.41 (s,1H)12.35(s,1H)
A13M1B05.HC1 1H NMR (400 MHz, DMSO-d6): S 0.82 (m, 2 H) 1.01 (s, 2 H) 1.65 (s,
6H)2.01(m,10H)2.78(m,1H)3.33(m,6H)4.77(s,2H)9.23(s,
1H)10.30(s,1H)12.25(s,1H)
A27M1B05.HC1 1H NMR (400 MHz, DMSO-d6): 6 0.82 (q, J=6.87 Hz, 2 H) 1.00 (m,
2H) 1.66 (s, 6H) 1.88 (m,4H)2.77(m, 1 H) 3.40 (m, 5 H) 4.75 (s, 2
H) 6.81 (m, 1 H) 7.09 (ddd, J8.11, 1.95, 0.79 Hz, 1 H) 7.32 (td,
J8.20, 7.01 Hz, 1 H) 7.52 (dt, J11.77, 2.23 Hz, 1 H) 9.10 (s, 111)
9.17 (m,1H)9.21(s,IH)12.99(s,1H)
AO1M1B06.HC1 1H NMR (400 MHz, DMSO-d6): S 1.68 (s, 6 H) 1.80 (m, 4 H) 2.81
(m, 1H)3.01 (m,2H)3.38(m,2H)4.78(s,2H)7.36(t,J8.84Hz,
2 H) 8.09 (dd, J=8.96, 5.43 Hz, 2 H) 8.35 (m, 1 H) 8.62 (d, J=9.88
Hz,1H)11.00(s,1H)12.52(s,1H)
A03M1B06.HC1 1H NMR (400 MHz, DMSO-d6): S 1.68 (s, 6 H) 1.83 (m, 4 H) 2.80
(m,1H)3.00(m,2H)3.37(m,2H)4.78(s,2H)7.61(m,1H)7.92
(m, 1 H) 8.07 (ddd, J=11.49, 7.83, 2.13 Hz, 1 H) 8.45 (m, 2 H) 11.11
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
73
(s, 1 H) 12.57 (s, 1 H)
A04M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.81 (s, 6 H) 2.21 (s, 3 H)
4.51 (s, 2 H) 6.96 (d, J=4.88 Hz, 1 H) 7.16 (t, J=7.68 Hz, 1 H) 7.35 (t,
J=10.97 Hz, 1 H) 7.54 (d, .5.00 Hz, 1 H) 7.69 (m, 1 H) 10.88 (s, 1
H) 12.56 (s, 1 H)
A12M1B07 1H NMR (400 MHz, DMSO-d6): S 12.37 (bs, 1H), 10.35 (s, 1H), 7.54
(d, 1H, J = 5.0 Hz), 6.96 (d, 1H, J = 5.0 Hz), 4.42 (s, 2H), 2.20 (s,
3H), 2.10 (d, 2H, J = 7.19 Hz), 1.98 (m, 1H), 1.77 (s, 3H), 0.87 (d,
6H, J = 6.47 Hz).
A13M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.74 (m, 1 H) 1.77 (s, 6 H)
1.88(m, 1H)2.02(m,2H)2.14(m,2H)2.20(s,3H)3.18(m, 1H)
4.44 (s, 2 H) 6.97 (d, J=5.00 Hz, 1 H) 7.55 (d, J=4.88 Hz, 1 H) 10.25
(s,IH)12.36(s,1H)
A14M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 0.72 (m, 4 H) 1.77 (s, 7 H)
2.18(s,3H)4.39(s,2H)6.95(d,.T--5.00Hz, 1 H) 7.54 (d, J=5.00
Hz,IH)10.69(s,1H)12.37(s,1H)
A21M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.82 (s, 6 H) 2.23 (s, 3 H)
4.53 (s, 2 H) 6.61 (s, 1 H) 6.98 (d, .5.00 Hz, I H) 7.56 (d, J=4.88
Hz, 1 H) 7.82 (s, 1 H) 7.96 (m, 2 H) 8.10 (d, J=7.44 Hz, 2 H) 8.64 (d,
.2.44 Hz, I H) 10.98 (s, 1 H) 12.57 (s, 1 H)
A23M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.83 (s, 6 H) 2.23 (s, 3 H)
4.57 (s, 2 H) 6.98 (d, J=5.00 Hz, 1 H) 7.56 (d, J=4.88 Hz, 1 H) 7.63
(m,2H)8.01(m,4H)8.63(m,IH)11.07(s,1H)12.58(s,IH)
A25M1B07 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.76 (s, 6 H) 2.19 (s, 3 H)
4.26 (d, J=5.85 Hz, 2 H) 4.36 (s, 2 H) 6.86 (s, 1 H) 6.95 (d, J=4.88
Hz, 1 H) 7.22 (s, 3 H) 7.32 (m, 2 H) 7.53 (d, J=4.88 Hz, 1 H) 8.82 (s,
IH)12.14(s,1H)
A27M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.79 (s, 6 H) 2.21 (s, 3 H)
4.44 (s, 2 H) 6.78 (m, 1 H) 6.97 (d, .x=4.88 Hz, 1 H) 7.07 (m, 1 H)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
74
7.29 (m, 1 H) 7.35 (m, I H) 7.55 (d, J=5.00 Hz, 1 H) 9.04 (s, 1 H)
12.32 (s, 1 H)
A30M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.81 (s, 6 H) 2.22 (s, 3 H)
4.52 (s, 2H) 6.97 (d, J=5.00 Hz, 1 H) 7.48 (m, 2 H) 7.56 (m, 1H)
7.56 (d, J=5.00 Hz, 1 H) 7.95 (d, J7.32 Hz, 2 H) 10.92 (s, 1 H) 12.55
(s, 1 H)
A48M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.73 (s, 6 H) 2.13 (s, 3 H)
3.71 (s, 2 H) 4.35 (s, 2 H) 6.89 (d, J=4.88 Hz, 1 H) 7.40 (dd, J=8.47,
1.65 Hz,1H)7.47(m,3H)7.74(s,1H)7.84(m,3H)10.74(s,1H)
12.40 (s, 1 H)
A53M1B07 1H NMR (400 MHz, DMSO-d6): S ppm 1.34 (m, 1 H) 1.50 (m, 1 H)
1.72(m,2H) 1.77(s,6H) 1.98(s,3H)2.19(s,3H)2.55(m,2H)
3.00 (m, I H) 3.81 (d, J12.56 Hz, 1 H) 4.35 (d, J12.07 Hz, 1 H)
4.42 (s, 2 H) 6.96 (d, J=5.00 Hz, 1 H) 7.54 (d, J=4.88 Hz, 1 H) 10.45
(s, 1 H) 12.40 (s, 1 H)
A54M1B07 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.82 (s, 6 H) 2.22 (s, 3 H)
4.53 (s, 2 H) 6.97 (d, J=5.00 Hz, 1 H) 7.56 (d, J=5.00 Hz, 1 H) 7.72
(m, 1 H) 7.91 (m, 1 H) 8.24 (m, 2 H) 11.24 (s, I H) 12.62 (s, 1 H)
A31MOIB19.HC1 'H NMR (400 MHz, DMSO-d6): S 1.80 (s, 6 H) 2.07 (m, 4 H) 2.81
(m,3H)3.14(m,4H)4.75(m, 1 H) 4.99 (s, 2H) 7.13 (m, 2H) 7.20
(dd, .J--4.94, 3.84 Hz, 1 H) 7.63 (dd, J3.72, 0.79 Hz, 1 H) 7.80 (d,
J5.00 Hz, 1 H) 8.02 (m, 2 H) 10.07 (m, I H) 10.86 (s, 1 H) 11.99 (s,
1H)
A31M1B20.HC1 1H NMR (400 MHz, DMSO-d6): (mixture of two conformers) S ppm
1.63 (m, 8 H) 1.67 (s, 12 H) 1.86 (m, 2 H) 2.10 (m, 4 H) 2.28 (d,
J14.0Hz,2H) 2.68(m,2H) 2.79(d,J=5.0Hz,3H) 2.81(d,
J=5.0 Hz, 3 H) ) 3.1-3.3 (m, 4 H) 3.46 (m, 2 H) 3.52 (d, J=14.0
Hz, 2 H) 3.90 (m, 8 H) 4.68 (m, 1 H) 4.76 (m, 4 H) 4.89 (m, 1 H)
7.11 (d, J=8.9 Hz, 2 H) 7.14 (d, J=8.9 Hz, 2 H) 8.01 (d, J=8.9 Hz,
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
2 H) 8.03 (d, J=8.9 Hz, 2 H) 10.02 (bs, 2 H) 10.81 (bs, 2 H)
A33M1B20.HC1 1H NMR (400 MHz, DMSO-d6):6 ppm 1.65 (m, 4 H) 1.68 (s, 6 H)
2.70 (m, 1 H) 2.81 (s, 3 H) 2.9-3-8 (bs, 8 H) 3.90 (m, 4 H) 4.06
(bs,2H) 4.77 (s,2H) 7.62(bs,21-1) 8.07 (d, J=7.8 Hz, 2 H) 10.60
(bs,1H) 11.01(s,1H)
A12M1B44 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.14 (m, 2 H) 0.46 (m, 2 H)
0.91 (d,J=6.58Hz,6H) 1.01 (m, 1H) 1.66 (s,6H)2.05(m, 1H)
2.16(d,J=7.07Hz,2H)2.24(d,J=6.58Hz,2H)4.54(s,2H) 10.35
(s,1H)12.27(s,1H)
A13M1B44 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.15 (m, 2 H) 0.47 (m, 2 H)
1.01 (m, 11-1) 1.66 (s, 6 H) 1.80 (m, 1 H) 1.92 (m, 1 H) 2.08 (m, 2 H)
2.17(m,2H)2.26(d,.I~=6.46 Hz, 2H) 3.25 (m, 111)4.58(s,2H)
10.25 (s,1H)12.26(s,1H)
A14M1B44 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.13 (m, 2 H) 0.44 (m, 2 H)
0.76 (m, 4 H) 0.98 (m, 1 H) 1.65 (s, 6 H) 1.81 (m, 1 H) 2.22 (d,
.f==6.58 Hz, 2 H) 4.51 (s, 2 H) 10.69 (s, 1 H) 12.27 (s, 1 H)
A25M1B44 1H NMR (400 MHz, DMSO-d6): 5 ppm 0.13 (m, 2 H) 0.45 (m, 2 H)
0.99 (m, 1 H) 1.65 (s, 6 H) 2.23 (d, J=6.46 Hz, 2 H) 4.31 (d, J 5.85
Hz, 2 H) 4.49 (s, 2 H) 6.89 (s, 1 H) 7.25 (m, 1 H) 7.28 (d, J=7.07 Hz,
2 H) 7.34 (m, 2 H) 8.83 (s, 1 H) 12.04 (s, 1 H)
A26M1B44 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.14 (m, 2 H) 0.47 (m, 2 H)
0.87 (t, J=7.44 Hz, 3 H) 1.00 (m, I H) 1.43 (m, 2 H) 1.64 (s, 6 H)
2.23 (d, J=6.58 Hz, 2 H) 3.04 (m, 2 H) 4.48 (s, 2 H) 6.43 (s, 111) 8.65
(s,1H)12.00(s,IE)
A30M1B44 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.16 (m, 2 H) 0.47 (m, 2 H)
1.02 (m,1H)1.70(s,6H)2.28(d,J-6.58 Hz, 2H) 4.65 (s,2H)7.51
(m, 2 H) 7.59 (m, I H) 8.01 (d, J=7.44 Hz, 2 H) 10.91 (s, 111) 12.46
(s, 1 H)
A54M1B44 1H NMR (400 MHz, DMSO-d6): 8 ppm 0.16 (m, 2 H) 0.47 (m, 2 H)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
76
1.02(m,11-1)1.70(s,6H)2.28(d,J=6.58Hz,2H)4.65(s,2H)7.78
(m,1H)7.98(m,1H)8.35(m,2H)11.25(s,1H)12.53(s,1H)
A04M1B45 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.60 (m, 1 H) 0.97 (m, 1 H)
1.12 (d, J=5.97 Hz, 3 H) 1.19 (m, 1 H) 1.51 (m, 1 H) 1.66 (s, 6 H)
4.86(s,2H)7.20(m,1H)7.40(m,1H)7.76(m,1H)10.89(s,1H)
12.48 (s,1H)
A30M1B45 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.61 (m, 1 H) 0.96 (m, 1 H)
1.13 (d, J=5.85 Hz, 3 H) 1.20 (m, 1 H) 1.53 (m, 1 H) 1.67 (s, 6 H)
4.87(s,2H)7.51(m,2H)7.60(m,1H)8.02(d,J=7.07 Hz,2H)
10.92 (s, I H) 12.47 (s, 1 H)
A54M1B45 1H NMR (400 MHz, DMSO-d6): 5 ppm 0.61 (m, 1 K) 0.96 (m, l H)
1.13 (d, J=5.85 Hz, 3 H) 1.20 (m, 1 H) 1.53 (m, 11-1) 1.67 (s, 6 H)
4.88 (s, 2 H) 7.77 (m, 1 H) 7.96 (m, 1 H) 8.31 (d, l H) 8.39 (m, 1 H)
11.26 (s,IH)12.54(s,1H)
AOIM1B47 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.79 (s, 6 H) 2.23 (s, 6 H)
3.52(s,2H)4.43(s,2H)7.26(t,J8.78Hz,2H)7.38(m,4H)7.95
(dd, J8.84, 5.55 Hz, 2 H) 10.90 (s, 1 H) 12.50 (s, 1 H)
A48M1B47 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.79 (s, 6 H) 2.14 (s, 6 H)
3.41 (s, 2 H) 3.67 (s, 2H), 4.33 (s, 2 H) 7.30 (m, 5 H) 7.45 (m, 2 H)
7.70 (m, I H) 7.80 (m, 3 H) 10.70 (s, 1 H) 12.37 (s, 111)
A48M1B48 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.76 (s, 6 H) 2.18 (s, 3 H)
2.35 (m, 8H), 3.45 (s, 2 H) 3.68 (s, 2H), 4.34 (s, 2 H) 7.30 (m, 5 H)
7.47 (m, 2 H) 7.70 (m, I H) 7.81 (m, 3 H) 10.70 (s, 1 H) 12.37 (s, 1
H)
AO1MIB50 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.87 (t, J=7.44 Hz, 3 H) 1.49
(m,2H) 1.68(s,6H)2.27(t,J7.38Hz,2H)4.64(s,2H)7.30(m,2
H) 8.04 (m, 2 H) 10.92 (s, 1 H) 12.43 (s, I H)
A04M1B50 'H NMR (400 MHz, DMSO-d6): 6 ppm 0.93 (t, J=7.44 Hz, 3 H) 1.56
(m,2H) 1.68 (s, 6 H) 2.28 (t,J7.38Hz,2H)4.68 (s, 2H) 7.22 (m, 1
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
77
H) 7.40 (m, 1 H) 7.75 (m, 1 H) 10.88 (s, 1 H) 12.47 (s, 1 H)
A13M1B50 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.93 (t, J=7.38 Hz, 3 H) 1.55
(m,2H) 1.64(s,6H) 1.80(m, 1 H) 1.93(m, 111) 2.07 (m, 2H) 2.18
(m,2H)2.27(t,J==7.38 Hz,2H)3.23(m,1H)4.61(s,2H)10.24(s,
1 H) 12.27 (s, 1 H)
A14M1B50 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.78 (d, J=1.95 Hz, 4 H) 0.91
(t, J=7.38 Hz, 3 H) 1.52 (m, 2 H) 1.64 (s, 6 H) 1.82 (m, 1 H) 2.24 (t,
J7.38Hz,2H)4.55(s,2H) 10.70 (s, 1H) 12.27 (s, 1H)
A30M1B50 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.94 (t, J=7.44 Hz, 3 H) 1.57
(m, 2H) 1.69(s,6H)2.30(t,J7.38Hz,2H)4.68(s,2H)7.52(m,2
H) 7.60 (m, 1 H) 8.01 (d, J=7.80 Hz, 2 H) 10.92 (s, 1 H) 12.46 (s, I
H)
A54M1B50 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.94 (t, J=7.44 Hz, 3 H) 1.57
(m, 2H) 1.69 (s, 6 H) 2.29 (t, J=7.38 Hz, 2H)4.70(s,2H) 8.31 (m, 4
H) 11.25 (s, 1H) 12.53 (s, 1H)
A04M1B51 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.68 (s, 6 H) 2.03 (m, 2 H)
3.27(m, 1H)3.73(m,3H)3.93(t,J=8.11 Hz, 1H)4.76(m,2H)
7.21 (m, I H) 7.39 (m, 1 H) 7.74 (m, 1 H) 10.90 (s, 1 H) 12.49 (s, 1
H
A12M1B51 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.92 (d, J6.58 Hz, 6 H) 1.65
(s,6H)2.03(m,3H)2.17(d,J7.07Hz,2H)3.21(m,IH)3.73(m,
3 H) 3.91 (t, J8.11 Hz, 1 H) 4.66 (m, 2 H) 10.38 (s, I H) 12.30 (s, 1
H)
A13M1B51 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.65 (s, 6 H) 1.80 (m, 1 H)
1.96(m,3H)2.07(m,2H)2.19(m,2H)3.26(m,2H)3.74(m,3H)
3.92 (t, J8.11 Hz, 1 H) 4.70 (m, 2 H) 10.27 (s, I H) 12.29 (s, 1 H)
A14M1B51 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.78 (m, 4 H) 1.64 (s, 6 H)
1.83 (m, 1 H) 2.01 (m, 2 H) 3.20 (m, 1 H) 3.72 (m, 3 H) 3.90 (t,
J=8.05 Hz, 1 H) 4.64 (m, 2 H) 10.71 (s, 1 H) 12.29 (s, 1 H)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
78
AOIM1B52 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.79 (s, 6 H) 4.43 (s, 2 H)
7.2-7.95 (m, 9 H) 10.90 (s, 1 H) 12.50 (s, 1 H)
AOIM1B53 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.82 (s, 6 H) 4.43 (s, 2 H)
7.15(m,H)7.27(m,H)7.34(m,H)7.58(m,H)7.68(m,H) 10.93 (s,
1H)12.62(s,1H)
A04M1B53 1H NMR (400 MHz, DMSO-d6): S ppm 1.82 (s, 6 H) 4.43 (s, 2 H)
7.15(m,1H)7.27(m,2H)7.34(m,1H)7.58(m,1H)7.68(m,1H)
10.93 (s, 1 H) 12.62 (s, 1 H)
A48M1B53 1H NMR (400 MHz, DMSO-d6): S ppm 1.73 (s, 6 H) 3.69 (s, 2 H)
4.27(s,2H)7.18(m,2H)7.38(m,1H)7.45(m,3H)7.71(m,1H)
7.80 (m, 3 H) 10.76 (s, 1 H) 12.45 (s, 1 H)
A54M1 B53 1H NMR (400 MHz, DMSO-d6): S ppm 1.83 (s, 6 H) 4.46 (s, 2 H)
7.28 (m, 2 H) 7.59 (m, 1 H) 7.71 (m, 1 H) 7.92 (m, 111) 8.21 (m, 1 H)
8.29 (m, 111) 11.26 (s, 1 H) 12.68 (s, 1 H)
AO1M1B54 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.81 (s, 6 H) 4.43 (s, 2 H)
7.24(m,2H)7.42(m,2H)7.63(d,J=8.26 Hz,2H)7.87(d,J=8.26
Hz, 2 H) 7.95 (m, 2 H) 10.93 (s, 1 H) 12.62 (s, 1 H)
A48M1B54 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.77 (s, 6 H) 3.69 (s, 2 H)
4.33 (s, 2 H) 7.32-7.89 (m, 13 H) 10.75 (s, 1 H) 12.41 (s, 1 H)
AO1M2B03 1H NMR (400 MHz, DMSO-d6): S 12.20 (bs, 1H), 11.00 (s, 1H), 8.10
(m, 2H), 7.36 (m, 2H), 4.91 (s, 2H), 2.84 (m, 2H), 2.4 (m, 1H), 2.23
(m, 511), 2.0 (m, 2H), 1.65 (m, 4H), 0.89 (m, 2H).
A02M2B03 1H NMR (400 MHz, DMSO-d6): 6 12.28 (bs, 111), 11.08 (s, 1H), 7.88
(m, 2H), 7.51 (m, 2H), 4.92 (s, 2H), 2.84 (m, 2H), 2.41 (m, 1H), 2.25
(m, 5H), 2.05 (m, 2H), 1.68 (m, 4H), 0.91 (m, 211).
A04M2B03 1H NMR (400 MHz, DMSO-d6): 6 12.24 (bs, 111), 10.91(s, 1H), 7.75
(m, 1H), 7.41 (m, 1H), 7.22 (m, 1H), 4.91 (s, 2H), 2.79 (m, 2H), 2.34
(m, 1H), 2.24 (m, 2H), 2.16 (s, 3H), 1.91 (m, 2H), 1.65 (m, 4H), 0.89
(m, 2H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
79
A05M2B03 1H NMR (400 MHz, DMSO-d6): 612.31 (bs, 1H), 11.16(s, 1H), 7.75
(m, 2H), 7.51 (m, 1H), 4.91 (s, 2H), 2.79 (m, 2H), 2.35 (m, 1H), 2.25
(m, 2H), 2.17 (s, 3H), 1.90 (m, 2H), 1.65 (m, 4H), 0.90 (m, 2H).
A06M2B03 1H NMR (400 MHz, DMSO-d6): 6 12.45 (bs, 1H), 11.06 (s, 1H), 8.03
(m, 2H), 7.61 (m, 2H), 4.91 (s, 2H), 2.84 (m, 2H), 2.41 (m, 1H), 2.21
(m, 5H), 2.0 (m, 2H), 1.65 (m, 4H), 0.89 (m, 211).
A07M2B03 1H NMR (400 MHz, DMSO-d6): 612.30 (bs, 1H), 11.25 (s, 1H), 8.20
(m, 2H), 7.92 (m, 2H), 4.94 (s, 2H), 2.95 (m, 2H), 2.45 (m, 1H), 2.27
(m, 5H), 2.2 (m, 2H), 1.73 (m, 4H), 0.91 (m, 211).
AlOM2BO3 1H NMR (400 MHz, DMSO-d6): 612.25 (bs, 1H), 11.04 (s, 1H), 8.15
(m, 1H), 7.87 (m, 1H), 7.22 (m, 1H), 4.89 (s, 2H), 2.82 (m, 2H), 2.37
(m, 111), 2.22 (m, 5H), 1.9 (m, 2H), 1.65 (m, 4H), 0.91 (m, 2H).
A1IM2B03 1H NMR (400 MHz, DMSO-d6): 612.22 (bs, 1H), 10.81 (s, 1H), 8.45
(m, 1H), 7.69 (m, 2H), 4.90 (s, 2H), 2.82 (m, 2H), 2.37 (m, 1H), 2.24
(m, 2H), 2.18 (m, 3H), 1.93 (m, 2H), 1.66 (m, 4H), 0.89 (m, 211).
A12M2B03 'H NMR (400 MHz, DMSO-d6): 612.06 (bs, 111), 10.04 (s, 1H), 4.82
(s, 2H), 2.85 (m, 2H), 2.34 (m, 1H), 2.22 (m, 7H), 2.05 (m, 311), 1.65
(m, 4H), 0.93 (d, 6H, J = 6.58Hz), 0.85 (m, 2H).
A13M2B03 1H NMR (400 MHz, DMSO-d6): 6 12.04 (bs, 1H), 10.08 (s, 1H), 4.85
(s, 2H), 3.25 (m, 1H), 2.85 (m, 2H), 2.39 (m, 1H), 2.25-1.75 (m,
13H), 1.67 (m, 4H), 0.85 (m, 2H).
A19M2B03 'H NMR (400 MHz, DMSO-d6): 6 12.24 (bs, 1H), 10.84 (s, 1H), 7.94
(m, 111), 7.51 (m, 1H), 6.70 (m, 1H), 4.88 (s, 2H), 2.85 (m, 2H), 2.40
(m, 1H), 2.22 (m, 5H), 2.01 (m, 2H), 1.67 (m, 4H), 0.89 (m, 211).
A38M2B03 1H NMR (400 MHz, DMSO-d6): 612.21 (bs, 1H), 10.81(s, 1H), 7.66
(m, 2H), 7.08 (m, 1H), 4.92 (s, 2H), 3.86 (s, 6H), 2.81 (m, 2H), 2.38
(m, 1H), 2.25 (m, 2H), 2.18 (s, 3H), 1.94 (m, 2H), 1.66 (m, 4H), 0.90
(m, 2H).
AO1M2B04 'H NMR (400 MHz, DMSO-d6): 6 12.45 (bs, 1H), 11.00 (s, 1H), 8.10
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
(m, 2H), 7.36 (m, 2H), 4.91 (s, 2H), 2.95 (m, 2H), 2.42 (m, 3H), 2.24
(m, 2H), 1.95 (m, 2H), 1.7 (m, 4H), 1.02 (t, 3H), 0.89 (m, 2H).
A02M2B04 'H NMR (400 MHz, DMSO-d6): S 12.27 (bs, 1H), 11.07 (s, 111), 7.85
(in, 2H), 7.68 (m, 1H), 7.45 (m, 1H), 4.91 (s, 2H), 2.90 (m, 2H), 2.34
(m, 3H), 2.25 (m, 2H), 1.92 (m, 2H), 1.65 (m, 4H), 1.0 (t, 3H), 0.90
(m, 2H).
A04M2B04 'H NMR (400 MHz, DMSO-d6): S 12.23 (bs, 111), 10.91(s, 111), 7.78
(m, 1H), 7.41 (m, 1H), 7.22 (m, 1H), 4.91 (s, 2H), 2.91 (m, 2H), 2.35
(m, 3H), 2.24 (m, 2H), 1.91 (m, 2H), 1.65 (m, 411), 1.00 (t, 3H), 0.89
(m, 2H).
A05M2B04 'H NMR (400 MHz, DMSO-d6): S 12.31 (bs, 1H), 11. 16(s, 1H), 7.75
(m, 2H), 7.54 (m, 1H), 4.92 (s, 2H), 2.92 (m, 2H), 2.35 (m, 3H), 2.25
(m, 2H), 1.92 (m, 2H), 1.65 (m, 4H), 1.01 (t, 3H), 0.90 (m, 211).
A06M2B04 1H NMR (400 MHz, DMSO-d6): S 12.25 (bs, 1H), 11.05 (s, 1H), 8.03
(m, 2H), 7.6 (m, 2H), 4.91 (s, 2H), 2.90 (m, 211), 2.45-2.20 (m, 5H),
1.85 (m, 2H), 1.67 (m, 4H), 1.02 (t, 3H), 0.89 (m, 2H).
A07M2B04 1H NMR (400 MHz, DMSO-d6): 612.31 (bs, 1H), 11.34 (s, 1H), 8.20
(m, 211), 7.91 (m, 2H), 4.95 (s, 2H), 3.15-1.5 (m, 13H), 1.06 (t, 3H),
0.91 (m, 2H).
AlOM2BO4 'H NMR (400 MHz, DMSO-d6): 612.25 (bs, 1H), 11.04 (s, 1H), 8.15
(m, 111), 7.88 (m, 1H), 7.22 (m, 1H), 4.89 (s, 2H), 2.92 (m, 2H), 2.45-
2.20 (m, 5H), 1.9 (m, 2H), 1.65 (m, 4H), 1.01 (t, 3H), 0.89 (m, 2H).
Al lM2B04 1H NMR (400 MHz, DMSO-d6): 612.22 (bs, 1H), 10.81 (s, 1H), 8.46
(m, 1H), 7.69 (m, 2H), 4.90 (s, 2H), 2.92 (m, 2H), 2.34 (m, 3H), 2.25
(m, 2H), 1.92 (m, 2H), 1.65 (m, 411), 1.01 (t, 3H), 0.89 (m, 2H).
A13M2B04 1H NMR (400 MHz, DMSO-d6): 612.04 (bs, 111), 10.27 (s, 1H), 4.86
(s, 2H), 2.89 (m, 211), 2.45-1.75 (m, 14H), 1.65 (m, 4H), 1.00 (t, 3H),
0.85 (m, 2H).
A14M2B04 'H NMR (400 MHz, DMSO-d6): 6 12.05 (bs, 1H), 10.71 (s, 1H), 4.79
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
81
(s, 2H), 2.88 (m, 2H), 2.31 (m, 3H), 2.21 (m, 2H), 1.89 (m, 311), 1.62
(m, 4H), 0.99 (t, 3H), 0.82 (m, 6H).
A19M2B04 1H NMR (400 MHz, DMSO-d6): S 12.24 (bs, 1H), 10.84 (s, 1H), 7.94
(m, 1H), 7.51 (m, 1H), 6.71 (m, 1H), 4.88 (s, 2H), 2.97 (m, 2H), 2.40
(m, 3H), 2.24 (m, 2H), 2.01 (m, 2H), 1.68 (m, 4H), 1.02 (t, 3H), 0.89
(m, 2H).
A38M2B04 1H NMR (400 MHz, DMSO-d6): 6 12.20 (bs, 1H), 10.81(s, 1H), 7.66
(m, 2H), 7.08 (m, 1H), 4.92 (s, 2H), 3.86 (s, 6H), 2.92 (m, 2H), 2.45-
2.20 (m, 5H), 1.84 (m, 2H), 1.66 (m, 4H), 1.01 (t, 3H), 0.89 (m, 2H).
AO1M2B05 1H NMR (400 MHz, DMSO-d6): 6 12.25 (bs, 1H), 11.00 (s, 1H), 8.11
(m, 211), 7.36 (m, 2H), 4.92 (s, 2H), 3.00 (m, 2H), 2.44 (m, 1H), 2.24
(m, 4H), 1.6 (m, 5H), 0.89 (m, 2H), 0.38 (m, 4H).
A06M2B05 1H NMR (400 MHz, DMSO-d6): 6 12.3 (bs, 111), 11.06 (s, 1H), 8.05
(m, 2H), 7.6 (m, 2H), 4.92 (s, 2H), 3.00 (m, 2H), 2.44 (m, 1H), 2.24
(m, 4H), 1.62 (m, 5H), 0.89 (m, 2H), 0.39 (m, 4H).
A07M2B05 1H NMR (400 MHz, DMSO-d6): 6 12.3 (bs, 111), 11.24 (s, 1H), 8.21
(m, 2H), 7.9 (m, 2H), 4.94 (s, 2H), 2.99 (m, 2H), 2.44 (m, 1H), 2.25
(m, 4H), 1.59 (m, 5H), 0.89 (m, 2H), 0.37 (m, 4H).
AO1M2B06.HC1 1H NMR (400 MHz, DMSO-d6): 6 0.92 (m, 211), 1.78 (m, 4 H) 2.24
(m,2H),2.81(m,1H)3.01(m,2H)3.38(m,2H)4.95(s,2H)7.37
(t, J=8.84 Hz, 2 H) 8.10 (dd, J=8.96, 5.43 Hz, 2 H) 8.35 (m, 1 H) 8.65
(d, .=9.88 Hz, I H) 11.00 (s, 1 H) 12.52 (s, 111)
A01M2B47 1H NMR (400 MHz, DMSO-d6): S ppm 1.01 (m, 2 H) 2.18 (s, 6 H)
2.36(m,2H)3.46(s,2H)4.62(s,2H)7.28(m,2H)7.36(m,2H)
7.41 (m, 2 H) 7.98 (m, 2 H) 10.93 (s, 1 H) 12.27 (s, 1 H)
A48M2B53 1H NMR (400 MHz, DMSO-d6): S ppm 1.13 (m, 2 H) 2.29 (m, 2 H)
3.72(s,2H)4.43(s,2H)7.18(m,2H)7.38(m, 1H)7.45(m,3H)
7.71 (m, 1 H) 7.80 (m, 3 H) 10.79 (s, I H) 12.23 (s, I H)
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
82
Example 19
N-{6,6-dimethyl-5-[(4-methylpiperazin-1-yl)carbonyl]-2,4,5,6-tetrahydro
pyrrolo [3,4-c]pyrazol-3-yl}-4-fluorobenzamide
To a solution of triphosgene (195 mg, 0.65 mmol, 0.56 eq) in DCM (15 ml) was
added a
solution of ethyl 3-[(4-fluorobenzoyl)amino]-6,6-dimethyl-5,6-
dihydropyrrolo[3,4-
c]pyrazole-2(4H)-carboxylate hydrochloride (442 mg, 1.15 mmol) in DCM (30 ml)
followed by N,N-diisopropylethylamine (760 l, 4.31 mmol, 3.75 eq). After 3
hours, a
solution of N-methylpiperazine (195 l, 1.72 mmol, 1.5 eq) and
diisopropylethylamine
(300 l, 1.72 mmol, 1.5 eq) in DCM (8 ml) was added. The reaction was stirred
overnight
at room temperature (TLC: CH2C12/MeOH 90/10). The solution was washed with
brine,
the organic phase was dried over sodium sulfate and concentrated. The residue
was
dissolved in methanol (16 ml), treated with TEA (1.6 ml, 11.5 mmol, 10 eq) and
stirred
overnight at room temperature. (TLC: CH2CI2/MeOH 90/10). After evaporation,
the solid
was purified by flash chromatography (eluent: CH2C12/MeOH 90/10). The solid
was
treated with diisopropylether and filtered to afford 0.294 g of the title
compound in 64%
yield.
ESI MS: m/z 401 (MH+);
'H NMR (400 MHz, DMSO-d6): S 12.39 (bs, 1H), 10.39 (s, 1H), 8.04 (m, 2H, Ar),
7.31
(m, 2H), 4.53 (bs, 2H), 3.04 (m, 4H), 2.40 (m, 4H), 2.22 (bs, 311), 1.60 (bs,
61-1).
By working in an analogous manner the following compounds were prepared:
N-[5-[(4-methylpiperazin-1-yl)carbonyl]-2,4,5,6-tetrahydropyrrolo [3,4-
c]pyrazo1-6-
spirocyclopropan-3-yl]-4-fluorobenzamide
ESI MS: m/z 399 (MH+);
'H NMR (400 MHz, DMSO-d6): S 12.19 (bs, 111), 10.95 (s, 111), 8.09 (m, 2H),
7.35 (m,
2H), 4.70 (bs, 211), 3.18 (m, 411), 2.34 (m, 7H), 1.92 (m, 2I1), 0.97 (m,
211).
Example 20
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
83
4-Chloro-N-[6,6-dimethyl-5-(4-pyrrolidin-1-ylmethyl-piperidine-l-carbonyl)-
1,4,5,6-
tetrahydro-pyrrolo[3,4-c]pyrazol-3-yl]-benzamide, hydrochloride
A mixture of N-[5-(4-aminomethyl-piperidine-l-carbonyl)-6,6-dimethyl-2,4,5,6-
tetrahydro-pyrrolo[3,4-c]pyrazol-3-yl]-4-chloro-benzamide (310 mg, 0.7
mmoles), 1,4-
dibromobutane (92 l, 0.7 mmoles) and NaHCO3 (600 mg, 7 mmoles) in absolute
ethanol
(15 ml) was heated at 150 C for 15 minutes in a microwave oven. After cooling,
the
solution was evaporated. The residue was taken up with dichloromethane/MeOH
(90:10)
and water, the suspension obtained filtered and the organic layer was
evaporated to
dryness. The residue was purified by flash chromatography with
dichloromethane/MeOH/30% N114OHaq (95/5/0.5). The product was obtained in 20%
yield (71 mg).
The compound was dissolved in methanol (3 ml), a solution of 4N HCl in dioxane
(40 l,
0.16 mmoles) was added and then the solution was evaporated. The solid
obtained was
triturated in ether to give the title hydrochloride salt as a white powder.
ESI MS: m/z 485 (MH+);
lH NMR (400 MHz, DMSO-D6) 6 ppm 1.24 (m, 2 H) 1.63 (s, 6 H) 1.92 (m, 7 H) 2.67
(t,
J=11.83 Hz,2H)3.01 (m, 211) 3.09 (t,J=6.46Hz,211)3.47(m,4H)4.56(s,2H)7.59
(d, J8.54 Hz, 2 H) 8.01 (d, J=8.66 Hz, 2 H) 9.49 (s, 1 H) 11.02 (s, 1 H) 12.50
(s, 1 H)
By working in analogous manner and by using the proper starting material and
any suitable
reactant, as per the aforementioned process, additional compounds of formula
(Ia) and (Ib)
were also prepared, as reported in the following table V.
Table V
A03M1B08.HC1 1H NMR (400 MHz, DMSO-d6): 6 1.65 (d, J=9.15 Hz, 6 H) 2.84 (d,
J=3.17
Hz,3H)3.06(s,4H)3.58(s,4H)4.62(s,2H)7.61 (m, I H) 7.91 (m, 1 H)
8.07(m,1H)9.98(s,1H)11.08(s,1H)12.61(s,1H)
A04MIB08 1H NMR (400 MHz, DMSO-d6): 6 12.44 (bs, 1H), 10.85 (s, 111), 7.74 (m,
11-1), 7.18 (m, 1H), 7.20 (s, 111), 4.59 (bs, 2H), 3.06 (m, 4H), 2.38 (m, 4H),
2.22 (bs, 3H), 1.64 (bs, 61-1).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
84
A06M1B08 'H NMR (400 MHz, DMSO-d6): S 12.46 (bs, 1H), 10.99 (s, 1H), 8.01 (m,
2H), 7.59 (m, 2H), 4.59 (bs, 21-1), 3.07 (m, 4H), 2.40 (m, 4H), 2.25 (bs, 3H),
1.64 (bs, 6H).
A07M1B08 'H NMR (400 MHz, DMSO-d6): 8 12.49 (bs, 1H), 11.16 (s, 1H), 8.19 (d,
2H, J = 7.80 Hz), 7.88 (d, 2H, J = 7.80 Hz), 4.60 (s, 2H), 3.06 (m, 4H), 2.38
(m, 4H), 2.22 (s, 3H), 1.64 (bs, 6H).
A12MlB08 1H NMR (400 MHz, DMSO-d6): 6 12.24 (bs, 1H), 10.32 (s, 111), 4.47 (s,
2H), 3.03 (m, 4H), 2.34 (m, 4H), 2.20 (s, 3H), 2.15 (d, 2H, J = 7.20 Hz), 2.05
(m, 1H), 1.59 (s, 6H), 0.92 (d, 6H, J = 6.59 Hz).
A13M1B08 'H NMR (400 MHz, DMSO-d6): 6 12.23 (bs, 1H), 10.22 (s, 1H), 4.50 (bs,
211), 3.32 (m, 1H), 3.04 (m, 4H), 2.35 (m, 4H), 2.21 (s, 3H), 1.91-1.8 (m,
6H), 1.59 (bs, 611).
A14M1B08 1H NMR (400 MHz, DMSO-d6): 8 12.23 (bs, 1H), 10.66 (s, 1H), 4.44 (bs,
2H), 3.02 (m, 4H), 2.33 (m, 4H), 2.19 (s, 3H), 1.82 (m, 1H), 1.59 (bs, 6H),
0.78 (m, 4H).
A16M1B08 'H NMR (400 MHz, DMSO-d6): 8 12.46 (bs, 1H), 11.04 (s, 1H), 8.12 (m,
2H), 7.51 (m, 2H), 4.57 (bs, 2H), 3.06 (m, 4H), 2.36 (m, 4H), 2.20 (s, 311),
1.64 (bs, 611).
A17M1B08 1H NMR (400 MHz, DMSO-d6): 6 12.44 (bs, 1H), 10.94 (s, 1H), 7.78 (m,
1H), 7.61 (bs, 1H), 7.51 (m, 1H), 7.45 (m, 2H), 7.20 (m, 2H), 7.09 (m, 2H),
4.55 (bs, 2H), 3.06 (m, 4H), 2.40 (m, 4H), 2.24 (bs, 3H), 1.63 (bs, 6H).
A18M1B08 1H NMR (400 MHz, DMSO-d6): 8 12.44 (bs, 111), 10.99 (s, 1H), 7.96 (m,
2H), 7.47-7.33 (m, 7H), 4.55 (bs, 2H), 3.03 (m, 4H), 2.52 (m, 4H), 2.28 (bs,
3H), 1.63 (bs, 6H).
A21M1B08 1H NMR (400 MHz, DMSO-d6): 6 12.44 (bs, 1H), 10.95 (bs, 2H), 8.66 (m,
1H), 8.14 (m, 2H), 8.00 (m, 2H), 7.83 (m, 1H), 6.82 (m, 1H), 4.59 (s, 2H),
3.06 (m, 4H), 2.36 (m, 411), 2.21 (s, 3H), 1.64 (bs, 611).
A22M1B08 'H NMR (400 MHz, DMSO-d6): 6 12.41 (bs, 1H), 11.06 (bs, 1H), 8.50-
7.60
(m, 711), 4.64 (s, 2H), 3.07 (m, 4H), 2.35 (m, 4H),2.18 (s, 3H),1.66 (bs, 6H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
A23M1B08 'H NMR (400 MHz, DMSO-d6): S 12.45 (bs, 1H), 11.05 (bs, 1H), 8.66
(bs,
1 H), 7.07 (m, 4H), 7.65 (m, 2H), 4.62 (s, 211), 3.07 (m, 4H), 2.37 (m, 4H),
2.21 (s, 3H), 1.65 (bs, 6H).
A24MlB08 1H NMR (400 MHz, DMSO-d6): S 12.02 (bs, 1H), 8.80 (s, 1H), 7.19 (m,
4H), 6.90 (bs, 1H), 4.42 (s, 2H), 4.31 (d, 2H J = 5.73 Hz), 3.02 (m, 4H), 2.34
(m, 4H), 2.30 (s, 3H), 2.20 (s, 3H), 1.59 (s, 6H).
A25M1B08 'H NMR (400 MHz, DMSO-d6): 6 12.02 (bs, 1H), 8.83 (s, 1H), 7.31 (m,
5H), 6.99 (bs, 1H), 4.42 (s, 2H), 4.33 (d, 2H J = 5.85 Hz), 3.02 (m, 4H), 2.34
(m, 411), 2.19 (s, 3H), 1.59 (s, 6H).
A26M1B08 'H NMR (400 MHz, DMSO-d6): 6 12.00 (bs, 1H), 8.65 (s, 1H), 6.54 (m,
111), 4.41 (s, 2H), 3.02 (m, 6H), 2.34 (m, 4H), 2.20 (s, 3H), 1.58 (s, 6H),
1.43 (m, 2H), 0.88 (t, 311).
A27MlB08 'H NMR (400 MHz, DMSO-d6): 6 12.22 (bs, 1H), 9.16 (s, 2H), 7.46 (m,
1H), 7.33 (m, 1H), 7.13 (m, 1H), 6.80 (m, 1H), 6.99 (bs, 1H), 4.48 (s, 2H),
3.05 (m, 411), 2.35 (m, 4H), 2.20 (s, 31f), 1.61 (s, 6H).
AO1M1B09 1H NMR (400 MHz, DMSO-d6): 6 12.37 (bs, 1H), 10.88 (s, 1H), 8.04 (m,
211), 7.31 (m, 2H), 4.51 (bs, 2H), 2.97 (m, 4H), 1.59 (bs, 6H), 1.50 (m, 6H).
A06M1B09 'H NMR (400 MHz, DMSO-d6): 6 12.44 (bs, 1H), 10.98 (s, 1H), 8.01 (d,
2H, J = 8.3 Hz), 7.58 (d, 2H, J = 8.3 Hz), 4.57 (bs, 2H), 3.00 (m, 4H), 1.63
(bs, 6H), 1.54 (m, 6H).
AO1M1B10 'H NMR (400 MHz, DMSO-d6): 6 12.41 (bs, 1H), 10.89 (s, 1H), 8.04 (m,
211), 7.30 (m, 2H), 4.56 (bs, 2H), 3.59 (m, 4H), 3.01 (m, 4H), 1.61 (bs, 6H).
AO1M1Bl l 1H NMR (400 MHz, DMSO-d6): 6 12.52 (bs, 1H), 10.91 (s, 1H), 8.07 (m,
2H), 7.35 (m, 2H), 4.54 (bs, 2H), 3.33 (m, 2H), 2.63 (m, 2H), 1.63 (m, 8H),
1.49 (m, 1H), 1.15 (m, 2H), 0.94 (d, 3H, J = 6.5 Hz).
A13M1BI1 'H NMR (400 MHz, DMSO-d6): 6 12.23 (bs, 1H), 10.19 (s, 1H), 4.50 (s,
2H), 3.33 (m, 3H), 2.62 (m, 2H), 2.4-1.4 (m, 15H), 1.15 (m, 2H), 0.95 (d,
3H, J = 6.58 Hz).
A14M1B11 1H NMR (400 MHz, DMSO-d6): 6 12.23 (bs, 1H), 10.63 (s, 111), 4.43 (s,
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
86
2H), 3.33 (in, 2H), 2.61 (m, 2H), 1.9-1.4 (m, 10H), 1.11 (m, 2H), 0.95 (d,
3H, J = 6.58 Hz), 0.77 (m, 4H).
A14M1B12 1H NMR (400 MHz, DMSO-d6): S 12.23 (bs, 1H), 10.64 (s, 1H), 4.43 (s,
3H), 3.33 (m, 4H), 2.60 (m, 2H), 1.59 (m, 10H), 1.11 (m, 2H), 0.78 (m, 4H).
AO1M1B13 'H NMR (400 MHz, DMSO-d6): S 12.42 (bs, 1H), 10.91 (s, 1H), 8.08 (m,
21-1), 7.33 (m, 2H), 4.56 (bs, 2H), 4.35 (bs, 1H), 3.46 (m, 4H), 2.65 (m, 2H),
1.75-1.05 (m, 13H).
A02M2B08 'H NMR (400 MHz, DMSO-d6): S 12.00 (bs, 1H), 11.02 (s, 1H), 7.86 (m,
2H), 7.57 (m, 2H), 4.70 (bs, 2H), 3.14 (m, 4H), 2.40 (m, 4H), 2.25 (bs, 3H),
1.91 (m, 21-1), 0.97 (m, 2H).
A04M2B08 1HNMR (400 MHz, DMSO-d6): S 12.16 (bs, 1H), 10.84 (s, 1H), 7.76 (m,
311), 4.69 (bs, 2H), 3.12 (m, 4H), 2.35 (m, 4H), 2.21 (bs, 3H), 1.90 (m, 2H),
0.97 (m, 2H).
A06M2B08 'H NMR (400 MHz, DMSO-d6): 6 12.20 (bs, 1H), 11.00 (s, 111), 8.02 (m,
2H), 7.59 (m, 2H), 4.70 (bs, 2H), 3.15 (m, 4H), 2.51 (m, 4H), 2.29 (bs, 3H),
1.92 (m, 2H), 0.89 (m, 2H).
A07M2B08 1H NMR (400 MHz, DMSO-d6): 612.24 (bs, 1H), 11.17 (s, 1H), 8.19 (m,
2H), 7.89 (m, 2H), 4.72 (bs, 2H), 3.14 (m, 4H), 2.41 (m, 4H), 2.26 (bs, 3H),
1.92 (m, 2H), 0.98 (m, 211).
A1OM2B08 1H NMR (400 MHz, DMSO-d6): 612.18 (bs, 1H), 10.98 (s, 1H), 8.11 (m,
11-1), 7.87 (m, 1H), 7.21 (m, 1H), 4.66 (bs, 2H), 3.13 (m, 4H), 2.37 (m, 4H),
2.23 (bs, 3H), 1.91 (m, 2H), 0.97 (m, 2H).
A14M2B08 'H NMR (400 MHz, DMSO-d6): 6 11.98 (bs, 1H), 10.66 (s, 111), 4.56
(bs,
2H), 3.10 (m, 411), 2.34 (m, 4H), 2.21 (bs, 3H), 1.87 (m, 2H), 1.86 (m, 1H),
0.92 (m, 2H), 0.82 (m, 4H).
A17M2B08 1H NMR (400 MHz, DMSO-d6): 612.17 (bs, 1H), 10.95 (s, 1H), 7.79 (m,
1H), 7.62 (bs, 1H), 7.51 (m, 1H), 7.45 (m, 2H), 7.27 (m, 1H), 7.20 (m, 111),
7.09 (m, 2H), 4.66 (bs, 2H), 3.12 (m, 411), 2.35 (m, 4H), 2.21 (s, 3H), 1.90
(m, 2H), 0.98 (m, 2H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
87
A18M2B08 'H NMR (400 MHz, DMSO-d6): S 12.17 (bs, 1H), 11.00 (s, 1H), 7.97 (bs,
1H), 7.94 (m, 1H), 7.42 (m, 7H), 4.67 (bs, 2H), 3.11 (m, 4H), 2.32 (m, 4H),
2.20 (s, 3H), 1.90 (m, 2H),0.98 (m, 2H).
A19M2B08 'HNMR (400 MHz, DMSO-d6): S 12.17 (bs, 1H), 10.77 (s, 1H), 7.92 (bs,
1H), 7.49 (m, 1H), 6.69 (m, 1H), 4.66 (bs, 2H), 3.12 (m, 4H), 2.37 (m, 4H),
2.23 (s, 3H), 1.90 (m, 2H), 0.96 (m, 2H).
A01M2B09 'H NMR (400 MHz, DMSO-d6): 6 12.13 (bs, 1H), 10.93 (s, 1H), 8.09 (m,
2H), 7.36 (m, 2H), 4.65 (bs, 2H), 3.08 (m, 4H), 1.87 (m, 2H), 1.53 (m, 6H),
0.96 (m, 2H).
AO1M2B10 'H NMR (400 MHz, DMSO-d6): S 12.10 (bs, 11-1), 10.95 (s, 1H), 8.09
(m,
2H), 7.34 (m, 2H), 4.70 (bs, 2H), 3.62 (m, 4H), 3.12 (m, 4H), 1.93 (m, 2H),
0.96 (m, 2H).
AO1M2B11 'H NMR (400 MHz, DMSO-d6): 6 12.15 (bs, 1H), 10.93 (s, 1H), 8.09 (m,
2H), 7.36 (m, 2H), 4.65 (bs, 2H), 3.54 (m, 2H), 2.65 (m, 2H), 1.87 (m, 2H),
1.61 (m, 2H), 1.50 (m, 1H), 1.12 (m, 2H), 0.94 (m, 5H).
AO1M2B12 lH NMR (400 MHz, DMSO-d6): S 11.88 (bs, 1H), 10.93 (s, 1H), 8.08 (m,
2H), 7.36 (m, 2H), 4.66 (bs, 2H), 3.54 (m, 211), 3.45 (m, 3H), 2.65 (m, 2H),
1.87 (m, 21D, 1.66 (m, 2H), 1.50 (m, 1H), 1.12 (m, 2H), 0.94 (m, 211).
AO1M2B13 lH NMR (400 MHz, DMSO-d6): S 11.33 (bs, 1H), 10.93 (s, 114), 8.08 (m,
2H), 7.36 (m, 2H), 4.65 (bs, 2H), 3.54 (m, 2H), 3.45 (m, 3H), 2.65 (m, 2H),
1.87 (m, 2H), 1.66 (m, 2H), 1.50 (m, 1H), 1.40 (m, 2H), 1.12 (m, 2H), 0.95
(m, 2H).
A48M1 B08 'H NMR (400 MHz, DMSO-d6): S 1.55 (s, 6H), 2.19 (s, 3H), 2.35 (m,
411),
2.98 (m, 4H), 3.75 (s, 2H), 4.44 (s, 2H), 7.5 (m, 3H), 7.75 (s, 1H), .7.85 (m,
3H), 10.7 (bs, 1H), 12.5 (bs, 1H).
A30M1 B08 lH NMR (400 MHz, DMSO-d6): 6 1.63 (s, 6H), 2.20 (s, 3H), 2.36 (m,
4H),
3.06 (m, 4H), 4.57 (s, 2H), 7.51 (m, 2H), 7.60 (m, 1H), 7.99 (m, 214), 10.89
(bs, 1H), 12.42 (bs, 1H).
A38M2B08 'H NMR (400 MHz, DMSO-d6): 5 0.96 (m, 2H), 1.91 (bs, 21-1), 2.23 (bs,
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
88
3H), 2.37 (bs, 4H), 3.13 (bs, 4H), 3.86 (s, 6H), 4.69 (s, 2H), 7.07 (s, 1H),
7.66 (bs, 2H), 10.76 (s, 1H), 12.14 (bs, 1H).
A54M1B08 1H NMR (400 MHz, DMSO-d6): S 1.64 (s, 6H), 2.20 (s, 3H), 2.36 (m,
4H),
3.06 (m, 4H), 4.59 (bs, 2H), 7.77 (m, 1H), 7.96 (m, 1H), 8.3 (m, 1H), 8.36 (s,
1H), 11.23 (s, 1H), 12.50 (bs, 1H).
A04M1B12 1H NMR (400 MHz, DMSO-d6): S 1.16 (m, 2H), 1.4-1.75 (m, 9H), 2.62 (m,
2H), 3.33 (m, 4H), 4.46 (t, 1H), 4.56 (bs, 2H), 7.2 (m, 2H), 7.75 (m, 1H),
10.84 (s, 1H), 12.43 (s, 1H).
AO1M1B12 1H NMR (400 MHz, DMSO-d6): S 1.17 (m, 2H), 1.51 (m, 1H), 1.63 (s,
6H),
1.66 (m, 2H), 2.62 (m, 2H), 3.32 (m, 4H), 4.54 (bs, 211), 7.35 (m, 2H), 8.07
(m, 2H), 10.92 (s, 1H), 12.4 (bs, 1H).
A48M1B13 1HNMR (400 MHz, DMSO-d6): S 12.25 (bs, 1H), 10.7 (s, 1H), 7.85 (m,
3H), 7.8 (s, 111), 7.45 (m, 3H), 4.4 (bs, 2H), 4.3 (t, 1H), 3.75 (s, 2H), 3.44
(m, 4H), 2.65 (m, 2H), 1.70 (m, 2H), 1.67 (s, 611), 1.52 (m, 1H), 1.39 (m,
211), 1.15 (m, 2H).
A30MIB13 1HNMR (400 MHz, DMSO-d6): S 7.99 (m, 2H), 7.59 (m, 1H), 7.51 (m, 2H),
4.56 (bs, 2H), 4.35"(t, 1H), 3.46 (m, 4H), 2.97 (m, 2H), 1.45-1.95 (m, 11H),
1.17(m,211).
A23M1B13 'H NMR (400 MHz, DMSO-d6): S 12.45 (bs, 1H), 11.02 (s, 1H), 8.67 (s,
1H), 8.07 (m, 4H), 7.65 (m, 2H), 4.61 (bs, 2H), 4.35 (t, 1H), 3.46 (m, 4H),
2.63 (m, 2H), 1.45-1.85 (m, 8H), 1.52 (m, 111), 1.42 (m, 2H), 1.18 (m, 2H).
A14M1B13 'H NMR (400 MHz, DMSO-d6): S 12.23 (bs, 111), 10.64 (s, 1H), 4.42
(bs,
2H), 4.35 (t, 1H), 3.47 (m, 2H), 3.33 (m, 2H), 2.56 (m, 2H), 1.82 (m, 1H),
1.65 (m, 2H), 1.59 (s, 6H), 1.52 (m, 1H),1.4 (m, 2H), 1.12 (m, 2H), 0.78 (m,
4H).
A04M1B13 1H NMR (400 MHz, DMSO-d6): S 12.43 (bs, 1H), 10.84 (s, 1H), 7.76 (m,
1H), 7.38 (m, 1H), 7.2 (m, 1H), 4.56 (bs, 2H), 4.34 (t, 1H), 3.45 (m, 2H),
3.33 (m, 2H), 2.56 (m, 2H), 1.75-1.55 (m, 8H), 1.53 (m, 1H), 1.40 (m, 2H),
1.15 (m, 2H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
89
A16M1B13 1HNMR (400 MHz, DMSO-d6): 612.45 (bs, 1H), 11.02 (s, 11-1), 8.12 (m,
2H), 7.51 (m, 2H), 4.56 (bs, 2H), 4.35 (t, 1H), 3.48-3.20 (m, 4H), 2.61 (m,
2H), 1.72-1.09 (m, 13H).
A22M1B13 1HNMR (400 MHz, DMSO-d6): 612.40 (bs, 1H), 11.02 (s, 1H), 7.3-8.4 (m,
7H), 4.65 (bs, 2H), 4.33 (t, 1H), 3.44 (m, 4H), 2.65 (m, 2H), 1.70 (m, 2H),
1.67 (s, 6H), 1.52 (m, 1H), 1.39 (m, 2H), 1.15 (m, 2H).
A13M1B13 1HNMR (400 MHz, DMSO-d6): 61.15 (m, 2 H) 1.40 (q, J=6.54 Hz, 2 H)
1.51 (m, 1 H) 1.59 (s, 6 H) 1.68 (m, 2 H) 1.79 (m, 111) 1.91 (m, 1 H) 2.07
(m, 2H)2.17(m,2H)2.61 (t,J=12.13Hz,2H)3.24(m, 1 H)3.39(d,
J=14.75 Hz,2H)3.47(m,2H)4.35(m,1H)4.49(s,2H)10.19(s,1H)
12.22 (s, 1H)
A21M1B13 1HNMR (400 MHz, DMSO-d6): 61.16 (m, 2 H) 1.40 (q, J=6.71 Hz, 2 H)
1.55 (m, 1 H) 1.64 (s, 6 H) 1.69 (d, .=12.80 Hz, 2 H) 2.62 (m, 211) 3.42 (d,
.X11.83 Hz,2H)3.47(m,2H)4.35(t,.=5.12Hz, 1H)4.58(s,2H)6.62
(m, 1 H) 7.83 (d, J=1.46 Hz, 1 H) 7.99 (d, J-9.39 Hz, 2 H) 8.15 (d, .]8.17
Hz, 2 H) 8.65 (d, J=2.44 Hz, 1 H) 10.94 (s, 1 H) 12.43 (s, 1 H)
A25M1B13 'H NMR (400 MHz, DMSO-d6): 6 12.02 (bs, 1H), 8.82 (bs, 1H), 7.3 (m,
5H), 7.0 (bs, 1H), 4.40 (s, 211), 4.33 (m, 3H), 3.45 (m, 2H), 3.33 (m, 2H),
2.59 (m, 2H), 1.66 (m, 211), 1.57 (m, 7H), 1.40 (m, 2H), 1.13 (m, 2H).
A27M1B13 1HNMR (400 MHz, DMSO-d6): 612.20 (bs, 1H), 9.02 (bs,1H), 7.45 (m,
1H), 7.31 (m, 1H), 7.12 (m, 1H), 6.81 (m, 1H), 4.47 (bs, 2H), 4.34 (t, 1H),
3.46 (m, 2H), 3.32 (m, 2H), 2.62 (m, 2H), 1.66 (m, 2H), 1.58 (m, 7H), 1.40
(m, 2H), 1.15 (m, 2H).
A24M1B13 1HNMR (400 MHz, DMSO-d6): 6 12.03 (bs, 1H), 8.79 (bs, 1H), 7.24 (m,
1H), 7.18 (m, 3H), 6.92 (bs, 1H), 4.39 (bs, 2H), 4.35 (t, 1H), 4.31 (m, 2H),
3.46 (m, 2H), 3.33 (m, 2H), 2.56 (m, 2H), 2.3 (s, 3H), 1.65 (m, 2H), 1.58 (m,
7H), 1.40 (m, 2H), 1.13 (m, 2H).
A26M1B13 1HNMR (400 MHz, DMSO-d6): 611.99 (bs, 11-1), 8.66 (bs, 1H), 6.56 (bs,
111), 4.38 (bs, 2H), 4.35 (t, 1H), 3.46 (m, 2H), 3.32 (m, 2H), 3.05 (m, 2H),
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
2.56 (m, 211), 1.66 (m, 2H), 1.57 (m, 7H), 1.46 (m, 4H), 1.14 (m, 2H), 0.88
(t, 3H).
A12M1B13 'H NMR (400 MHz, DMSO-d6): 8 ppm 0.92 (d, J=6.46 Hz, 6 H) 1.12 (m, 2
H) 1.39 (q, J6.58 Hz, 2 H) 1.54 (m, 1 H) 1.59 (s, 6 H) 1.67 (d, J=14.51 Hz,
2H) 2.06 (m, 1H)2.16(d,J 6.95 Hz, 2H) 2.60 (m,2H)3.38(m,2H)3.46
(m, 2 H) 4.35 (t, J=5.12 Hz, I H) 4.46 (s, 2 H) 10.30 (s, 1 H) 12.23 (s, I H)
A54M1B13 1H NMR (400 MHz, DMSO-d6): S ppm 1.15 (m, 2 H) 1.40 (q, J=6.63 Hz, 2
H) 1.53 (m, 1 H) 1.64 (s, 6 H) 1.68 (d, J=12.93 Hz, 2 H) 2.62 (t, Jl 1.89 Hz,
2H) 3.42 (d,J=11.22 Hz,2H)3.46(m,2H)4.35 (t, .) 4.88Hz, 1 H) 4.57
(s, 2 H) 7.77 (t, J=8.72 Hz, 1 H) 7.97 (d, J=6.10 Hz, 1 H) 8.30 (d, J=7.68 Hz,
1H)8.36(s,1H)11.21(s,1H)12.49(s,1H)
AO1M1B27 'H NMR (400 MHz, DMSO-d6): S ppm 0.86 (t, 3 H), 1.27 (m, 2 H), 1.38
(m,
2 H), 1.61 (s, 6H), 3.0 (m, 2 H), 4.41 (m, 2 H), 5.98 (bs, 1H), 7.31 (m, 2 H),
8.06 (m, 2 H), 10.86 (s, 1 H) 12.39 (s, 1 H).
A01M2B27 1H NMR (400 MHz, DMSO-d6): 6 ppm 0.78 (m, 2 H), 0.86 (t, 3 H), 1.27
(m,
2H), 1.38(m,2H),2.06(m,2H),3.0(m,2H),4.41 (m,2H),5.98(bs, 1
H), 7.31 (m, 2 H), 8.05 (m, 2 H), 10.86 (s, 1 H) 12.38 (s, I M.
AO1M1B28 'H NMR (400 MHz, DMSO-d6): S ppm 1.00 (t, 3 H), 1.62 (s, 6H), 3.04
(m,
2 H), 4.42 (m, 2 H), 6.01 (bs, 1H), 7.30 (m, 2 H), 8.07 (m, 2 H), 10.85 (s, 1
H) 12.38 (s,1H).
A55M1B28 1H NMR (400 MHz, DMSO-d6): S ppm 1.00 (t, 3 H), 1.49 (d, J7.50 Hz, 3
H), 1.55 (s, 3 H), 1.58 (s, 3 H), 3.01 (m, 2 H), 4.04 (q, 1 H), 4.34 (m, 2 H),
5.99 (bs, 1H), 7.48 (m, 3 H), 7.87 (m, 4 H), 10.61 (s, I H) 12.23 (s, I M.
A01M2B28 1H NMR (400 MHz, DMSO-d6): S ppm 0.78 (m, 2 H), 0.99 (m, 3 H), 2.06
(m,2H),2.98(m,2H),4.56(m,2H),6.14(bs, 1 H), 7.33 (m,2H), 8.07
(m, 2 H), 10.88 (s, 1 H) 12.09 (s, 111).
A48M2B28 1H NMR (400 MHz, DMSO-d6): S ppm 0.74 (m, 2 H), 0.96 (m, 3 H), 2.03
(m, 2 H), 2.96 (m, 2 H), 3.80 (s, 2 H), 4.45 (s, 2 H), 5.68 (bs, 1 H), 6.06
(bs,
1 H), 7.4-8.0 (m, 7 H), 10.70 (s, I H).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
91
AO1MI B49 1H NMR (400 MHz, DMSO-d6): S ppm 1.06 (d, J=6.55 Hz, 6 H), 1.61 (s,
6
11), 3.78 (m, 1 H), 4.41 (m, 2 H), 5.66 (m, 1 H), 7.31 (m, 2 H), 8.06 (m, 2
H),
10.85 (s, 1 H) 12.39 (s, 1 H).
A48M1B49 1H NMR (400 MHz, DMSO-d6): S ppm 1.01 (d, J=6.5 Hz, 6 H), 1.56 (s, 6
H), 3.76 (m, 1 H), 4.29 (m, 2 H), 5.66 (m, 111), 7.47 (m, 3 H), 7.78 (m, 1 H),
7.85 (m, 3 H), 10.67 (s, 1 H) 12.24 (s, 1 M.
A01M2B49 1H NMR (400 MHz, DMSO-d6): S ppm 0.81 (m, 2 H), 1.09 (d, J=6.64 Hz, 6
H), 2.09 (m, 2 H), 3.74 (m, I H), 4.60 (m, 2 H), 5.85 (m, 1 H), 7.36 (m, 2 H),
8.10 (m, 2 H), 10.92 (s, 1 H) 11.76 (s, 1 H).
AO1M1B55 1H NMR (400 MHz, DMSO-d6): S ppm 1.57 (m, 2 H), 1.63 (s, 6 H), 1.73
(m, 2 H), 2.25 (m, 1 H), 2.64 (m, 2 H), 3.43 (m, 2 H), 4.56 (m, 2 H), 6.75 (s,
1 H), 7.27 (s, 1 H), 7.34 (m, 2 H), 8.09 (m, 2 H), 10.92 (s, 1 H) 12.45 (s, 1
H).
AO1M2B55 1H NMR (400 MHz, DMSO-d6): S ppm 0.96 (m, 2H), 1.55 (m, 2 H), 1.71
(m, 2 H), 1.82 (m, 2 H), 2.34 (m, I H), 2.75 (m, 2 H), 3.48 (m, 2 H), 4.67 (m,
2 H), 6.75 (s, 1 H), 7.28 (s, I H), 7.35 (m, 2 H), 8.10 (m, 2 H), 10.98 (s, 1
H)
12.19 (s, 1 H).
Example 21
Several compounds of the invention of formula (Ia) and (Ib), being prepared as
formerly
reported, were also characterised by means of PLC/Mass techniques, hence
through
retention time (r.t.) and Mass [M+H]+=
The operative conditions are reported below:
HPLC/MS Method 1
The HPLC equipment consisted of a Waters 2790 HPLC system equipped with a 996
Waters PDA detector and Micromass mod. ZQ single quadrupole mass spectrometer,
equipped with an electrospray (ESI) ion source. Instrument control, data
acquisition and
data processing were provided by Millennium 4.0 and MassLynx 3.5 software.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
92
HPLC was carried out at 25 C at a flow rate of 1 ml/min using a RP 18 Waters X
Terra (4,6
x 50 mm, 3.5 m) column. Mobile phase A was ammonium acetate 5 mM buffer (pH
5.5
with acetic acid/acetonitrile 95:5), and Mobile phase B was H20/acetonitrile
(5:95); the
gradient was from 10 to 90% B in 8 minutes then hold 90% B 2 minutes. The
injection
volume was 10 l.
The mass spectometer was operated in positive and in negative ion mode, the
capillary
voltage was set up at 2.5 KV; the source temperature was 120 C; cone was 10 V;
full scan,
mass range from 100 to 800 amu was set up.
HPLC/MS Method 2
The HPLC equipment consisted of a Waters 2790 HPLC system equipped with a 996
Waters PDA detector and Micromass mod. ZQ single quadrupole mass spectrometer,
equipped with. an electrospray (ESI) ion source. Instrument control, data
acquisition and
data processing were providen by Millennium 4.0 and MassLynx 3.5 software.
IIPLC was carried out at 25 C at a flow rate of 1 ml/min using a RP18 Waters X
Terra (4,6
x 50 mm, 3.5 m) column. Mobile phase A was ammonium acetate 5 mM buffer (pH
5.5
with acetic acid/acetonitrile 95:5), and Mobile phase B was H20/acetonitrile
(5:95); the
gradient was from 10 to 90% B in 4 min then hold 90% B 1 minute. The injection
volume
was l0 l.
The mass spectometer was operated in positive and in negative ion mode, the
capillary
voltage was set up at 2.5 KV; the source temperature was 120 C; cone was 10 V;
full scan,
mass range from 100 to 800 amu was set up.
HPLC/MS Method 3
Mass spectra were recorded on a Finnigan LCQ ion trap mass spectrometer using
the
electrospray (ESI) ionization technique with positive and negative ion
detection. The mass
spectrometer was directly connected to a SSP4000 HPLC system (Thermo
Separation),
equipped with an LcPal autosampler (CTC Analytics) and a UV 6000LP PDA
detector
(Thermo Separation). Instrument control, data acquisition and processing were
performed
by using Xcalibur 1.2 software. HPLC analysis were carried out at room
temperature at a
flow rate of 1 ml/min using an RP C18 Waters X-Terra column (4.6x 50mm; 3.5
m).
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
93
Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid):
acetonitrile
90:10, and Mobile phase B was ammonium acetate 5 mM buffer (pH 5.5 with acetic
acid):
acetonitrile 10:90; the gradient was from 0 to 100% B in 7 minutes then hold
100% B for 2
minutes before requilibration. Total LC time is 12 minutes. The injection
volume was
1 Ogl. UV Detection was performed between 215 and 400 nm.
Ions were generated under the following conditions: ESI sprayer voltage 4.0
kV, heated
capillary temperature 255 C, sheath gas nitrogen with a pressure of 5.0 Bar. A
full scan
detection mode (from 50 to 1000 amu) was used with an MS/MS analysis of the
most
intense ion (normalized collision energy: 35%).
W Detection: 215-400 nm.
HPLC/MS Method 4
The HPLC system used (Alliance 2790, with thermostated autosampler and divert
valve
LabPro, UV detector 2487 and satin interface, ZQ mass spectrometer with ESI
interface) is
a product of Waters Inc., Milford, Massachusetts. The chemiluminescent
nitrogen detector
(CLND) mod. 8060 is a product of ANTED Instruments Inc., Houston, Texas. The
liquid
handler Miniprep 75 is a product of Tecan Group Ltd., Maennedorf, Switzerland.
The chromatographic conditions used were as follows: The flow rate was set at
1 mL/min.
Two mobile phases (mobile phase A: 0.1% formic acid, mobile phase B: 0.1%
formic acid
in methanol) were employed to run in 10 min a linear gradient from 5 % B to 95
% B,
which was maintained for 2 min, and followed by re-equilibration at 5% B for
the next 3
minutes. Run time was 15 min. Injection volume 10 L, autosampler temperature
25 C,
detection wavelength 220 nm.
As reported in the following table VI, some other compounds of formula (la)
and (Ib) were
prepared, each identified through the aforementioned A-M-B coding system, and
further
characterised through BPLC/Mass, according to the experimental conditions
being above
reported.
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
94
Table VI
Compound HPLC Method r.t. (min) [M+H]+
A01 M1 B09 3 4.60 386.0
A0IM1B10 3 3.52 388.0
A01M1B11 1 5.55 400.5
A01MIB16 1 2.82 415.5
A01 M1 B18 1 3.06 455.5
A01 M 1 B23 3 2.71 406.0
A01 M 1 B24 3 5.05 434.0
A01MIB25 3 3.10 376.0
A01 M 1 B26 3 2.80 362.1
A01 M I B29 1 4.00 431.5
A01 M 1 B30 1 3.39 402.4
A01 M 1 B31 1 2.60 431.5
A01 M1 B32 3 6.07 430.0
AOIM1B33 3 3.67 416.0
A01 M 1 B35 1 3.66 402.4
A01 M 1 B36 1 2.70 401.5
A01 M 1 B37 1 4.75 404.4
A01 M 1 B38 1 2.76 401.5
A01 M 1 B40 1 2.74 475.5
A01 M I B41 3 4.75 510.1
A01 M1 B42 1 3.79 480.5
A0IM1B46 3 2.68 419.0
A01 M 1 B49 3 3.87 360.0
A02MIBll 2 2.35 400.5
A02M1 B16 2 1.09 415.5
A02M1 B18 2 1.16 455.5
A02MIB29 2 1.64 431.5
A02MIB30 2 1.36 402.4
A02M1 B31 2 0.96 431.5
A02M1B35 2 1.48 402.4
A02M 1 B36 2 1.01 401.5
A02M1B37 2 1.96 404.4
A02M1B38 2 1.03 401.5
A02M1 B40 2 1.01 475.5
A02MIB42 2 1.59 480.5
A04M1 B09 1 5.02 404.4
A04M1 B10 1 3.77 406.4
A04M1B11 1 5.57 418.5
A04M1B25 1 3.25 394.4
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
A04M 1 B27 1 4.72 392.4
A04M1B28 1 3.68 364.4
A04M1B30 1 3.34 420.4
A04M1B33 1 3.88 434.5
A04M1B34 1 3.40 447.5
A04M1B41 5.25 528.5
A04M1B49 1 4.18 378.4
A05MIBll 1 6.03 418.5
A05M1B18 1 3.08 473.5
A05M 1 B29 1 4.30 449.5
A05M1B30 1 0.72 420.4
A05M1B31 1 2.66 449.5
A05M 1 B35 1 4.00 420.4
A05M1B36 1 2.83 419.4
A05M1B37 1 5.17 422.4
A05M 1 B38 1 2.79 419.4
A05M 1 B40 1 2.82 493.5
A05M1B42 1 4.07 498.5
A06MIBll 1 6.09 416.9
A06M1B16 1 3.17 431.9
A06M1B18 1 3.39 472.0
A06M1B29 1 4.42 447.9
A06M1B31 1 2.99 447.9
A06M1B36 1 3.04 417.9
A06M 1 B39 3.15 447.0
A06M1B40 1 3.08 492.0
A06M1B42 1 4.17 497.0
A07M1B11 2 3.07 450.5
A07M1B16 2 1.78 465.5
A07M1B18 2 1.86 505.6
A07M1B29 2 2.36 481.5
A07M 1 B30 2 2.11 452.4
A07M 1 B31 2 1.69 481.5
A07M1B35 2 2.24 452.4
A07M 1 B36 2 1.72 451.5
A07M 1 B37 2 2.73 454.4
A07M 1 B38 2 1.71 451.5
A07M 1 B40 2 1.73 525.5
A07M 1 B42 2 2.25 530.5
A10M1B11 1 3.83 388.5
A10M1B16- 2.56 403.5
A10M1B18 1 2.58 443.6
A10M1B29 1 3.76 419.5
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
96
A10M1B30 1 3.13 390.5
A10M1B31 1 2.24 419.5
A10M1B37 1 4.45 392.5
A10M1B38 1 2.35 389.5
AlOMIB40 1 2.34 463.6
A10M1B42 1 3.54 468.6
A12M1B09 1 4.43 348.5
A12M1B10 1 3.18 350.4
A12M 1 B25 1 2.71 338.4
A12M1B28 1 3.08 308.4
A12M1B31 1 1.89 393.5
A12M 1 B33 1 3.40 378.5
A12M1B41 1 4.80 472.6
A12M 1 B49 1 3.56 322.4
A13M1B09 1 4.24 346.4
A13M1B10 1 2.98 348.4
A13M1B11 1 4.82 360.5
A13M1B25 1 2.52 336.4
A13M1B28 1 2.86 306.4
A13M1B30 1 2.66 362.4
A13M1B31 1 1.86 391.5
A13M1B33 1 3.22 376.5
A13M1B41 1 4.67 470.6
A13M1B49 1 3.37 320.4
A14MIB09 1 3.80 332.4
A14M1B10 1 2.57 334.4
A14M1B11 4 8.32 346.2
A14M 1 B30 1 2.28 348.4
A14M1B31 1 1.39 377.5
A14M1B33 1 2.87 362.4
A14M1 B34 1 2.41 375.4
A14M1B35 1 2.52 348.4
A14M1541 1 4.30 456.5
A14M1B49 1 2.94 306.4
A16M 1 B09 1 5.93 452.4
A16M1B10 1 4.78 454.4
A16MIBll 1 6.43 466.5
A16M1B25 1 4.27 442.4
A16M1B28 1 4.73 412.4
A16MIB30 1 4.32 468.4
A16M1B31 1 3.37 497.5
A16M 1 B32 1 5.20 496.5
A16M1B33 1 4.82 482.5
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
97
A16M1B34 1 4.34 495.5
A16M1B35 1 4.60 468.4
A16M1B49 1 5.15 426.4
A17M1B11 2 3.37 474.6
A17M1B16 2 2.29 489.6
A17MIB18 2 2.33 529.7
A17M1B29 2 2.60 505.6
A17M1B30 2 2.39 476.5
A17MIB31 2 2.08 505.6
A17M1B35 2 2.53 476.5
A17M1B36 2 2.08 475.6
A17M1 B37 2 3.01 478.5
A21 M 1 B09 1 4.92 434.5
A21M1B10 1 3.78 436.5
A21 M 1 B25 1 3.33 424.5
A21 M 1 B28 1 3.71 394.4
A21 M 1 B31 1 2.66 479.6
A21 M 1 B33 1 3.90 464.5
A21 M 1 B49 1 4.13 408.5
A22M1B09 1 5.54 418.5
A22M1B10 1 4.65 420.5
A22M1B11 1 6.05 432.5
A22M 1 B25 1 3.81 408.5
A22M1B27 1 5.27 406.5
A22M1B28 1 4.33 378.4
A22M1B30 1 3.86 434.5
A22M 1 B31 1 2.92 463.6
A22M1 B32 1 4.81 462.6
A22M 1 B33 1 4.40 448.5
A22M1B34 1 3.90 461.5
A22M 1 B35 1 4.46 434.5
A22M1 B41 1 4.11 542.6
A22M 1 B49 1 4.77 392.5
A23M1 B09 1 5.91 418.5
A23M1B10 1 4.67 420.5
A23M1 B11 1 6.45 432.5
A23M1B25 1 4.16 408.5
A23M1B27 1 5.56 406.5
A23M1B28 1 4.62 378.4
A23M1B30 1 4.20 434.5
A23M1 B31 1 3.21 463.6
A23M1B32 1 5.13 462.6
A23M 1 B33 1 4.72 448.5
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
98
A23M1B34 1 4.24 461.5
A23M1 B35 1 4.49 434.5
A23M1B41 1 5.98 542.6
A23M1B49 1 5.05 392.5
A24MlB09 1 5.02 411.5
A24M1 B10 3.91 413.5
A24M1B28 1 3.87 371.5
A24M1B31 1 2.73 456.6
A24M1B33 1 4.05 441.5
A24M1B49 1 4.28 385.5
A25M1B09 1 4.65 397.5
A25M1 B10 1 3.53 399.5
A25M1B25 3.13 387.5
A25M1B28 1 3.48 357.4
A25M1B30 1 3.20 413.5
A25M1B31 1 2.26 442.5
A25M1B33 1 3.47 427.5
A25M1B41 4.94 521.6
A25M 1 B49 1 3.91 371.5
A26M1 B09 1 3.87 349.4
A26M1B10 2.72 351.4
A26M1 B28 1 2.62 309.4
A26M1 B33 1 3.00 379.5
A26M1 B49 1 3.06 323.4
A27M1B09 1 5.34 401.5
A27M1 B10 1 4.13 403.4
A27M1B25 1 3.65 391.4
A27M1 B31 1 2.85 446.5
A27M1B33 1 4.22 431.5
A27M1B49 1 4.52 375.4
A30MlB09 1 4.78 368.5
A30M1 B10 1 3.53 370.4
A30MlBll 1 5.33 382.5
A30M1 B25 1 3.04 358.4
A30MlB27 1 4.45 356.4
A30M1 B28 1 3.43 328.4
A30MlB30 1 3.13 384.4
A30M1 B31 1 2.27 413.5
A30M1B33 1 3.69 398.5
A30M1 B34 1 3.21 411.5
A30M1 B35 1 3.38 384.4
A30MlB41 1 5.06 492.6
A30M 1 B49 1 3.91 342.4
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
99
A48M1B09 3 5.30 432.1
A48M1B10 3 4.18 434.1
A48M1 B23 3 3.38 452.1
A48M1B24 3 3.78 480.1
A48M1B25 3 3.83 422.1
A48M 1 B26 3 3.48 408.2
A48M1B30 3 4.00 448.2
A48M 1 B31 3 3.22 477.1
A48M1B32 3 4.28 476.3
A48M1B33 3 4.23 462.1
A48M1B40 3 3.33 521.3
A48M 1 B41 3 4.72 556.2
A48M1B46 3 3.43 465.1
A48M1B49 3 4.77 406.1
A53M1B09 1 3.10 417.5
A53M1B28 1 2.02 377.5
A53M1B49 1 2.37 391.5
A54M1B09 1 5.87 436.4
A54M1B10 1 4.65 438.4
A54M1 B11 4 9.71 450.1
A54M1B25 1 4.14 426.4
A54M 1 B28 1 4.60 396.4
A54M1B31 1 3.22 481.5
A54M1B33 1 4.70 466.5
A54M1B34 1 4.20 479.5
A54M1B35 1 4.46 452.4
A54M1B41 1 5.93 560.6
A54M1B49 1 5.05 410.4
A01 M2B11 2 2.75 398.5
A01 M2B16 2 1.40 413.5
A01 M2B18 2 1.50 453.5
A01 M2B29 2 2.08 429.5
A01 M2B30 2 1.71 400.4
A01 M2B31 2 1.27 429.5
A01 M2B35 2 1.84 400.4
A01 M2B36 2 1.31 399.2
A01 M2B37 2 2.33 402.4
A01 M2B38 2 1.34 399.4
A01 M2B40 2 1.34 473.5
A01 M2B42 2 1.93 478.5
A06M2B09 1 5.52 400.9
A06M2B11 1 6.04 414.9
A06M2B16 1 2.95 429.9
CA 02508069 2005-05-31
WO 2004/056827 PCT/EP2003/050942
100
A06M2B18 1 3.16 470.0
A06M2B29 1 4.57 445.9
A06M2B30 1 3.82 416.9
A06M2B31 1 2.90 445.9
A06M2B35 1 4.08 416.9
A06M2B36 1 2.94 415.9
A06M2B37 1 5.20 418.9
A06M2B38 1 3.00 415.9
A06M2B40 1 3.03 490.0
A07M2B11 2 3.10 448.5
A07M2B16 2 1.80 463.5
A07M2B18 2 1.90 503.5
A07M2B29 2 2.46 479.5
A07M2B30 2 2.13 450.4
A07M2B31 2 1.71 479.5
A07M2B35 2 2.26 450.4
A07M2B36 2 1.74 449.4
A07M2B37 2 2.75 452.4
A07M2B38 2 1.78 449.4
A07M2B40 2 1.76 523.5
A07M2B42 2 2.29 528.5
A17M2B16 2 2.10 487.6
A17M2B18 2 2.17 527.6
A17M2B29 2 2.73 503.6
A17M2B30 2 2.40 474.5
A17M2B31 2 2.01 503.6
A17M2B35 2 2.55 474.5
A17M2B36 2 2.03 473.5
A17M2B37 2 3.05 476.5
A17M2B38 2 2.07 473.5
A17M2B40 2 2.04 547.6
A17M2B42 2 2.55 552.6
